DE69032425T2 - Immersion test strips for nucleic acid hybridization assays and methods for covalently immobilizing oligonucleotides - Google Patents

Immersion test strips for nucleic acid hybridization assays and methods for covalently immobilizing oligonucleotides

Info

Publication number
DE69032425T2
DE69032425T2 DE69032425T DE69032425T DE69032425T2 DE 69032425 T2 DE69032425 T2 DE 69032425T2 DE 69032425 T DE69032425 T DE 69032425T DE 69032425 T DE69032425 T DE 69032425T DE 69032425 T2 DE69032425 T2 DE 69032425T2
Authority
DE
Germany
Prior art keywords
oligonucleotide
polymer
amine
beads
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69032425T
Other languages
German (de)
Other versions
DE69032425D1 (en
Inventor
Charles E. Woodinville Washington 98072 Petrie
John C. Bothell Washington 98011 Tabone
Jeffrey Bothell Washington 98011 Van Ness
Nicolaas M.J. Woodinville Washington 98072 Vermeulen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanogen Inc
Original Assignee
MicroProbe Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MicroProbe Corp filed Critical MicroProbe Corp
Application granted granted Critical
Publication of DE69032425D1 publication Critical patent/DE69032425D1/en
Publication of DE69032425T2 publication Critical patent/DE69032425T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6834Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Saccharide Compounds (AREA)

Abstract

The invention provided a dipstick for a nucleic acid hybridization assay comprising a non-porous solid support having at least one perforation, a polymer-coated bead being attached to the perforation, wherein the polymer-coated bead is covalently attached to an oligonucleotide. Preferably the polymer-coated bead is covalently attached to more than one oligonucleotide having the same or different nucleic acid sequence. Furthermore, the polymer-coated bead is preferably nylon and is spherical in shape, with the diameter of the bead preferably being in the range of from 0.025 cm to 1.27 cm. <IMAGE>

Description

Die vorliegende Erfindung betrifft einen Tauchstaub für eine Nukleinsäure-Hybridisierungs-Untersuchung zur Bestimmung spezifischer Polynukleotidsequenzen.The present invention relates to a dip dust for a nucleic acid hybridization assay for determining specific polynucleotide sequences.

Die Nukleinsäure-Hybridisierung ist eine bekannte Methode zur Identifizierung spezifischer Sequenzen von Nukleinsäuren. Die Hybridisierung basiert auf dem Basenpaaren zwischen komplementären Nukleinsäuresträngen. Wenn Nukleinsäuren mit einfachen Strängen inkubiert werden in geeigneten Pufferlösungen, paaren sich komplementäre Basensequenzen zur Bildung von doppelsträngigen stabilen Molekülen. Die Gegenwart oder Abwesenheit solcher Paarung kann durch mehrere unterschiedliche Methoden bestimmt werden, die im Stand der Technik beschrieben sind.Nucleic acid hybridization is a well-known method for identifying specific sequences of nucleic acids. Hybridization is based on base pairing between complementary nucleic acid strands. When nucleic acids are incubated with single strands in appropriate buffer solutions, complementary base sequences pair to form double-stranded stable molecules. The presence or absence of such pairing can be determined by several different methods described in the art.

Viele bekannte Hybridisierungsuntersuchungen umfassen zahlreiche Schritte, beispielsweise die Hybridisierungstechnik, die von Dunn, et al., in Cell 12:23- 36 (1977) beschrieben wurde, bei der eine Untersuchung vom Sandwichtyp besteht in einer ersten Hybridisierung zwischen einer "Ziel"-Nukleinsäure und einer "Einfang"-Nukleinsäuresonde, die immobilisiert wurde an einen festen Träger und einer zweiten Hybridisierung zwischen einer "Signal"-Nukleinsäuresonde, die typischerweise mit einem radioaktiven Isotop markiert ist, und einer unterschiedlichen Region an der immobilisierten Zielnukleinsäure. Die Hybridisierung der Signalsonde kann z.B. bestimmt werden durch Autoradiographie.Many known hybridization assays involve numerous steps, for example the hybridization technique described by Dunn, et al., in Cell 12:23-36 (1977), in which a sandwich-type assay consists of a first hybridization between a "target" nucleic acid and a "capture" nucleic acid probe immobilized to a solid support and a second hybridization between a "signal" nucleic acid probe, typically labeled with a radioactive isotope, and a different region on the immobilized target nucleic acid. Hybridization of the signal probe can be determined, for example, by autoradiography.

Ranki, et al., U.S. 4,486,539 und U.S. 4,563,419, beschreiben Sandwichtyp-Untersuchungen, die zunächst Schritte erfordern um die Nukleinsäuren einzelsträngig zu machen, bevor die einfachsträngigen Nukleinsäuren hybridisieren können mit einer Nukleinsäure die an einen festen Träger fixiert ist und mit einer Nukleinsäure, die mit einem Radioisotop markiert ist.Ranki, et al., U.S. 4,486,539 and U.S. 4,563,419, describe sandwich-type assays that first require steps to render the nucleic acids single-stranded before the single-stranded nucleic acids can hybridize with a nucleic acid fixed to a solid support and with a nucleic acid labeled with a radioisotope.

Carrico, et. al., U.S. 4,806,546, und Carrico, et al., Europäische Patentanmeldung 86112899.9, veröffentlicht als EP-A-0219695, haben die Behandlung eines Nylonträgers mit einem Alkylierungsagenz beschrieben, um Amidingruppen an der Oberfläche des Nylon einzuführen. Die derivatisierte Nylonoberfläche besitzt die Fähigkeit nicht kovalent einfachsträngige Nukleinsäuren zu binden. Die nicht kovalent gebundenen Nukleinsäuren werden dann verwendet als Sonden zur spezifischen Bestimmung von Zielnukleinsäuren in Lösungen.Carrico, et al. al., US 4,806,546, and Carrico, et al., European patent application 86112899.9, published as EP-A-0219695, described the treatment of a nylon support with an alkylating agent to introduce amidine groups on the surface of the nylon. The derivatized nylon surface has the ability to non-covalently bind single-stranded nucleic acids. The non-covalently bound nucleic acids are then used as probes for the specific determination of target nucleic acids in solutions.

Hunger, et. al., Analytical Biochemistry 165:45-55 (1987); Hunger, et. al., Analytical Biochemistry 156:286-299 (1986); Hunger et. al., Europäische Patentanmeldung 84109485.7, veröffentlicht als EP-A-0134025, beschreiben die Verwendung von Cyanurchlorid aktiviertem Zellulosepapier das immobilisierte beschränkte Genom-DNA hat in Southern blot Techniken für die Bestimmung von Subpicogrammmengen an komplementärer DNA.Hunger, et. al., Analytical Biochemistry 165:45-55 (1987); Hunger, et. al., Analytical Biochemistry 156:286-299 (1986); Hunger et. al., European Patent Application 84109485.7, published as EP-A-0134025, describe the use of cyanuric chloride activated cellulose paper having immobilized restricted genomic DNA in Southern blot techniques for the determination of subpicogram amounts of complementary DNA.

Biagoni, et. al., Analytical Biochemistry 89:616-619 (1978), beschreiben ein Verfahren zur Herstellung von DNA-Zellulose unter Verwendung von Cyanurchlorid, bei dem die DNA-Zellulose eingesetzt wird in Affinitäts-Chromatographie-Verfahren.Biagoni, et al., Analytical Biochemistry 89:616-619 (1978), describe a method for producing DNA-cellulose using cyanuric chloride, in which the DNA-cellulose is used in affinity chromatography procedures.

Herzberg, et. al., Europäische Patentanmeldung 0171150, beschreiben die Verwendung von Oligonukleotiden, die immobilisiert sind an feste Träger in Untersuchungen mit Tauchstäben.Herzberg, et al., European Patent Application 0171150, describe the use of oligonucleotides immobilized to solid supports in dipstick assays.

Litmann, et. al., U.S. 4,391,904, beschreiben Kits mit Teststreifen bei denen ein Glied eines immunologischen Paar an einen festen Träger gebunden wird. Ebenfalls beschreiben Miller et. al., Clin. Chem. 30:1467-1472 (1984), und Brown, et. al., Clin. Chem. 31:1500-1505 (1985), eine analytische Testkammer die Zellulosefasern enthält, die an einen Antikörper als eine Festmatrix gebunden sind, die es erlaubt, Vielfachtests aus einer einzigen Probe durchzuführen.Litmann, et al., U.S. 4,391,904, describe kits containing test strips in which one member of an immunological pair is bound to a solid support. Also, Miller et al., Clin. Chem. 30:1467-1472 (1984), and Brown, et al., Clin. Chem. 31:1500-1505 (1985), describe an analytical test chamber containing cellulose fibers bound to an antibody as a solid matrix that allows multiple tests to be performed from a single sample.

Pedley et. al. (GB 2197720 A)beschreibt die Immobilisierung eines Polynukleotids an einem Plastikträger mit Vertiefungen durch Binden eines Polyethylenimins (PEI) an den Plastikträger mit Vertiefungen und Verwendung von Glutaraldehyd zur Bildung von Brücken zwischen den Aminogruppen des PEI und direkt den Aminogruppen in den Adenin, Guanin und Cytosinresten des Polynukleotids.Pedley et al. (GB 2197720 A) describes the immobilization of a polynucleotide on a plastic carrier with wells by binding a polyethyleneimine (PEI) to the plastic support with recesses and using glutaraldehyde to form bridges between the amino groups of the PEI and directly the amino groups in the adenine, guanine and cytosine residues of the polynucleotide.

Gemäß der vorliegenden Erfindung wird eine Zusammensetzung zur Verfügung gestellt, die ein Oligonukleotid umfaßt, das kovalent an einen festen Träger gebunden ist, beschichtet mit einem aminhaltigen Polymeren, wobei die kovalente Bindung auftritt zwischen dem Amin des polymerbeschichteten festen Trägers und einem Amin, das mit dem Oligonukleotid verknüpft ist.According to the present invention, there is provided a composition comprising an oligonucleotide covalently bound to a solid support coated with an amine-containing polymer, wherein the covalent bond occurs between the amine of the polymer-coated solid support and an amine linked to the oligonucleotide.

Der feste Träger der beschichtet ist mit einem aminhaltigen Polymeren ist vorzugsweise eine Nylonkugel und ist kugelförmig in der Form. Der Durchmesser einer solchen Kugel liegt vorzugsweise im Bereich von zwischen 0,025 cm bis 1,27 cm, weiter vorzugsweise von 0,15 cm bis 0,23 cm.The solid support coated with an amine-containing polymer is preferably a nylon bead and is spherical in shape. The diameter of such a bead is preferably in the range of between 0.025 cm to 1.27 cm, more preferably from 0.15 cm to 0.23 cm.

Außerdem wird im Einklang mit der Erfindung ein Verfahren zur Herstellung eines Oligonukleotids zur Verfügung gestellt, das kovalent an ein aminhaltiges Polymeres gebunden ist, über ein Amin, das mit dem 5- Ende oder dem 3- Ende oder an einer Stelle zwischen dem 5- Ende und dem 3- Ende eines Oligonukleotids verknüpft ist, wobei dieses Verfahren umfaßt:Also provided in accordance with the invention is a process for preparing an oligonucleotide covalently linked to an amine-containing polymer via an amine linked to the 5-end or the 3-end or at a site between the 5-end and the 3-end of an oligonucleotide, which process comprises:

Das Aktivieren eines Aminoalkyl-substituierten Oligonukleotids mit Cyanurchlorid und das konjugieren des aktivierten Oligonukleotids an ein aminhaltiges Polymeres.Activating an aminoalkyl-substituted oligonucleotide with cyanuric chloride and conjugating the activated oligonucleotide to an amine-containing polymer.

Die Verwendung von Kugeln oder ähnlichen Strukturen in einem Tauchstabformat erzielt eine bedeutende Abnahme in dem nicht spezifischen Hintergrundlevel von Signalsystemen, weil ein einfacher Drucksitz gegeben ist, mittels dessen die Kugel oder ähnliche Struktur an dem Tauchstab angebracht ist, verglichen mit Membranträgern und dergleichen, die notwendigerweise zwischen zwei Trägern als Sandwich vorliegen müssen oder an einer Stelle angeleimt oder angebracht werden müssen.The use of spheres or similar structures in a dipstick format achieves a significant reduction in the non-specific background level of signaling systems because there is a simple pressure fit by which the sphere or similar structure is attached to the dipstick, compared to membrane supports and the like which are necessarily sandwiched between two supports or must be glued or attached in one place.

Ein weiteres Verständnis der Natur und der Vorteile der vorliegenden Erfindung ergibt sich durch Bezugnahme auf den weiteren Teil der Beschreibung und die Zeichnungen.A further understanding of the nature and advantages of the present invention will be obtained by reference to the remainder of the specification and the drawings.

Kurze Beschreibung der ZeichnungenShort description of the drawings

Fig. 1 ist eine Ausbildung eines Tauchstabs gemäß der vorliegenden Erfindung;Fig. 1 is an embodiment of a dipstick according to the present invention;

Fig. 2 ist eine Indikatorkarte mit vielen Stellen, die für die Diagnose von Periodontitis verwendet werden kann;Fig. 2 is a multi-site indicator card that can be used for the diagnosis of periodontitis;

Fig. 3 sind HPLC Profile (Hochauflösende Flüssigchromatographie) die zeigen, daß Cyanurchlorid selektiv mit dem 5- angebundenen Amin eines Oligonukleotids reagiert und nicht mit dessen Zuckern oder Basen.Fig. 3 are HPLC (high-resolution liquid chromatography) profiles showing that cyanuric chloride reacts selectively with the 5-linked amine of an oligonucleotide and not with its sugars or bases.

Detaillierte Beschreibung der ErfindungDetailed description of the invention

Die vorliegende Erfindung umfaßt Zusammensetzungen, die verwendbar sind in Nukleinsäure-Hybridisierungs- Untersuchungen. Diese Zusammensetzungen umfassen ein Dichlortriazin-Oligonukleotid und andere aktivierte Oligonukleotide, die kovalent an eine polymerbeschichtete Kugel oder eine ähnliche Struktur gebunden sind.The present invention includes compositions useful in nucleic acid hybridization assays. These compositions comprise a dichlorotriazine oligonucleotide and other activated oligonucleotides covalently linked to a polymer-coated bead or similar structure.

Weiterhin sind Verfahren für das kovalente Immobilisieren eines Oligonukleotids an einem festen Nylonträger, vorzugsweise einer Kugel, eingeschlossen. Im allgemeinen umfassen diese Verfahren die Schritte das Behandelns eines festen Nylonträgers mit einem Alkylierungsagenz, das zur Reaktion bringen des behandelten festen Trägers mit einem aminhaltigen Polymeren, wobei das Polymer kovalent den festen Träger beschichtet, das Aktivieren eines Oligonukleotids mit einem monofunktionalen oder multifunktionalen Reagenz, vorzugsweise mit einem homotrifunktionalen Reagenz, Cyanurchlorid (d.h. 2, 4, 6- Trichlortriazin); und das Konjugieren des aktivierten Oligonukleotids und des polymerbeschichteten festen Trägers. Die unreagierten Amine werden dann blockiert durch Acylierung um der festen Trägeroberfläche die geeignete Oberflächenladung zu verleihen.Furthermore, methods for covalently immobilizing an oligonucleotide to a solid nylon support, preferably a bead, are included. Generally, these methods comprise the steps of treating a solid nylon support with an alkylating agent, reacting the treated solid support with an amine-containing polymer, wherein the polymer covalently coats the solid support, activating an oligonucleotide with a monofunctional or multifunctional reagent, preferably with a homotrifunctional reagent, cyanuric chloride (ie, 2, 4, 6-trichlorotriazine); and conjugating the activated oligonucleotide and the polymer-coated solid support. The unreacted amines are then blocked by acylation to impart the appropriate surface charge to the solid support surface.

Der Begriff "fester Träger" bezieht sich auf irgendeine Oberfläche, die von Lösung zu Lösung übertragbar ist oder eine Struktur bildet für die Durchführung von Untersuchungen auf Basis von Oligonukleotiden, und dieser Begriff schließt ein Kugeln, Membranen, Miktrotiter-Vertiefungen, Fäden oder Drähte, Kunststoffstreifen, oder irgendeine Oberfläche an die die Nukleinsäuresonden immobilisiert werden können.The term "solid support" refers to any surface that is transferable from solution to solution or forms a structure for conducting oligonucleotide-based assays, and this term includes beads, membranes, microtiter wells, threads or wires, plastic strips, or any surface to which the nucleic acid probes can be immobilized.

So wie hierin verwendet umfaßt der Begriff "Kugel" irgendeinen Typ einer festen oder hohlen Kugel, eines Balls, Lagers, Zylinders, oder einer anderen ähnlichen Konfiguration bestehend aus Kunststoff, Keramik, Metall oder polymerem Material an das eine Nukleinsäure kovalent immobilisiert werden kann. Somit umfaßt dieser Begriff auch einen Nylonfaden oder Nylonfäden. Vorzugsweise wird in den vorliegenden Zusammensetzungen eine Nylonkugel verwendet, die in ihrer Form sphärisch ist, und ein bevorzugter Durchmesserbereich für eine solche Kugel liegt von etwa 0,025 bis 1,27 cm (0,01 inch bis etwa 0,5 inch), weiter vorzugsweise von etwa 0,15 bis 0,23 cm (0,06 inch bis etwa 0,09 inch, (entsprechend den kommerziell erhältlichen 0,23 cm oder 3/32 inch Nylonkugeln), und am meisten bevorzugt etwa 0,23 cm (0,09 inch) (entsprechend den kommerziell erhältlichen 0,23 cm oder 3/32 inch Nylonkugeln). Außerdem ist es bevorzugt, daß die Nylonkugeln unpoliert sind oder wenn sie poliert sind aufgerauht werden bevor die Behandlung mit einem Akylierungsagenz erfolgt.As used herein, the term "sphere" includes any type of solid or hollow sphere, ball, bearing, cylinder, or other similar configuration made of plastic, ceramic, metal, or polymeric material to which a nucleic acid can be covalently immobilized. Thus, this term also includes a nylon thread or threads. Preferably, the present compositions employ a nylon ball that is spherical in shape, and a preferred diameter range for such a ball is from about 0.025 to 1.27 cm (0.01 inch to about 0.5 inch), more preferably from about 0.15 to 0.23 cm (0.06 inch to about 0.09 inch, corresponding to commercially available 0.23 cm or 3/32 inch nylon balls), and most preferably about 0.23 cm (0.09 inch) (corresponding to commercially available 0.23 cm or 3/32 inch nylon balls). In addition, it is preferred that the nylon balls be unpolished or, if polished, roughened prior to treatment with an alkylating agent.

Im Rahmen der vorliegenden Erfindung wird eine Nylonkugel oder Kugeln oder irgendeine Zusammensetzung oder Struktur aus Nylon zunächst derivatisiert (präpariert) durch Behandlung der Kugeln mit einem Alkylierungsagenz. Alkylierungsagenzien die auf diese Weise verwendet werden reagieren mit Amiden die in dem Nylon vorhanden sind zur Bildung eines reaktiven Imidadesters.In the present invention, a nylon ball or beads or any composition or structure of nylon is first derivatized (prepared) by treating the beads with an alkylating agent. Alkylating agents used in this manner react with amides present in the nylon to form a reactive imide ester.

Bevorzugte Alkylierungsagenzien umfassen, ohne darauf beschränkt zu sein, die Alkylsulfate, Alkyltriflate, Alkyldiphenylsulfoniumsalze, Alkylperchlorate und vorzugsweise Trialkyloxoniumsalze. Die letztgenannten umfassen die niederen Alkylsalze, Trilmethyloxonium und Triethyloxoniumsalze. Das Salzgegenion kann ausgewählt werden aus der Gruppe bestehend aus Hexachlorantimonat, Hexafluorophosphat und Tetrafluoroborat, wobei das letztgenannte Gegenion bevorzugt ist. Jedoch können auch andere Salzgegenionen ebenso verwendet werden und es ist für den Fachmann auf dem relevanten Fachgebiet offensichtlich, daß dies möglich ist.Preferred alkylating agents include, but are not limited to, the alkyl sulfates, alkyl triflates, alkyl diphenyl sulfonium salts, alkyl perchlorates, and preferably trialkyloxonium salts. The latter include the lower alkyl salts, trimethyloxonium and triethyloxonium salts. The salt counterion can be selected from the group consisting of hexachloroantimonate, hexafluorophosphate and tetrafluoroborate, with the latter counterion being preferred. However, other salt counterions can also be used and it will be apparent to one skilled in the relevant art that this is possible.

Die Auswahl eines Lösungsmittels für das Alkylierungsagenz ist für die vorliegende Erfindung bedeutsamt. Ein Solvenz sollte verwendet werden, das Nylon nicht löst oder klebrig macht während der Alkylierung. Nicht nucleophile organische Solvenzien, wie z.B. Dichlormethan, Dimethylsulfoxid, Tetrahydrofuran, N-Methyl-Pyrrolidon und andere sind geeignete Solvenzien. Insbesondere wird N-Methyl-Pyrrolidon bevorzugt.The selection of a solvent for the alkylating agent is important to the present invention. A solvent should be used that does not dissolve or tackify nylon during alkylation. Non-nucleophilic organic solvents such as dichloromethane, dimethyl sulfoxide, tetrahydrofuran, N-methyl-pyrrolidone and others are suitable solvents. In particular, N-methyl-pyrrolidone is preferred.

Die resultierenden Imidatester an der Kugeloberfläche werden dann unter geeigneten Bedingungen mit einem aminhaltigen Polymeren zur Reaktion gebracht, wobei Amidinreste gebildet werden. Irgendein primäres oder sekundäres aminhaltiges Polymeres kann verwendet werden zur Bildung von Amidinresten, so daß es kovalent immobilisiert das Polymere an die Oberfläche der Kugel. Poly (Ethylenimin), Polyallylamine und Polyvinylamin sind bevorzugte Beispiele. Das bevorzugte Solvenz das zum Lösen des Polymeren während der Konjugation des Polymeren zu der aktivierten Nylonkugel verwendet wird ist N-Methyl-Pyrrolidon.The resulting imidate esters on the sphere surface are then reacted under appropriate conditions with an amine-containing polymer to form amidine moieties. Any primary or secondary amine-containing polymer can be used to form amidine moieties so that it covalently immobilizes the polymer to the surface of the sphere. Poly(ethyleneimine), polyallylamines and polyvinylamine are preferred examples. The preferred solvent used to dissolve the polymer during conjugation is of the polymer to the activated nylon ball is N-methyl-pyrrolidone.

Nylon kann auch partiell hydrolisiert werden um reaktives Amin oder Carboxyl-Gruppen zu liefern, die reaktiv sind gegenüber Amin- oder carboxylhaltigen Polymeren. In ähnlicher Weise können Carboxylanteile, die die Oberfläche eines festen Trägers beschichten, mit aminhaltigen Polymeren unter ähnlichen chemischen Bedingungen wie oben beschrieben beschichtet werden.Nylon can also be partially hydrolyzed to provide reactive amine or carboxyl groups that are reactive toward amine or carboxyl-containing polymers. Similarly, carboxyl moieties coating the surface of a solid support can be coated with amine-containing polymers under similar chemical conditions as described above.

Außerdem ist jedes andere Polymere, das geeignet ist mit irgendeinem primären oder sekundären aliphatischem oder aromatischem Amin zu derivatisieren, geeignet für die vorliegende Erfindung. Die Einheiten eines solchen Polymers werden verbunden durch direktes Binden über einen Polymerisierungsprozeß oder durch Verknüpfen über ein Kopplungsagenz. Die direkte Polymerisierung produziert eine Verknüpfung untereinander von geeigneten chemischen Gruppen oder Gerüsteinheiten in benachbarten Einheiten. Beispielsweise können oxidative Enzyme verwendet werden, um Monomereinheiten zu polymerisieren durch oxidatives Crossvernetzen. Alternativ kann ein Kopplungsagenz, das von einem bifunktionalen oder multifunktionalen organischen Crossvernetzungsreagenz abgeleitet ist, mit der geeigneten chemischen Gruppe oder Gerüsteinheit dieser Einheiten verknüpft werden. In diesem Kontext bedeutet der Begriff "Kopplungsagenz" die Verknüpfungsgruppe nach dem Binden und der Begriff "Crossvernetzungsreagenz" bezeichnet die Verknüpfungsverbindung vor dem Binden.In addition, any other polymer capable of derivatizing with any primary or secondary aliphatic or aromatic amine is suitable for the present invention. The units of such a polymer are linked by direct bonding via a polymerization process or by linking via a coupling agent. Direct polymerization produces interlinking of appropriate chemical groups or backbone units in adjacent units. For example, oxidative enzymes can be used to polymerize monomer units by oxidative cross-linking. Alternatively, a coupling agent derived from a bifunctional or multifunctional organic cross-linking agent can be linked to the appropriate chemical group or backbone unit of these units. In this context, the term "coupling agent" means the linking group after bonding and the term "cross-linking agent" means the linking compound before bonding.

Das Crossvernetzungsreagenz hat die allgemeine Formel: The cross-linking reagent has the general formula:

Worin die reaktiven Gruppen A, B und E unabhängig voneinander ausgewählt werden aus der Gruppe bestehend aus Wasserstoff, einer Carboxylsäuregruppe, einem Säurehalogenid, einem aktivierten Ester, einem gemischten Anhydrid, einem Iminoester, einem primären Amin, einer Aldehydgruppe, einer &alpha;-Halomethylcarbonylgruppe einer Hydrazingruppe, einer Acylhydrazidgruppe, einer Azidgruppe, und einer N- Maleimidgruppe, worin wenigstens zwei von A, B und E nicht Wasserstoff sind. R¹ ist eine aliphatische Gruppe mit wenigstens zwei Kohlenstoffatomen oder eine aromatische oder heterocyclische Gruppe mit wenigstens 6 Kohlenstoffatomen.Wherein the reactive groups A, B and E independently selected from the group consisting of hydrogen, a carboxylic acid group, an acid halide, an activated ester, a mixed anhydride, an imino ester, a primary amine, an aldehyde group, an α-halomethylcarbonyl group, a hydrazine group, an acyl hydrazide group, an azide group, and an N-maleimide group, wherein at least two of A, B and E are not hydrogen. R¹ is an aliphatic group having at least two carbon atoms or an aromatic or heterocyclic group having at least 6 carbon atoms.

Multifunktionale Crossvernetzungsreagenzien mit mehr als drei reaktiven Gruppen die ähnliche sind mit A, B und E liegen ebenfalls innerhalb des Schutzumfangs der vorliegenden Erfindung. Diese zusätzlichen reaktiven Gruppen werden unabhängig voneinander ausgewählt aus den vorangegangenen Definitionen für A, B und E.Multifunctional crosslinking reagents having more than three reactive groups similar to A, B and E are also within the scope of the present invention. These additional reactive groups are independently selected from the foregoing definitions for A, B and E.

Die Auswahl der reaktiven Gruppen hängt ab von der Auswahl der chemischen Gruppen oder Gerüsteinheiten der Polymereinheiten (monomere Einheiten) die miteinander verknüpft werden sollen. Jeder Typ einer chemischen Gruppe oder Gerüsteinheit reagiert mit einer geeigneten reaktiven Gruppe oder Gruppen. Beispielsweise wird eine Amingruppe mit einer Carboxylsäuregruppe reagieren, einem Säurehalogenid, einem aktivierten Ester, einem gemischten Anhydrid, einem Acylimidazolid, einer N-(Carbonyloxy)Imidgruppe, einem Iminoester oder einer Aldehydgruppe. Eine oxidierte 1, 2- Diolgruppe (ein Dialdehyd) wird reagieren mit einem primären Amin, einer Hydrazingruppe, einem Azid oder einer Acylhydrazidgruppe. Eine Carbonylgruppe wird reagieren mit einem primären Amin, einer Hydrazingruppe, oder einer Acylhydrazidgruppe. Eine Mercaptangruppe wird reagieren mit einer Carbonsäuregruppe, einem Säurehalogenid, einem aktivierten Ester, einem gemischten Anhydrid, einem Acylimidazolid, oder einem N-(Carbonyloxy)imid. Eine Kohlenstoff-Wasserstoff Bindung wird reagieren mit einem Azid (Nitren). Die festen Träger werden somit beschichtet mit dem ausgewählten Polymeren, einschließlich multifunktionaler Polymere, die eine große Anzahl an aktivierbaren primären und sekundären Aminen enthalten.The choice of reactive groups depends on the choice of chemical groups or backbone units of the polymer units (monomeric units) to be linked together. Each type of chemical group or backbone unit will react with an appropriate reactive group or groups. For example, an amine group will react with a carboxylic acid group, an acid halide, an activated ester, a mixed anhydride, an acyl imidazolide, an N-(carbonyloxy)imide group, an imino ester, or an aldehyde group. An oxidized 1, 2-diol group (a dialdehyde) will react with a primary amine, a hydrazine group, an azide, or an acyl hydrazide group. A carbonyl group will react with a primary amine, a hydrazine group, or an acyl hydrazide group. A mercaptan group will react with a carboxylic acid group, an acid halide, an activated ester, a mixed anhydride, an acyl imidazolide, or an N-(carbonyloxy)imide. A carbon-hydrogen bond will react with an azide (nitrene). The solid supports are thus coated with the selected polymers, including multifunctional polymers containing a large number of activatable primary and secondary amines.

Die unten wiedergegebene Tabelle erläutert, ohne die Erfindung einzuschränken, die Typen an Reaktionen, die im Rahmen der vorliegenden Erfindung anwendbar sind, um entweder direkt oder über einen Distanzarm ein Polymeres an einen festen Träger kovalent anzubinden. Wie man sehen kann, können andere Polymere, die Thiol oder Carboxylgruppen enthalten ebenfalls verwendet werden, obwohl aminhaltige Polymere bevorzugt sind. The table below illustrates, without limiting the invention, the types of reactions that are applicable within the scope of the present invention to covalently attach a polymer to a solid support, either directly or through a spacer arm. As can be seen, other polymers containing thiol or carboxyl groups can also be used, although amine-containing polymers are preferred.

Die polymerbeschichteten festen Träger werden dann konjugiert mit aktivierten Oligonukleotiden unter Verwendung ähnlicher oder identischer Chemie wie sie oben beschrieben wurde. In der Verwendung hierin bezieht sich Oligonukleotide auf kurze Nukleinsäuresequenien die etwa 16 bis 100 Basen in der Länge umfassen. Solche Oligonukleotide können verwendet werden als Einfangsonden in Hybridisierungsuntersuchungen und sie werden vorzugsweise chemisch synthetisiert unter Verwendung kommerziell erhältlicher Methoden und Ausrüstungen. Beispielsweise kann die Festphasen-Phosphoramiditmethode verwendet werden zur Erzeugung kurzer Sonden mit zwischen 15 und 20 Basen die ein Molekulargewicht von weniger als 16.000 Dalton haben. Für die Synthese von Oligonukleotiden siehe Caruthers, et al., Cold Spring Harbour Symp. Quant. Biol., 47:411-418 (1982); Adams, et al., J. Am. Chem. Soc., 105:661 (1983).The polymer-coated solid supports are then conjugated with activated oligonucleotides using similar or identical chemistry as described above. As used herein, oligonucleotides refer to short nucleic acid sequences comprising about 16 to 100 bases in length. Such oligonucleotides can be used as capture probes in hybridization assays and are preferably chemically synthesized using commercially available methods and equipment. For example, the solid phase phosphoramidite method can be used to generate short probes of between 15 and 20 bases having a molecular weight of less than 16,000 daltons. For the synthesis of oligonucleotides, see Caruthers, et al., Cold Spring Harbor Symp. Quant. Biol., 47:411-418 (1982); Adams, et al., J. Am. Chem. Soc., 105:661 (1983).

Wenn eine Oligonukleotidsonde für eine spezifische Zielnukleinsäure synthetisiert wird, bestimmt die Auswahl der Nukleotidsequenz die Spezifität des Tests. Beispielsweise, wenn man DNA-Sequenzen aus verschiedenen Bakterienisolaten vergleicht, kann man eine Sequenz für die Bakterienbestimmung auswählen, die entweder typenspezifisch oder genusspezifisch ist. Vergleiche von DNA Regionen und Sequenzen können erreicht werden unter Verwendung kommerziell erhältlicher Computerprogramme.When an oligonucleotide probe is synthesized for a specific target nucleic acid, the selection of the nucleotide sequence determines the specificity of the test. For example, when comparing DNA sequences from different bacterial isolates, one can select a sequence for bacterial identification that is either type-specific or genus-specific. Comparisons of DNA regions and sequences can be accomplished using commercially available computer programs.

Die bevorzugten Einfangoligonukleotide für die Verwendung in der vorliegenden Erfindung sind synthetische Oligonukleotide von etwa 20 bis etwa 100 Basen in der Länge. Ein Distanzarm (Verknüpfungsarm), d.h. eine chemische Einheit, die andere chemischen Gruppen verlängert oder verknüpft, und vorzugsweise ist dies eine Kohlenstoffkette die von etwa 2 bis 12 Kohlenstoffatome enthält, weiter vorzugsweise etwa 6 Kohlenstoffatome, die eine blockierte Aminogruppe enthält, die während der Synthese unter Verwendung herkömmlicher Chemie an eine 5'-Hydroxylgruppe eines Oligonukleotids gekoppelt werden kann. Eine primäre Aminogruppe ist die bevorzugte Gruppe für die Anknüpfung an monofunktionale oder multifunktionale Reagenzien und seine Anknüpfung über einen Hexylarm ist bevorzugt. Die Reagenzien für die Anknüpfung eines primären Distanzarms der in einem primären Amin endet sind kommerziell erhältlich sind. Ausgangsmaterialien die für die Verwendung in der vorliegenden Erfindung geeignet sind werden beschrieben in Wo-A-86 / 07363; Nucl. Acids Res. 15:3131 (1987); Nucl. Acids Res. 15:2891 (1987); und Nucl. Acids Res. 14:7985 (1986).The preferred capture oligonucleotides for use in the present invention are synthetic oligonucleotides from about 20 to about 100 bases in length. A spacer arm (linking arm), i.e., a chemical moiety that extends or links other chemical groups, and preferably this is a carbon chain containing from about 2 to 12 carbon atoms, more preferably about 6 carbon atoms, containing a blocked amino group that can be coupled to a 5'-hydroxyl group of an oligonucleotide during synthesis using conventional chemistry. A primary amino group is the preferred group for attachment to monofunctional or multifunctional reagents and its attachment via a hexyl arm is preferred. The reagents for attachment of a primary spacer arm terminating in a primary amine are commercially available. Starting materials suitable for use in the present invention are described in WO-A-86/07363; Nucl. Acids Res. 15:3131 (1987); Nucl. Acids Res. 15:2891 (1987); and Nucl. Acids Res. 14:7985 (1986).

Vorzugsweise wird hierin ein Oligonukleotid verwendet, das eine 5'-Endstruktur hat wie z.B. Preferably, an oligonucleotide is used herein which has a 5'-end structure such as

als ein Distanzarm, n ist 2 bis 12 einschließlich, vorzugsweise 6; X ist -NH- oder -NHC:O (CH&sub2;)m NH-, vorzugsweise -NH-; worin m 2 bis 12 ist einschließlich; Y ist ein 4,6-Dichlortriazin (bevorzugt) oder eine reaktive Thiol (Sulfhydryl) Einheit; und A ist ein Oligonucleotid, im Bereich von zwischen etwa 9 bis 50 Basen, vorzugsweise zwischen etwa 15 bis 30 Basen, mit lediglich der 5'- Hydroxylgruppe die modifiziert werden muß für die Anknüpfung.as a spacer arm, n is 2 to 12 inclusive, preferably 6; X is -NH- or -NHC:O(CH2)m NH-, preferably -NH-; where m is 2 to 12 inclusive; Y is a 4,6-dichlorotriazine (preferred) or a reactive thiol (sulfhydryl) moiety; and A is an oligonucleotide, ranging from between about 9 to 50 bases, preferably between about 15 to 30 bases, with only the 5'-hydroxyl group needing to be modified for attachment.

Alternativ dazu kann ein Oligonukleotid modifiziert werden an dem 3'-Ende mit einem Distanzarm, der eine blockierte Aminogruppe enthält. Dies kann erfolgen durch Ausführung einer DNA-Synthese an einem festen Träger, der ein konjugiertes Ribonukleotid enthält. Nach der Entfernung von dem festen Träger wird ein DNA Oligonukleotid erhalten, das ein einziges 3'-End-Ribonukleotid enthält. Dieses kann modifiziert werden mit einem Distanzarm, der ein nucleophiles Amin enthält, beispielsweise durch oxidieren des Ribonukleotid cis-Glycols mit Periodat; behandeln des Oligonukleotids, das so modifiziert wurde mit beispielsweise Butandiamin zur Bildung einer Schiffschen Base und behandeln mit Natriumborhydrid oder Cyanoborhydrid zur Bildung eines stabilen reduzierten Derivats einer Schiffschen Base, in der eines der Amine frei bleibt für eine nachfolgende Konjugation.Alternatively, an oligonucleotide can be modified at the 3' end with a spacer arm containing a blocked amino group. This can be done by carrying out DNA synthesis on a solid support containing a conjugated ribonucleotide. After removal from the solid support, a DNA oligonucleotide containing a single 3' end ribonucleotide is obtained. This can be modified with a spacer arm containing a nucleophilic amine, for example by oxidizing the ribonucleotide cis-glycol with periodate; treating the oligonucleotide so modified with, for example, butanediamine to form a Schiff base and treating with sodium borohydride or cyanoborohydride to form a stable reduced derivative of a Schiff base in which one of the amines remains free for subsequent conjugation.

Die ausgewählten Oligonukleotide können dann aktiviert werden mit einem monofunktionalen oder multifunktionalen Reagenz. "Aktivierte Oligonukleotide" bedeutet im allgemeinen Oligonukleotide, die mit einer chemischen Verbindung reagiert haben und chemisch aktiv gemacht wurden. So wie hierin verwendet bezieht sich "aktivierbar" auf das Potential chemisch reaktiv zu werden. Multifunktionelle Reagenzien umfassen, ohne darauf beschränkt zu sein, homotrifunktionale, heterotrifunktionale, homobifunktionale und heterobifunktionale Reagenzien.The selected oligonucleotides can then be activated with a monofunctional or multifunctional reagent. "Activated oligonucleotides" generally means oligonucleotides that react with a chemical compound and have been made chemically active. As used herein, "activatable" refers to the potential to become chemically reactive. Multifunctional reagents include, but are not limited to, homotrifunctional, heterotrifunctional, homobifunctional, and heterobifunctional reagents.

Aktivierte Oligonukleotide können an polymerbeschichtete feste Träger geknüpft werden gemäß der nachfolgenden Chemie. Im allgemeinen gibt es zwei Arten mittels derer das Oligonukleotid kovalent an das Polymere an diesem Punkt angebunden werden kann. Ein Oligonukleotid mit einem Aminschwanz kann aktiviert werden durch ein monofunktionales oder multifunktionales Reagenz, beispielsweise Cyanurchlorid, wodurch ein Alkylaminodichlortriazin gebildet wird, welches dann reaktiv ist gegenüber einem aminhaltigen Polymeren. Alternativ kann das Polymer an der Oberfläche der Kugel aktiviert werden mit einem Reagenz, vorzugsweise mit dem homotrifunktionalen Reagenz Cyanurchlorid, welches aktiv ist gegenüber dem Aminschwanz oder einem Aminderivaten des Oligonukleotids.Activated oligonucleotides can be attached to polymer-coated solid supports according to the chemistry below. In general, there are two ways by which the oligonucleotide can be covalently attached to the polymer at that point. An oligonucleotide with an amine tail can be activated by a monofunctional or multifunctional reagent, for example cyanuric chloride, to form an alkylaminodichlorotriazine which is then reactive towards an amine-containing polymer. Alternatively, the polymer on the surface of the bead can be activated with a reagent, preferably the homotrifunctional reagent cyanuric chloride, which is active towards the amine tail or an amine derivative of the oligonucleotide.

Obwohl Cyanurchlorid&sub1; ein homotrifunktionales Reagenz bevorzugt ist, können auch andere Reagenzien verwendet werden. Beispielsweise ist N-Succinimidyl-4-(Iodacetamido)- Benzoat (SIAB) ein heterobifunktionales Reagenz und Disuccinimidylsuberat ist ein homobifunktionales Reagenz. Wenn Carboxylgruppen involviert sind, kann das Heterobifunktionale Reagenz 1-Ethyl-3-(Dimethylaminopropyl)- Carbodiimid verwendet werden. Andere ähnliche monofunktionale und multifunktionale (heteromultifunktionale und homomultifunktionale) Reagenzien sind für die Verwendung in den Verfahren gemäß der vorliegenden Erfindung eingeschlossen.Although cyanuric chloride₁ is a homotrifunctional reagent, other reagents may also be used. For example, N-succinimidyl 4-(iodoacetamido)-benzoate (SIAB) is a heterobifunctional reagent and disuccinimidyl suberate is a homobifunctional reagent. When carboxyl groups are involved, the heterobifunctional reagent 1-ethyl-3-(dimethylaminopropyl)-carbodiimide may be used. Other similar monofunctional and multifunctional (heteromultifunctional and homomultifunctional) reagents are included for use in the methods of the present invention.

Die Chemie die in der vorliegenden Erfindung angewandt wird resultiert in der selektiven Aktivierung einer Aminogruppe an einem Oligonukleotid, ohne Modifikation irgendeiner der Purin und Pyrimidinbasen des Oligonukleotids, wie unten in Beispiel 1 demonstriert wird. Die Anbringung des aminhaltigen Polymeren an die Kugeloberfläche und die kovalente Immobilisierung eines aktivierten Einfangoligonukleotids an eine solche Oberfläche erhöht die Geschwindigkeit oder das Ausmaß des Einfangens der Zielnukleinsäure 5 bis 25 fach verglichen mit Diaminverbindungen, beispielsweise Hexandiamin. Außerdem wird die nicht spezifische Bindung eines biologischen Materials an die Oberfläche der Kugel wesentlich reduziert.The chemistry employed in the present invention results in the selective activation of an amino group on an oligonucleotide without modification of any of the purine and pyrimidine bases of the oligonucleotide, as demonstrated below in Example 1. Attachment of the amine-containing polymer to the bead surface and covalent immobilization of an activated capture oligonucleotide to such a surface increases the rate or extent of capture of the target nucleic acid 5 to 25 fold compared to diamine compounds, e.g., hexanediamine. In addition, nonspecific binding of a biological material to the surface of the bead is substantially reduced.

Die bevorzugte Chemie verwendet Cyanurchlorid (d.h. 2, 4, 6- Trichlortriazin). Die Chemie der Cyanurchloridreaktion ist wie folgt: The preferred chemistry uses cyanuric chloride (i.e. 2, 4, 6- trichlorotriazine). The chemistry of the cyanuric chloride reaction is as follows:

worin R ein Oligonukleotid ist und vorzugsweise die Struktur hat wie sie für ein 5'-Aminohexyloligonukleotid beschrieben wurde.wherein R is an oligonucleotide and preferably has the structure as described for a 5'-aminohexyl oligonucleotide.

Oligonukleotide die eine 5'- oder 3'- verknüpfte (über einen Hexylarm) nucleophile Amineinheit enthalten (oder interne Aminoalkylgruppen die substituiert sind an Pyrimidine oder Purinbasen) werden mit einem Überschuß, vorzugsweise etwa dem 50 fachen bis etwa dem 200 fachen Überschuß, weiter vorzugsweise dem 125 fachen Überschuß an recrystallinisiertem Cyanurchlorid bei vorzugsweise 15-50º C, weiter vorzugsweise 19-25º C, in einem Teil organisches Lösungsmittel für eine bevorzugte Zeitdauer von etwa 30 Minuten bis etwa 6 Stunden, weiter vorzugsweise von etwa 1 bis 2 Stunden zur Reaktion gebracht.Oligonucleotides containing a 5'- or 3'-linked (via a hexyl arm) nucleophilic amine moiety (or internal aminoalkyl groups substituted on pyrimidines or purine bases) are reacted with an excess, preferably about 50-fold to about 200-fold excess, more preferably 125-fold excess, of recrystallized cyanuric chloride at preferably 15-50°C, more preferably 19-25°C, in one part organic solvent for a preferred period of time of about 30 minutes to about 6 hours, more preferably about 1 to 2 hours.

Wenn einmal ein Oligonukleotid aktiviert wurde mit Cyanurchlorid, kann es kovalent mit Molekülen verknüpft werden, die Amine enthalten. Genauer, zusätzlich zu kovalenten Anknüpfungen an feste Träger wie sie oben diskutiert wurden, können Dichlortriazin-Oligonukleotide als Electrophile dienen für eine kovalente Anknüpfung an viele Zusammensetzungen, einschließlich, ohne darauf beschränkt zu sein: Proteine, wie z.B. Enzyme, Antikörper, Lectine und Proteinträger die zur Erzeugung von Antikörpern verwendet werden; von Nucleophilen abgeleitete Oligonukleotide, wie z.B. Oligonukleotide mit 5'- oder 3'-Aminohexyl-Schwänzen; nucleophilhaltige Polymere, wie z.B. Poly (Ethylenimin), Polyallylamine und Polyvinylamine; Verbindungen mit niederem Molekulargewicht, die Nucleophile enthalten, wie z.B. radioaktive Markierer, Chemilumineszenz-Markierer, Fluoreszenz-Markierer, farbige Markierer und immunogene Markierer; etc. Dichlortriazin-Oligonukleotide sind von der vorliegenden Erfindung umfaßt, ebenso wie Prozesse zur Aktivierung von Oligonukleotiden mit Cyanurchlorid zur Bildung von Dichlortriazin-Oligonukleotiden wie sie weiter unten diskutiert werden.Once an oligonucleotide has been activated with cyanuric chloride, it can be covalently linked to molecules containing amines. Specifically, in addition to covalent attachments to solid supports as discussed above, dichlorotriazine oligonucleotides can serve as electrophiles for covalent attachment to many compounds, including, but not limited to: proteins, such as enzymes, antibodies, lectins, and protein carriers used to generate antibodies; nucleophile-derived oligonucleotides, such as oligonucleotides with 5'- or 3'-aminohexyl tails; nucleophile-containing polymers, such as poly(ethyleneimine), polyallylamines, and polyvinylamines; Low molecular weight compounds containing nucleophiles such as radioactive labels, chemiluminescent labels, fluorescent labels, colored labels, and immunogenic labels; etc. Dichlorotriazine oligonucleotides are encompassed by the present invention, as are processes for activating oligonucleotides with cyanuric chloride to form dichlorotriazine oligonucleotides as discussed below.

Das nicht abreagierte Cyanurchlorid kann entfernt werden durch Ausschlußchromatographie oder Ultrafiltration, und die Kugel und das abgeleitete Oligonukleotid, das daran konjugiert ist, werden zusammen vermischt und bei vorzugsweise 20 bis 50º C eine bis 24 Stunden lang inkubiert. Die restlichen (nicht abreagierten) Amine an der Kugeloberfläche können blockiert werden (verdeckt werden) mit einem Agenz wie z.B. Succinanhydrid, vorzugsweise in N- Methylpyrrolidon in der Gegenwart einer geeigneten Base wie z.B. Natriumborat, um die Oberfläche kompatibel zu machen (negativ geladen) für die Nukleinsäure-Hybridisierung. Ein solches Blockieren von Aminen tritt während einer Acylierungsreaktion auf oder einer Reaktion von Aminen mit einem aktivierten Ester, was zu einer nicht aktivierbaren Einheit führt. Es ist festzustellen, daß die Fähigkeit der Kugeloberfläche gegeben ist, chemisch derivatisiert zu werden, so daß eine positive, negative oder neutrale Ladung an der Kugel angebracht werden kann.The unreacted cyanuric chloride can be removed by size exclusion chromatography or ultrafiltration, and the bead and the derived oligonucleotide conjugated thereto are mixed together and incubated at preferably 20 to 50°C for one to 24 hours. The remaining (unreacted) amines on the bead surface can be blocked (capped) with an agent such as succinic anhydride, preferably in N-methylpyrrolidone in the presence of a suitable base such as sodium borate, to make the surface compatible (negatively charged) for nucleic acid hybridization. Such blocking of amines occurs during an acylation reaction or a reaction of amines with an activated ester, resulting in a non-activatable unit. It is noted that the sphere surface has the ability to be chemically derivatized so that a positive, negative or neutral charge can be attached to the sphere.

Die vorliegende Erfindung umfaßt auch Tauchstäbe, die geeignet sind in Nukleinsäure-Hybridisierungen und einen nicht porösen festen Träger umfassen und Mittel für die Anknüpfung einer Kugel. Nicht poröse feste Träger sind im Stand der Technik bekannt und die vorliegende Erfindung betrifft das Anknüpfen einer Kugel an einen Tauchstab. Ein Beispiel für eine Kugel-Anknüpfung ist die Gegenwart einer Perforation oder von Perforationen (oder eine Vertiefung oder Vertiefungen) in dem Tauchstab, wo die Kugeln angebunden werden können. Vorzugsweise werden Perforationen verwendet und die Kugeln werden über einen Drucksitz in dem Umfang der Öffnung angeknüpft. Eine solche Druckanbindung kann beispielsweise erfolgen, wenn der Umfang der Perforation (oder Vertiefung) geringfügig geringer ist als der Umfang der Kugel, so daß die Kugel in ihren Sitz gepreßt wird.The present invention also includes dipsticks useful in nucleic acid hybridizations comprising a non-porous solid support and means for attaching a bead. Non-porous solid supports are known in the art and the present invention relates to attaching a bead to a dipstick. An example of bead attachment is the presence of a perforation or perforations (or a depression or depressions) in the dipstick where the beads can be attached. Preferably, perforations are used and the beads are attached via a pressure fit in the perimeter of the opening. Such pressure attachment can be made, for example, if the perimeter of the perforation (or depression) is slightly less than the perimeter of the bead so that the bead is pressed into its seat.

Bevorzugte Kugeln sind unten aufgeführt und können kovalent gebunden werden entweder direkt oder über einen Distanzarm an aktivierte Oligonukleotide der gleichen oder einer unterschiedlichen Sequenz über eine gegebene Kugel, wie oben ebenfalls beschrieben wurde.Preferred beads are listed below and can be covalently linked either directly or via a spacer arm to activated oligonucleotides of the same or a different sequence on a given bead, as also described above.

Der Tauchstab kann mehr als eine Kugel enthalten, vorzugsweise von etwa 2 bis 10, jede in ihrer eigenen Öffnung, und vorzugsweise untergebracht in einer Reihe entlang einer Kante des Tauchstabs. Ein solcher Tauchstab kann als eine Indikatorkarte dienen, bei der eine Vielzahl von Kugeln kovalent an Oligonukleotide mit verschiedenen Sequenzen oder Spezifitäten gebunden sind und nahe nebeneinander in Reihe an einem Tauchstab mit einer Vielzahl von Stellen angeordnet werden können, mittels dessen eine Vielzahl von Pathogenen in einer einzigen biologischen Probe bestimmt werden kann. Eine einzelne Kugel kann Oligonukleotide mit mehr als einer Nukleinsäuresequenz enthalten, beispielsweise Sequenzen aus verwandten Organismen, oder eine Kugel kann nur Oligonukleotide mit einer vorgegebenen Nukleinsäuresequenz enthalten.The dipstick may contain more than one bead, preferably from about 2 to 10, each in its own aperture, and preferably housed in a row along one edge of the dipstick. Such a dipstick may serve as an indicator card in which a plurality of beads are covalently bound to oligonucleotides having different sequences or specificities and may be arranged in close proximity in a row on a dipstick having a plurality of locations by which a plurality of pathogens in a single biological sample may be determined. A single bead may Oligonucleotides may contain more than one nucleic acid sequence, for example sequences from related organisms, or a bead may contain only oligonucleotides with a given nucleic acid sequence.

Zahlreiche Organismen und Zelltypen, einschließlich pathogene und nicht pathogene Einheiten, können auf diese Weise aus verschiedenartigen Typen von biologischen Proben bestimmt werden. Die Organismen schließen ein Bakterien und Viren sowie andere Mikroorganismen, die Zelltypen umfassen beispielsweise diejenigen, die für Erbkrankheiten und metabolische Störungen verantwortlich sind. Viele andere Anwendungen zur Bestimmung sind für den durchschnittlichen Fachmann offensichtlich. Beispielsweise können bakterielle Agenzien, die angeblich Periodontitis verursachen, wie z.B. Actinobazillus Actinomycetemcomitans, Bacteroides gingivalis, Bateroides forsythus, Bacteroides intermedius, Eikenella corrodens, Fusobacterum nucleatum und Wolinella recta, identifiziert werden.Numerous organisms and cell types, including pathogenic and non-pathogenic entities, can be identified in this way from various types of biological samples. The organisms include bacteria and viruses, as well as other microorganisms, the cell types including, for example, those responsible for hereditary diseases and metabolic disorders. Many other applications for identification will be obvious to the average person skilled in the art. For example, bacterial agents believed to cause periodontitis, such as Actinobacillus actinomycetemcomitans, Bacteroides gingivalis, Bacteroides forsythus, Bacteroides intermedius, Eikenella corrodens, Fusobacterum nucleatum and Wolinella recta, can be identified.

Es ist für den durchschnittlichen Fachmann offensichtlich, daß viele andere Anwendungen dieser Tauchstäbe möglich sind, auch wenn die vorliegende Erfindung von Nukleinsäure- Hybridisierungsuntersuchungen spricht. Irgendein Mitglied eines Ligandenpaars kann an Kugeln in dem Tauchstab angebunden werden, und der Tauchstab kann dann verwendet werden, um das korrespondierende Ligandglied zu identifizieren. Beispielsweise könnten Antigene oder Antikörper an Kugeln gebunden werden, wie dies oben beschrieben wurde, an einem Tauchstab und dann können ihre korrespondierenden Antikörper oder Antigene jeweils bestimmt werden. Auf ähnliche Weise können Biotin und Streptavidin verwendet werden.It will be apparent to one of ordinary skill in the art that many other applications of these dipsticks are possible, even though the present invention is directed to nucleic acid hybridization studies. Any member of a ligand pair can be attached to beads in the dipstick and the dipstick can then be used to identify the corresponding ligand member. For example, antigens or antibodies could be attached to beads as described above on a dipstick and then their corresponding antibodies or antigens can be determined, respectively. Biotin and streptavidin can be used in a similar manner.

Weiterhin schließt die vorliegende Erfindung auch Verfahren ein für die Bestimmung von Nukleinsäuren, bei denen eine Zusammensetzung umfassend eine polymerbeschichtete Kugel, die vorzugsweise aktivierbare Amingruppen hat, kovalent gebunden an ein aktiviertes Oligonukleotid, mit einer Zielnukleinsäure unter geeigneten Bedingungen für die Hybridisierung in Kontakt gebracht wird und das hybridisierte Produkt bestimmt wird. Solche Verfahren können in einer Mikrotitervertiefung, einer Durchflußkolonne und unter Verwendung eines Tauchstabs erfolgen, wie dies oben beschrieben wurde.Furthermore, the present invention also includes methods for the determination of nucleic acids in which a composition comprising a polymer-coated bead, which preferably has activatable amine groups, is covalently bound to an activated oligonucleotide, is contacted with a target nucleic acid under suitable conditions for hybridization and the hybridized product is determined. Such methods can be carried out in a microtiter well, a flow column and using a dipstick as described above.

Die Zielnukleinsäure ist im allgemeinen ein Polynukleotid mit einer durchschnittlichen Länge von etwa 20 bis 20.000 Basen oder Nukleotiden in der Länge. Geeignete Bedingungen für die Hybridisierung sind strenge Bedingungen bei denen keine Fehlbildung bei der Basenpaarung auftritt und das hybridisierte Produkt eine perfekte Basenpaarung aufweist.The target nucleic acid is generally a polynucleotide with an average length of about 20 to 20,000 bases or nucleotides in length. Suitable conditions for hybridization are stringent conditions where no base pairing mismatch occurs and the hybridized product exhibits perfect base pairing.

Eine besondere Hybridisierungstechnik ist für die Erfindung nicht wesentlich und ein durchschnittlicher Fachmann ist sich der verschiedenen Möglichkeiten solcher Techniken bewußt. Hybridisierungstechniken sind allgemein beschrieben bei Hames, B.D., et al. (ed.), Nucleic Acid Hybridization, A Practical Approach, IRL Press, New York (1985). Soweit Verbesserungen in Hybridisierungstechniken erfolgen, können sie ohne weiteres auf die vorliegende Erfindung angewandt werden.A particular hybridization technique is not essential to the invention and one of ordinary skill in the art will be aware of the various possibilities of such techniques. Hybridization techniques are generally described in Hames, B.D., et al. (ed.), Nucleic Acid Hybridization, A Practical Approach, IRL Press, New York (1985). As improvements in hybridization techniques are made, they can be readily applied to the present invention.

Sandwich Untersuchungen können vorzugsweise in dem vorliegenden Verfahren angewandt werden, wobei die Zielnukleinsäure, die zu bestimmen ist, entweder extrahiert wird oder sich in der Originalprobe befindet und sequestriert wird (eingefangen) an dem festen Träger, wie z.B. an Kugeln, durch Hybridisierung (d.h. Paaren der Komplementären Basen) an Einfangoligonukleotidsonden, die kovalent an der Oberfläche des Trägers immobilisiert sind. Die eingefangene Nukleinsäure wird dann hybridisiert an eine Signaloligonukleotidsonde oder alternativ kann dieser Schritt gleichzeitig durchgeführt werden mit dem Einfangen des Ziels, wobei man beispielsweise die Signalsonde in die Hybridisierungslösung mit einbringt. Die Signalsonde kann beispielsweise mit Biotin markiert werden. Dies führt zu einem "Sandwich" aus der Einfangoligonukleotidsonde: Zielnukleinsäure: Signaloligonukleotidsonde, was zu einer Sandwich Untersuchung führt. Der feste Träger wird dann gewaschen zur Entfernung von unhybridisiertem Material und die markierte Nukleinsäure wird dann gemessen im Einklang mit bestimmbaren Charakteristika des Markiermittels.Sandwich assays can preferably be used in the present method, wherein the target nucleic acid to be determined is either extracted or present in the original sample and is sequestered (captured) on the solid support, such as beads, by hybridization (i.e. pairing of complementary bases) to capture oligonucleotide probes covalently immobilized on the surface of the support. The captured nucleic acid is then hybridized to a signal oligonucleotide probe or alternatively this step can be performed simultaneously with the capture of the target, for example by including the signal probe in the hybridization solution. The signal probe can be labeled with, for example, biotin. This leads to a "sandwich" of the capture oligonucleotide probe: target nucleic acid: signal oligonucleotide probe, resulting in a sandwich assay. The solid support is then washed to remove unhybridized material and the labeled nucleic acid is then measured according to determinable characteristics of the label.

Verschiedene Markierer können in Hybridisierungsuntersuchungen für diese Erfindung geeignet sein. Solche Markierer fungieren als Berichtsgruppen (Reportergruppen) für die Bestimmung der Duplexbildung zwischen der Zielsequenz und ihrer komplementären Signalsequenz. Eine Reportergruppe wie sie hierin verwendet wird ist eine Gruppe die eine chemische oder physikalische Eigenschaft hat, die gemessen oder bestimmt werden kann. Die Bestimmbarkeit kann durch solche Charakteristika erzielt werden wie eine Farbänderung, Lumineszenz, Fluoreszenz oder Radioaktivität, oder erzeugt werden durch die Fähigkeit der Reportergruppe als eine Ligandenerkennungsstelle zu dienen. Irgendeine Hapten oder Antigenverbindung kann verwendet werden in Komibination mit einem geeigneten markierten Antikörper.Various labels may be useful in hybridization assays for this invention. Such labels function as reporting groups for determining duplex formation between the target sequence and its complementary signal sequence. A reporter group as used herein is a group that has a chemical or physical property that can be measured or determined. The detectability may be achieved by such characteristics as a color change, luminescence, fluorescence, or radioactivity, or may be created by the ability of the reporter group to serve as a ligand recognition site. Any hapten or antigen compound may be used in combination with an appropriate labeled antibody.

Enzyme die als Reportergruppen interessant sind, sind in erster Linie Hydrolasen, insbesondere Phosphotasen, Esterasen, Ureasen und Glycosidasen oder Oxidoreductasen, insbesondere Peroxidasen. Fluoreszierende Verbindungen umfassen Fluorescein und seine Derivate, Rhodamin und seine Derivate, Dansyl, Umbelliferon usw. Chemilumineszenzstoffe umfassen Luciferin, Luminol und Oxetandione. Die obige Liste ist nicht vollständig und die Auswahl des Markiermittels hängt ab von der erforderlichen Sensibilität, von der Leichtigkeit der Konjugation mit der Sonde, Stabilitätserfordernissen und einer geeigneten Instrumentierung.Enzymes of interest as reporter groups are primarily hydrolases, especially phosphotases, esterases, ureases and glycosidases, or oxidoreductases, especially peroxidases. Fluorescent compounds include fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, etc. Chemiluminescent compounds include luciferin, luminol and oxetanediones. The above list is not exhaustive and the choice of labeling agent depends on the sensitivity required, the ease of conjugation to the probe, stability requirements and appropriate instrumentation.

Es versteht sich, daß die obige Beschreibung und der nachfolgende experimentelle Abschnitt nur erläuternden und nicht beschränkenden Charakter haben. Viele Variationen und Anwendungen ergeben sich ohne weiteres für einen durchschnittlichen Fachmann, wenn er diese Beschreibung liest.It is understood that the above description and the following experimental section are only illustrative and are not limiting in nature. Many variations and applications will readily occur to an average person skilled in the art upon reading this description.

In dem nachfolgenden experimentellen Abschnitt beschreibt Beispiel 1 die selektive Aktivierung von Oligonukleotiden die einen Aminohexylschwanz haben mit Cyanurchlorid. Beispiel 2 beschreibt den Vergleich von Nylonkugeln die von verschiedenen Diaminen und Poly (Ethylenimin) abgeleitet sind, ausgedrückt als Fähigkeit des festen Trägers, die Hybridisierung zu fördern. Beispiel 3 beschreibt die Verwendung eines Oligonukleotids abgeleitet von Nylonkugeln in einer Sandwich Untersuchung, in der die Hybridisierung bestimmt wird unter Verwendung eines unlöslichen kolorimetrischen Substrats. Beispiel 4 beschreibt die Verwendung von Nylonkugeln, die von Oligonukleotiden abgeleitet sind in einer Sandwich Untersuchung, bei der das Ziel in komplexen biologischen Proben bestimmt wird.In the experimental section below, Example 1 describes the selective activation of oligonucleotides having an aminohexyl tail with cyanuric chloride. Example 2 describes the comparison of nylon beads derived from various diamines and poly(ethyleneimine), expressed as the ability of the solid support to promote hybridization. Example 3 describes the use of an oligonucleotide derived from nylon beads in a sandwich assay in which hybridization is determined using an insoluble colorimetric substrate. Example 4 describes the use of nylon beads derived from oligonucleotides in a sandwich assay in which the target is determined in complex biological samples.

Beispiel 5 beschreibt die Verwendung von von Oligonukleotiden abgeleiteten Nylonkugeln in einem Sandwich, bei dem das Ziel durch Chemilumineszenz bestimmt wird. Beispiel 6 beschreibt die Verwendung von von Oligonukleotiden abgeleiteten Nylonkugeln, die an einem Tauchstab immobilisiert sind, um eine Platte oder Karte mit Vielfachbestimmungsstellen zu bilden.Example 5 describes the use of oligonucleotide-derived nylon beads in a sandwich where the target is determined by chemiluminescence. Example 6 describes the use of oligonucleotide-derived nylon beads immobilized to a dipstick to form a plate or card with multiple target sites.

Der nachfolgende Abschnitt Materialien und Methoden betrifft die oben zusammenfassend angegebenen Beispiele 1 bis 6.The following section Materials and Methods concerns Examples 1 to 6 summarized above.

Materialienmaterials

APB Puffer ist 0,18 M NaCl, 0,05 M Tris-HCl pH = 7,6, 5 mM EDTA und 0,5% Tween 20.APB buffer is 0.18 M NaCl, 0.05 M Tris-HCl pH = 7.6, 5 mM EDTA and 0.5% Tween 20.

TMNZ Puffer ist 0,05 M Tris pH = 9,5, 1 mM MgCl&sub2;, 0,5 mM ZnCl&sub2;.TMNZ buffer is 0.05 M Tris pH = 9.5, 1 mM MgCl₂, 0.5 mM ZnCl₂.

FW (Filterwäsche) ist 0,09 M Natriumchlorid, 50 mM Tris pH 7,6, 25 mM EDTA.FW (filter wash) is 0.09 M sodium chloride, 50 mM Tris pH 7.6, 25 mM EDTA.

SDS/FW ist FW und 0,1 % Natriumdodecylsulfat (SDS).SDS/FW is FW and 0.1% sodium dodecyl sulfate (SDS).

HRP (Meerrettichperoxidase) Substratlösung ist 0,1 M Natriumcitrat pH 6,5, 0,2 M NaPhosphat, 0,5 mg/ml.HRP (horseradish peroxidase) substrate solution is 0.1 M sodium citrate pH 6.5, 0.2 M NaPhosphate, 0.5 mg/ml.

4-Methoxy-1-Naphthol, 0,02 mg/ml 3-Methyl-2-Benzothiazolinon Hydrazon und 0,0135 % Wasserstoffperoxid.4-methoxy-1-naphthol, 0.02 mg/ml 3-methyl-2-benzothiazolinone hydrazone and 0.0135% hydrogen peroxide.

AP (Alkaliphosphatase) Substratlösung ist 1 mM 5-Brom-4- Chlorindoyl-3-Phosphat, 1 mM nitro Blau tetrazolium und 0,01 % Tween 20 in TMNZ.AP (alkali phosphatase) substrate solution is 1 mM 5-bromo-4-chloroindoyl-3-phosphate, 1 mM nitro blue tetrazolium and 0.01% Tween 20 in TMNZ.

Lysis und Hybridisierungslösung ist 3 M Guanidinium Thiocyanat, 2 % N-Lauroylsarcosin (Sarcosyl), 50 mM Tris pH 7,6, 25 mM EDTA.Lysis and hybridization solution is 3 M guanidinium thiocyanate, 2% N-lauroylsarcosine (sarcosyl), 50 mM Tris pH 7.6, 25 mM EDTA.

CAP Puffer ist 0,1 M NaCitrat pH = 6,5 und 0,2 M Naphosphat.CAP buffer is 0.1 M Na citrate pH = 6.5 and 0.2 M Na phosphate.

Das Fluoreszenzsubstrat für Alkaliphosphatase ist 0,02 mM 4- Methyl-Umbelliferonphosphat, 0,05 M Tris pH = 9,5, 1 mM MgCl&sub2;, 0,5 mM ZnCl&sub2;.The fluorescent substrate for alkaline phosphatase is 0.02 mM 4-methyl-umbelliferone phosphate, 0.05 M Tris pH = 9.5, 1 mM MgCl2, 0.5 mM ZnCl2.

Das Chemilumineszenzsubstrat für Alkaliphosphatase war ein vorbereiteter Cocktail von Lumigen, Inc. (Detroit, MI). Oligonukleotidsequenzen The chemiluminescent substrate for alkaline phosphatase was a prepared cocktail from Lumigen, Inc. (Detroit, MI). Oligonucleotide sequences

Poly (Ethylenimin) wurde erhalten von Polysciences (Warrington, PA).Poly(ethyleneimine) was obtained from Polysciences (Warrington, PA).

Polierte oder Unpolierte Nylonkugeln wurden erhalten von Precision Ball Company (Chicago,IL) und The Hoover Group (Sault St. Marie, MI.)Polished or unpolished nylon balls were obtained from Precision Ball Company (Chicago,IL) and The Hoover Group (Sault St. Marie, MI.)

Triethyloxoniumtetrafluoroborat, Hexandiamin, Phenylendiamin, Succinsäureanhydrid und N-Methyl-Pyrrolidon (N-Methyl- Pyrrolidon, M-Pyrol) wurden erhalten von Aldrich Chemical (Milwaukee, IL).Triethyloxonium tetrafluoroborate, hexanediamine, phenylenediamine, succinic anhydride and N-methyl-pyrrolidone (N-methyl- pyrrolidone, M-pyrol) were obtained from Aldrich Chemical (Milwaukee, IL).

N-Succinimidyl 4-(Iodacetamido)-Benzoat (SIAB) und Tween 20 wurden erhalten von Pierce (Rockford, IL).N-Succinimidyl 4-(iodoacetamido)benzoate (SIAB) and Tween 20 were obtained from Pierce (Rockford, IL).

Guanidiumisothioscyanat (GuSCN) wurden erhalten von Kodak (Rochester, NY).Guanidium isothiocyanate (GuSCN) was obtained from Kodak (Rochester, NY).

Nylonmembran, Nytran , wurde erhalten von Schleicher & Schuell (Keene, NH).Nylon membrane, Nytran , was obtained from Schleicher & Schuell (Keene, NH).

Die Di- und Triamine EDR-148, ED-400, ED-6000 und T-3000 waren ein Geschenk von Texaco Chemical Company, (Housten, TX).The di- and triamines EDR-148, ED-400, ED-6000 and T-3000 were a gift from Texaco Chemical Company, (Housten, TX).

VerfahrenProceedings Oligonukleotidsynthese:Oligonucleotide synthesis:

Oligonukleotide komplementär zu Abschnitten die konserviert wurden oder hypervariablen Abschnitten der 16S-Ribosomal RNA von entweder Actinobazillus Actinomycetemcomitans (Aa), Bacteroides gingivalis (Bg), Bacteroides intermedius (Bi), Eikenella corrodens (Ek), Fusobacterium nucleatum (Fn), oder Wolinella recta (Wr) wurden synthetisiert unter Verwendung der Phosporamiditchemie an entweder einem ABI 380B oder einem automatischen Milligen 7500 DNA Synthesizer. Die Oligonukleotide wurden hergestellt unter Verwendung der Standardphosphoramiditchemie die von dem Verkäufer geliefert wurde oder der H-Phosphonatchemie. Geeignet blockierte dA, dG, dC und T-Phosphoramidite sind in dieser Form kommerziell erhältlich und synthetische Nucleoside können ohne weiteres in die geeignete Form gebracht werden. Die Oligonukleotide wurden gereinigt durch Anpassung von Standardmethoden. Oligonukleotide mit 5'-Tritylgruppen wurden an HPLC chromatographiert unter Verwendung einer 12 um, 300 Å Rainin (Woburn, MA) Dynamax C-8 4.2x250 mm Umkehrphasenkolonne unter Verwendung eines Gradienten von 15 % bis 55 % MeCN in 0,1 N Et&sub3;NH&spplus;OAc&supmin;, pH 7,0, 20 Minuten lang. Wenn die Detritylierung ausgeführt war, wurden die Oligonukleotide weiter gereinigt durch Gelausschlußchromatographie. Analytische Untersuchungen der Qualität der Oligonukleotide wurden durchgeführt mit einer Toso-Haas DEAE-NPR Kolonne bei alkalischem pH und mittels Polyacrylamid-Gel-Elektrophorese (PAGE).Oligonucleotides complementary to regions of conserved or hypervariable regions of the 16S ribosomal RNA of either Actinobacillus actinomycetemcomitans (Aa), Bacteroides gingivalis (Bg), Bacteroides intermedius (Bi), Eikenella corrodens (Ek), Fusobacterium nucleatum (Fn), or Wolinella recta (Wr) were synthesized using phosphoramidite chemistry on either an ABI 380B or a Milligen 7500 automated DNA synthesizer. Oligonucleotides were prepared using the Standard phosphoramidite chemistry supplied by the vendor or H-phosphonate chemistry. Appropriately blocked dA, dG, dC and T-phosphoramidites are commercially available in this form and synthetic nucleosides can be readily made into the appropriate form. Oligonucleotides were purified by adaptation of standard methods. Oligonucleotides containing 5'-trityl groups were chromatographed on HPLC using a 12 µm, 300 Å Rainin (Woburn, MA) Dynamax C-8 4.2x250 mm reversed phase column using a gradient of 15% to 55% MeCN in 0.1 N Et₃NH⁺OAc⁻, pH 7.0, for 20 minutes. Once detritylation was accomplished, oligonucleotides were further purified by gel exclusion chromatography. Analytical investigations of the quality of the oligonucleotides were performed using a Toso-Haas DEAE-NPR column at alkaline pH and by polyacrylamide gel electrophoresis (PAGE).

Herstellung der polymerbeschichteten Nylonkugel:Manufacturing of the polymer coated nylon ball:

25.000 unpolierte Nylonkugeln mit einem Durchmesser von 0,23 cm (3/32 inch) wurden in einen Kolben gebracht, der 1.800 mm 100 % wasserfreies N-Methyl-Pyrrolidon enthielt und wurden 5 Minuten lang gemischt bei Raumtemperatur. 200 mm an 1 molarem Triethyloxonium Tetrafluoroborat in Dichlormethan wurden zugegeben und die Mischung wurde 30 Minuten lang bei Raumtemperatur gerührt. Die Kugeln wurden dann dekantiert und rasch gewaschen mit 4x500 ml Mengen an 100 % N-Methyl- Pyrrolidon. Die Kugeln wurden dann in eine Lösung überführt, die aus 3 % w/v 10.000 MW Poly (Ethylenimin) bestand, hergestellt aus einer 30 % Lösung an Poly (Ethylenimin), in N-Methyl-Pyrrolidon und gerührt für 12 bis 24 Stunden bei Raumtemperatur. Die Kugeln wurden gewaschen mit 2.000 mm N- Methyl-Pyrrolidon, 1.000 mm SDS/FW und schließlich 10 x 2 Liter destilliertem Wasser. Die Kugeln wurden dann getrocknet unter einem hohem Vakuum für 4 bis 5 Stunden lang unter Verwendung von Wärme. Der Amingehalt der Kugeln wurde bestimmt durch Reaktion mit Picrylsulfonsäure.25,000 unpolished nylon beads of 0.23 cm (3/32 inch) diameter were placed in a flask containing 1800 mm of 100% anhydrous N-methyl-pyrrolidone and were mixed for 5 minutes at room temperature. 200 mm of 1 molar triethyloxonium tetrafluoroborate in dichloromethane was added and the mixture was stirred for 30 minutes at room temperature. The beads were then decanted and washed rapidly with 4x500 mL portions of 100% N-methyl-pyrrolidone. The beads were then transferred to a solution consisting of 3% w/v 10,000 MW poly(ethyleneimine), prepared from a 30% solution of poly(ethyleneimine), in N-methyl pyrrolidone and stirred for 12 to 24 hours at room temperature. The beads were washed with 2,000 mM N-methyl pyrrolidone, 1,000 mM SDS/FW and finally 10 x 2 liters of distilled water. The beads were then dried under a high vacuum for 4 to 5 hours using heat. The amine content of the beads was determined by reaction with picrylsulfonic acid.

Herstellung von Cyanurchlorid-derivatisierten Oligonukleotiden:Preparation of cyanuric chloride-derivatized oligonucleotides:

10 bis 1.000 ug an 5'-Amino verknüpftem Oligonukleotid wurden zur Reaktion gebracht mit einem Überschuß an rekristallisiertem Cyanurchlorid in 10 % N-Methyl-Pyrrolidon in einem Alkalipuffer (pH 8,3 bis 8,5 vorzugsweise) bei 19º bis 25º C für 30 bis 120 Minuten lang. Die abschließenden Reaktionsbedingungen bestanden in 0,15 M Natriumborat bei pH 8,3, 2 mg/ml rekristallisiertes Cyanurchlorid und 500 ug/ml jeweils Aminohexyloligonukleotid. Das nicht reagierte Cyanurchlorid wurde entfernt durch Größenausschlußchromatigraphie an einer G-50 Sephadex (Pharmacia, Uppsala, Schweden) Säule.10 to 1,000 µg of 5'-amino linked oligonucleotide was reacted with an excess of recrystallized cyanuric chloride in 10% N-methyl-pyrrolidone in an alkaline buffer (pH 8.3 to 8.5 preferably) at 19º to 25º C for 30 to 120 minutes. The final reaction conditions consisted of 0.15 M sodium borate at pH 8.3, 2 mg/ml recrystallized cyanuric chloride and 500 µg/ml each aminohexyl oligonucleotide. The unreacted cyanuric chloride was removed by size exclusion chromatography on a G-50 Sephadex (Pharmacia, Uppsala, Sweden) column.

Herstellung von Iodacetamidobenzoylierten Oligonukleotiden:Preparation of iodoacetamidobenzoylated oligonucleotides:

100 bis 1.000 ug an 5'-Amino verknüpftem Oligonukleotid (UP9A) Oligonukleotid wurde zur Reaktion gebracht mit einem Überschuß an N-Succinimidyl 4-(Iodacetamido)-Benzoat (SIAB) in einem Alkalipuffer (vorzugsweise pH 8,0) bei 18º bis 25º C für 30 bis 120 Minuten lang. Das unreagierte SIAB wurde entfernt durch Größenausschlußchromatographie an G-50 Sephadex (Pharmacia, Uppsala, Schweden).100 to 1,000 µg of 5'-amino linked oligonucleotide (UP9A) oligonucleotide was reacted with an excess of N-succinimidyl 4-(iodoacetamido)-benzoate (SIAB) in an alkaline buffer (preferably pH 8.0) at 18º to 25º C for 30 to 120 minutes. The unreacted SIAB was removed by size exclusion chromatography on G-50 Sephadex (Pharmacia, Uppsala, Sweden).

Herstellung von Oligonukleotid derivatisierten Nylonkugeln:Preparation of oligonucleotide derivatized nylon beads:

Für Cyanurchlorid derivatisierte Oligonukleotide wurden Poly (Ehtylenimin) beschichtete Nylonkugeln wie sie oben beschrieben sind in ein Volumen von 0,1 M Natriumborat mit pH 8,3 gebracht entsprechend dem Volumen der Kugeln bei 4º C. Das gereinigte Cyanurchlorid-derivatisierte Oligonukleotid wurde dann zu den Kugeln zugegeben und die Mischung wurde heftig geschüttelt bei Raumtemperatur (19º bis 23º C) für 60 Minuten. Die Kugeln wurden dann zweimal mit 0,1 M Natriumborat bei pH 8,3 gewaschen. Bernsteinsäureanhydrid wurde dann zugegeben bei einer Konzentration von 10 mg/ml in 90 % N-Methyl-Pyrrolidon, 10 % 1 M Natriumborat pH 8,3 mit einem Volumen 3 mal so groß wie das Volumen der Kugeln. Die Reaktion ließ man eine Stunde bei Raumtemperatur ablaufen. Die Kugeln wurden dann dreimal gewaschen mit 250 ml an 100 % N-Methyl-Pyrrolidon, zweimal mit destilliertem Wasser, fünfmal mit 250 ml SDS/FW und dann viermal mit einem Liter destilliertes Wasser. Die Kugeln wurden trocken gelagert oder in 25 mM EDTA. Radioaktivität pro Kugel wurde bestimmt durch Flüssigszintillationszählung.For cyanuric chloride derivatized oligonucleotides, poly(ethylene imine) coated nylon beads as described above were placed in a volume of 0.1 M sodium borate pH 8.3 corresponding to the volume of the beads at 4ºC. The purified cyanuric chloride derivatized oligonucleotide was then added to the beads and the mixture was shaken vigorously at room temperature (19º to 23ºC) for 60 minutes. The beads were then washed twice with 0.1 M sodium borate pH 8.3. Succinic anhydride was then added at a concentration of 10 mg/ml in 90% N-methyl-pyrrolidone, 10% 1 M sodium borate pH 8.3 in a volume 3 times the volume of the beads. The Reaction was allowed to proceed for one hour at room temperature. Beads were then washed three times with 250 ml of 100% N-methyl-pyrrolidone, twice with distilled water, five times with 250 ml of SDS/FW, and then four times with one liter of distilled water. Beads were stored dry or in 25 mM EDTA. Radioactivity per bead was determined by liquid scintillation counting.

Für Iodacetamidobenzoylierte Oligonukleotide wurden Poly(Ethylenimin) beschichtete Nylonkugeln wie sie oben beschrieben sind in ein Volumen von 0,1 M Natriumborat bei pH 8,3 gebracht entsprechend dem Volumen der Kugeln, und Iminothiolan wurde zugegeben bis zu einem abschließenden Volumen von 5 mg/ml. Die Kugeln ließ man dann reagieren eine Stunde lang bei Raumtemperatur und sie wurden zehnmal gewaschen mit 0,1 M Natriumborat bei pH 8,3 und 10 mM EDTA bei 40 C. Die thiolierten Poly (Ethylenimin) beschichteten Nylonkugeln die oben beschrieben wurden wurden in ein Volumen von 0,1 M Natriumborat bei pH 8,3 und 25 mM EDTA gebracht entsprechend dem Volumen der Kugeln bei 4º C. Die gereinigten Iodacetamidobenzoylierten Oligonukleotide wurden dann zu den Kugeln zugegeben und die Mischung wurde heftig geschüttelt (gerührt) bei Raumtemperatur (19º bis 23º C) 4 Stunden lang. Die Kugeln wurden dann zweimal mit 0,1 M Natriumborat und 25 mM EDTA gewaschen und dann inkubiert mit einem Volumen entsprechend dem dreifachen der Kugeln mit 10 mg/ml Iodacetamid in einem 1:1 v/v Verhältnis N-Methyl-Pyrrolidon und 0,1 M Natriumborat bei pH 8,3. Die Reaktion ließ man bei Raumtemperatur eine Stunde lang ablaufen. Die Kugeln wurden dann dreimal mit 250 ml an 100 % N-Methyl-Pyrrolidon gewaschen, zweimal mit destilliertem Wasser, fünfmal mit 250 ml SDS/FW und dann viermal mit einem Liter an destilliertem Wasser. Die Kugeln wurden trocken gelagert oder in 25 mM EDTA. Die Radioaktivität pro Kugel wurde dann bestimmt durch Flüssigszintillationszählung.For iodoacetamidobenzoylated oligonucleotides, poly(ethyleneimine) coated nylon beads as described above were placed in a volume of 0.1 M sodium borate at pH 8.3 equal to the volume of the beads, and iminothiolane was added to a final volume of 5 mg/ml. The beads were then allowed to react for one hour at room temperature and washed ten times with 0.1 M sodium borate at pH 8.3 and 10 mM EDTA at 40°C. The thiolated poly(ethyleneimine) coated nylon beads described above were placed in a volume of 0.1 M sodium borate at pH 8.3 and 25 mM EDTA equal to the volume of the beads at 4°C. The purified iodoacetamidobenzoylated oligonucleotides were then added to the beads and the mixture was vigorously shaken (stirred) at room temperature (19° to 23°C) for 4 hours. The beads were then washed twice with 0.1 M sodium borate and 25 mM EDTA and then incubated with a volume equivalent to three times the beads with 10 mg/ml iodoacetamide in a 1:1 v/v ratio of N-methyl-pyrrolidone and 0.1 M sodium borate at pH 8.3. The reaction was allowed to proceed at room temperature for one hour. The beads were then washed three times with 250 ml of 100% N-methyl-pyrrolidone, twice with distilled water, five times with 250 ml of SDS/FW and then four times with one liter of distilled water. The beads were stored dry or in 25 mM EDTA. The radioactivity per bead was then determined by liquid scintillation counting.

Herstellung des festen Membranträgers:Production of the solid membrane carrier:

Ein 16 cm² Stück von Nytran (Schleicher & Schuell, Keene, NH) wurde mit 10 ml an 5 mg/ml Iminothiolan in 0,1 M Natriumborat bei einem pH von 8,3 30 Minuten lang bei Raumtemperatur inkubiert. Die Membran wurde mit 5 Wechselmengen an Natriumboratpuffer wie oben beschrieben gewaschen. Die eingeführten Thiolgruppen wurden dann bestimmt unter Verwendung von 5,5-Dithio-Bis (2-Nitrobenzoesäure). Die derivatisierte Membran wurde dann geschnitten in 0,28 cm² Scheiben und wurde einmal gewaschen mit 0,1 M Natriumboratpuffer. IAB-Oligonukleotid wurde hergestellt wie oben beschrieben und gemischt mit den Membranscheiben. 300 Membranscheiben wurden eingetaucht in 2 ml an 0,1 M Natriumboratpuffer der 1,0 mg an IAB-Oligonukleotid enthält, und man ließ die Reaktion ablaufen bei Raumtemperatur mit konstantem Rühren 16 Stunden lang in der Dunkelheit. Die Scheiben wurden dann nachfolgend gewaschen mit 0,1 M Natriumborat, SDS/FW. 1,2 mikrogramm an Bg5B Oligonukleotid wurde gebunden pro Filterscheibe. Die nicht abreagierten Thiolgruppen wurden blockiert mit 50 mg/ml Iodacetamid in 0,1 M Natriumborat pH = 8,3. Die Filter wurden dann weiter gewaschen mit Natriumborat und SDS/FW.A 16 cm² piece of Nytran (Schleicher & Schuell, Keene, NH) was treated with 10 ml of 5 mg/ml iminothiolane in 0.1 M sodium borate at pH 8.3 for 30 minutes at room temperature. The membrane was washed with 5 changes of sodium borate buffer as described above. The introduced thiol groups were then determined using 5,5-dithio-bis(2-nitrobenzoic acid). The derivatized membrane was then cut into 0.28 cm2 disks and was washed once with 0.1 M sodium borate buffer. IAB oligonucleotide was prepared as described above and mixed with the membrane disks. 300 membrane disks were immersed in 2 ml of 0.1 M sodium borate buffer containing 1.0 mg of IAB oligonucleotide and the reaction was allowed to proceed at room temperature with constant stirring for 16 hours in the dark. The disks were then subsequently washed with 0.1 M sodium borate, SDS/FW. 1.2 micrograms of Bg5B oligonucleotide was bound per filter disk. The unreacted thiol groups were blocked with 50 mg/ml iodoacetamide in 0.1 M sodium borate pH = 8.3. The filters were then further washed with sodium borate and SDS/FW.

Lysis von Bakterien und Hybridisierungsbedingungen:Lysis of bacteria and hybridization conditions:

1 x 10&sup8; Zellen an Bakteroides gingivalis (Bg) wurde aufgelöst in 100 ul an Lysislösung bei 190 C. Das Zell-Lysat wurde dann erhitzt in einem 65º Wasserbad zehn Minuten lang. Die biotinylierte Probe wurde zu der Lysatlösung zugegeben und zu dem Verdünnungsmittel (GuSCN Lysislösung) bis zu einer abschließenden Konzentration an 100 ng/ml und 5 bis 8fache Serienverdünnungen wurden von dem Ausgangslysat hergestellt. Die Lösungen wurden dann inkubiert mit entweder der derivatisierten Nylonkugel oder dem Nytran das kovalent immobilisiert wurde mit 0,1 ug der jeweiligen Oligonukleotidsonde (Einfangsonde) eine Stunde lang bei Raumtemperatur mit mildem Rühren. Die festen Träger wurden dann gewaschen einmal mit der Lysis und Hybridisierungslösung, einmal mit FW und einmal mit SDS/FW. Streptavidin / HRP Konjugat wurde zugegeben bis zu einer abschließenden Konzentration von 1 microgramm/ml (auf Bais von Streptavidin) in SDS/FW und inkubiert 10 bis 15 Minuten lang bei Raumtemperatur unter mildem Rühren. Die Kugeln und Filter wurden dann dreimal gewaschen mit SDS/FW und dann einmal mit CAP Puffer. 4-Methoxy-Naphtol Naphtolsubstratlösung wie oben beschrieben wurde zugegeben und man ließ die Reaktion 15 Minuten lang bei Raumtemperatur ablaufen. Die Kugeln oder Filter wurden dann rasch gewaschen einmal mit SDS/FW und dann einmal mit FW und man erlaubte ihnen an der Luft in der Dunkelheit zu trocknen. Das Ausmaß der Hybridisierung ist direkt korrelierbar mit der Dichte der gefärbten Substrate die auf den Kugeln abgelagert sind.1 x 10⁸ cells of Bacteroides gingivalis (Bg) were dissolved in 100 µl of lysis solution at 190 C. The cell lysate was then heated in a 65º water bath for ten minutes. The biotinylated sample was added to the lysate solution and to the diluent (GuSCN lysis solution) to a final concentration of 100 ng/ml and 5- to 8-fold serial dilutions were made from the starting lysate. The solutions were then incubated with either the derivatized nylon bead or the Nytran covalently immobilized with 0.1 µg of the respective oligonucleotide probe (capture probe) for one hour at room temperature with gentle agitation. The solid supports were then washed once with the lysis and hybridization solution, once with FW and once with SDS/FW. Streptavidin / HRP conjugate was added to a final concentration of 1 microgram/ml (based of streptavidin) in SDS/FW and incubated for 10 to 15 minutes at room temperature with gentle agitation. The beads and filters were then washed three times with SDS/FW and then once with CAP buffer. 4-Methoxy-naphthol naphthol substrate solution as described above was added and the reaction was allowed to proceed for 15 minutes at room temperature. The beads or filters were then quickly washed once with SDS/FW and then once with FW and allowed to air dry in the dark. The extent of hybridization is directly correlated with the density of the colored substrates deposited on the beads.

Beispiel 1example 1

Beispiel 1 beschreibt die selektive Modifikation und Aktivierung des angeknüpften 5'-Amins der Oligonukleotide mit Cyanurchlorid. Es wird gezeigt, daß die Derivatisierung des Oligonukleotids nur an dem angeknüpften Amin auftritt.Example 1 describes the selective modification and activation of the attached 5'-amine of the oligonucleotides with cyanuric chloride. It is shown that derivatization of the oligonucleotide occurs only at the attached amine.

Die Sequenz UP9A, die entweder einen 5'-Aminohexylschwanz besaß oder nicht, wurde verglichen im Hinblick auf die Reaktivität mit Cyanurchlorid. 50 ug jedes Typs des Oligonukleotids wurden in einem 400 ul Volumen zur Reaktion gebracht, das 0,15 M Natriumborat bei pH = 8,3, enthielt, 2 mg/ml Cyanurchlorid (aus 50 mg/ml frisch präpariertem Vorrat in 100 % Acetonitril) . Man ließ die Reaktion bei 19º C 30 Minuten lang ablaufen. Das Reaktionsgemisch wurde dann analysiert durch C-18 Umkehrphasen HPLC unter Verwendung von 5 bis 45 % Acetonitril-Gradientem in TEA. Die Chromatogramme aus den jeweiligen Reaktionsmischungen und von beiden Typen des Ausgangsoligonukleotids sind in Fig. 3 dargestellt.The sequence UP9A, either possessing or not possessing a 5'-aminohexyl tail, was compared for reactivity with cyanuric chloride. 50 µg of each type of oligonucleotide was reacted in a 400 µl volume containing 0.15 M sodium borate at pH = 8.3, 2 mg/ml cyanuric chloride (from 50 mg/ml freshly prepared stock in 100% acetonitrile). The reaction was allowed to proceed at 19°C for 30 minutes. The reaction mixture was then analyzed by C-18 reversed-phase HPLC using 5 to 45% acetonitrile gradients in TEA. The chromatograms from the respective reaction mixtures and from both types of starting oligonucleotide are shown in Figure 3.

Die Oligonukleotidsequenz UP9A ohne Schwanz ist in Panel A dargestellt und tritt aus der Säule aus bei 9,025 Minuten wohingegen die Oligonukleotidsequenz UP9A mit Aminschwanz bei 9,205 Minuten austritt (Panel B). Der Chromatograph in Panel C zeigt daß die Oligonukleotidsequenz UP9A ohne Schwanz nicht mit Cyanurchlorid reagiert, wobei das Oligonukleotid weiterhin bei 9,005 Minuten austritt. In Panel D reagiert die Oligonukleotidsequenz UP9A mit Aminschwanz nahezu vollständig mit Cyanurchlorid was zu einem Dichlortriazinderivat führt, das bei 11,6 Minuten eluiert, nahezu 2,5 Minuten später als das Startmaterial UP9A mit Aminschwanz. Die Profile zeigen, daß nur die UP9A Sequenz die das 5'-angeknüpfte Amin enthält mit Cyanurchlorid reagiert, was demonstriert, daß das Cyanurchlorid selektiv mit dem Amin reagiert und nicht mit einem der Zucker oder Basen die in dem Oligonukleotid anwesend sind. Daher konnte gezeigt werden, daß 5'-Aminohexyl Oligonukleotide selektiv mit Cyanurchlorid aktiviert werden, was zu einer Sonde führt, die nur an dem 5'-Ende an einen festen Träger immobilisiert wird.The oligonucleotide sequence UP9A without a tail is shown in panel A and exits the column at 9.025 minutes, whereas the oligonucleotide sequence UP9A with an amine tail exits at 9.205 minutes (panel B). The chromatograph in panel C shows that the oligonucleotide sequence UP9A without a tail does not react with cyanuric chloride, with the oligonucleotide still exiting at 9.005 minutes. In panel D, the Amine-tailed oligonucleotide sequence UP9A reacts almost completely with cyanuric chloride, resulting in a dichlorotriazine derivative that elutes at 11.6 minutes, almost 2.5 minutes later than the amine-tailed starting material UP9A. The profiles show that only the UP9A sequence containing the 5'-attached amine reacts with cyanuric chloride, demonstrating that the cyanuric chloride reacts selectively with the amine and not with any of the sugars or bases present in the oligonucleotide. Therefore, 5'-aminohexyl oligonucleotides have been shown to be selectively activated with cyanuric chloride, resulting in a probe that is immobilized to a solid support only at the 5'-end.

Beispiel 2Example 2

Dieses Beispiel beschreibt die Derivatisierung von Nylonkugeln mit verschiedenen Typen von Diaminen und Poly (Ethylenimin) und dann die nachfolgende Anknüpfung von 4,6- Dichlortriazin-Oligonukleotiden. Ein Vergleich der Hybridisierungseigenschaften der jeweiligen Kugeln ist ebenfalls beschrieben.This example describes the derivatization of nylon beads with various types of diamines and poly(ethyleneimine) and then the subsequent attachment of 4,6-dichlorotriazine oligonucleotides. A comparison of the hybridization properties of the respective beads is also described.

200 Kugelansätze wurden derivatisiert entweder mit Hexandiamin, Jeffamin EDR 148, 1,4-Phenylendiamin, Jeffamin T3000, oder Poly (Ethylenimin) unter Verwendung des Verfahrens das oben beschrieben wurde in Verbindung mit der Herstellung von polymerbeschichteten Kugeln. Jeder Diamin oder Triamin-Kugeltyp enthielt zwischen 200 nmoles bis 2 umoles an Amin und das Poly (Ethylenimin) enthielt annähernd 100 nmoles an Amin.200 bead batches were derivatized with either hexanediamine, Jeffamine EDR 148, 1,4-phenylenediamine, Jeffamine T3000, or poly(ethyleneimine) using the procedure described above in connection with the preparation of polymer-coated beads. Each diamine or triamine bead type contained between 200 nmoles to 2 umoles of amine and the poly(ethyleneimine) contained approximately 100 nmoles of amine.

Jeder Kugeltyp wurde dann zur Reaktion gebracht mit 4,6- Dichlortriazin-aktiviertem Oligonukleotid (BgS Sequenz) wie oben beschrieben. Die nicht reagierten Amine wurden dann blockiert mit Succinanhydrid wie oben beschrieben und untersucht in Hybridisierungsuntersuchungen gemäß obiger Beschreibung. Die Phenylendiaminkugeln zeigten keine Fähigkeit Zielnukleinsäure einzufangen, währen die Jeffamine EDR-148, T-3000 und die Kugeln vom Hexandiamintyp Zielnukleinsäuren einfingen, jedoch mit einer Geschwindigkeit die etwa 25fach geringer war als die der Poly (Ethylenimin) Kugeln. Die Ergebnisse sind in der nachfolgenden Tabelle zusammengefaßt. Each bead type was then reacted with 4,6-dichlorotriazine-activated oligonucleotide (BgS sequence) as described above. The unreacted amines were then blocked with succinic anhydride as described above and examined in hybridization assays as described above. The phenylenediamine beads showed no ability to capture target nucleic acid, whereas the Jeffamine EDR-148, T-3000 and the hexanediamine-type beads captured target nucleic acids, but at a rate that was approximately 25-fold slower than that of the poly(ethyleneimine) beads. The results are summarized in the table below.

Die Resultate zeigen an, daß polymerbeschichtete Kugeln ungefähr 25fach stärker effizient waren im Einfangen von Zielnukleinsäure und daher den besten Oberflächentyp für die kovalente Immobilisierung von Oligonukleotiden und das Einfangen von Zielnukleinsäuren darstellen.The results indicate that polymer-coated beads were approximately 25-fold more efficient in capturing target nucleic acids and therefore represent the best surface type for covalent immobilization of oligonucleotides and capture of target nucleic acids.

Beispiel 3Example 3

Beispiel 3 vergleicht die festen Träger die aus den Nytranmembranen und Nylonkugeln gebildet wurden in einem Sandwichuntersuchungsformat, in dem eine Zielnukleinsäuresequenz sequestriert wurde und dann bestimmt wurde unter Verwendung eines kolorimetrischen Untersuchungsformats.Example 3 compares the solid supports formed from the Nytran membranes and nylon beads in a sandwich assay format in which a target nucleic acid sequence was sequestered and then determined using a colorimetric assay format.

3 M GnSCN Lysislösung wurde dann verwendet um 1 x 10&sup8; Zellen an Actinobazillus Acinomycetemcomitans aufzulösen (Aa), Bakteroides gingivalis (Bg), Bakteroides intermedius (Bi), Eikenella corrodens (Ec), Fusobakterium nucleatum (Fn), und Wolinella recta (Wr) in 100 Mikroliter Volumen bei 19º C. Das Lysat wurde dann erwärmt auf 65º C für 5 Minuten. Eine biotinylierte 24-Mer Oligonukleotidsonde komplementär zu konservierten Bereichen an bakterieller 16s rRNA (Signalsonde) wurde zugegeben bis zu einer abschließenden Konzentration von 100 Nanogramm pro ml.3 M GnSCN lysis solution was then used to solubilize 1 x 10⁸ cells of Actinobacillus acinomycetemcomitans (Aa), Bacteroides gingivalis (Bg), Bacteroides intermedius (Bi), Eikenella corrodens (Ec), Fusobacterium nucleatum (Fn), and Wolinella recta (Wr) in 100 microliter volumes at 19ºC. The lysate was then heated to 65ºC for 5 minutes. A biotinylated 24-mer oligonucleotide probe complementary to conserved regions of bacterial 16s rRNA (signal probe) was added to a final concentration of 100 nanograms per ml.

5fache Serienverdünnungen der Lysate wurden durchgeführt unter Verwendung von Verdünnungsmitteln die biotinylierte Signaloligonukleotide enthielten und 1 x 10&sup8; Gesamtzellen an Aa, Bi, Ek, Fn und Wr. Die Lösungen wurden dann inkubiert für 30 Minuten bei Raumtemperatur mit Nytranscheiben oder zwei Nylonkugeln, die kovalent immobilisiert aufwiesen 0,1 ug an Bgl spezifischer Oligonukleotidsonde (Einfangsonde). Die festen Träger wurde dann gewaschen mit SDS/FW bei Raumtemperatur und dann inkubiert mit 10 ng/ml an Strepatividin/Meerrettichperoxidase (SA/HRP) Konjugat in SDS/FW für fünf Minuten bei Raumtemperatur. Die festen Träger wurden dann gewaschen mit SDS/FW, FW und dann wurde die Anwesenheit der Peroxidase bestimmt durch Inkubieren der Filter mit der HRP Substratlösung wie oben beschrieben zur Bildung eines unlöslichen Produkts.Five-fold serial dilutions of the lysates were performed using diluents containing biotinylated signal oligonucleotides and 1 x 108 total cells of Aa, Bi, Ek, Fn and Wr. The solutions were then incubated for 30 minutes at room temperature with Nytran disks or two nylon beads covalently immobilized with 0.1 µg of Bgl specific oligonucleotide probe (capture probe). The solid supports were then washed with SDS/FW at room temperature and then incubated with 10 ng/ml of strepatividin/horseradish peroxidase (SA/HRP) conjugate in SDS/FW for five minutes at room temperature. The solid supports were then washed with SDS/FW, FW and then the presence of peroxidase was determined by incubating the filters with the HRP substrate solution as described above to form an insoluble product.

Die Resultate zeigten an, daß in der 30 Minuten Hybridisierung, 2 x 10&sup5; Zellen bestimmt wurden bei Verwendung der Nylonkugeln als feste Träger, wohingegen 1 x 10&sup6; Zellen bestimmt wurden bei der Verwendung von festen Nytranträgern. Die Kontrolle in der Aa, Bi, Ek und Wr Zellen anwesend waren und Bg abwesend war zeigte keine Farbe, was anzeigte, daß das Einfangen von Bg spezifisch war. Es wurde auch festgestellt, daß die meisten unlöslichen HRP Substrate verblaßten beim Färben an den Nytranmembranen, wohingegen kein Ausbleichen auftrat an den Nylonkugeln.The results indicated that in the 30 minute hybridization, 2 x 10⁵ cells were detected using the nylon beads as solid supports, whereas 1 x 10⁵ cells were detected using solid Nytran supports. The control in which Aa, Bi, Ek and Wr cells were present and Bg was absent showed no color, indicating that the capture of Bg was specific. It was also found that most insoluble HRP substrates faded when stained on the Nytran membranes, whereas no fading occurred on the nylon beads.

Beispiel 4Example 4

Beispiel 4 vergleicht die festen Träger, die mit der Nytranmembran gebildet wurden und den Nylonkugeln in einem Sandwich Untersuchungsformat, in dem eine Zielnukleinsäuresequenz sequestriert wird und dann bestimmt wird in einer komplexen biologischen Probe, die Gesamtblut enthielt.Example 4 compares the solid supports formed with the Nytran membrane and the nylon beads in a sandwich assay format in which a target nucleic acid sequence is sequestered and then determined in a complex biological sample containing whole blood.

3 M GnSCN Lösung wurde verwendet, um 1 x 10&sup8; Zellen von Bakteroides gingivalis (Bg) aufzulösen, die in eine Plattenprobe gespießt waren, die sichtbare Mengen an Blut enthielt (ungefähr 25 Mikroliter gepacktes Zeilvolumen) in 250 Mikroliter Volumen bei 19º C und dann aufgeteilt in zwei gleiche Volumina. Die Lysate wurden dann erhitzt auf 65º C für 5 Minuten. Eine biotinylierte 24-Mer Oligonukleotidsonde komplementär zu den konservierten Regionen der bakteriellen 16s rRNA (Signalsonde) wurde zugegeben bis zu einer abschließenden Konzentration von 100 Nanogramm pro ml.3 M GnSCN solution was used to dissolve 1 x 10⁸ cells of Bacteroides gingivalis (Bg) spiked into a plate sample containing visible amounts of blood (approximately 25 microliters of packed cell volume) in 250 microliter volumes at 19ºC and then divided into two equal volumes. The lysates were then heated to 65ºC for 5 minutes. A biotinylated 24-mer oligonucleotide probe complementary to the conserved regions of the bacterial 16s rRNA (signal probe) was added to a final concentration of 100 nanograms per ml.

5fache Serienverdünnungen der Lysate wurden durchgeführt unter Verwendung von Verdünnungsmitteln in 3 M GuSCN Lysis und Hybridisierungslösung, die die biotinylierten Signaloligonukleotide enthielten und einen Teil auf zehn des Gesarntbluts. Die Lösungen wurden dann inkubiert für 30 Minuten bei Raumtemperatur mit einer Nytranscheibe oder zwei Nylonkugeln, die kovalent daran immobilisiert hatten 0,1 ug an Bgl spezifischer oligonukleotidsonde (Einfangsonde) - Die festen Träger wurden dann gewaschen mit SDS/FW bei Raumtemperatur und inkubiert mit 10 ng/ml an Strepatividin/Meerrettichperoxidase (SA/HRP) Konjugat in SDS/FW für 5 Minuten bei Raumtemperatur. Die festen Träger wurden dann gewaschen mit SDS/FW, FW und die Gegenwart an Peroxidase wurde bestimmt durch Inkubieren der Filter mit der HRP Substratlösung wie oben beschrieben zur Bildung eines unlöslichen Produkts.5-fold serial dilutions of the lysates were performed using diluents in 3 M GuSCN Lysis and Hybridization Solution containing the biotinylated signal oligonucleotides and a ten-fold portion of whole blood. The solutions were then incubated for 30 minutes at room temperature with a Nytran disk or two nylon beads covalently immobilized with 0.1 µg of Bgl specific oligonucleotide probe (capture probe) - The solid supports were then washed with SDS/FW at room temperature and incubated with 10 ng/ml of strepatividin/horseradish peroxidase (SA/HRP) conjugate in SDS/FW for 5 minutes at room temperature. The solid supports were then washed with SDS/FW, FW and the presence of peroxidase was determined by incubating the filters with the HRP substrate solution as described above to form an insoluble product.

Die Ergebnisse zeigten an, daß in der 30 Minuten Hybridisierung 8 x 10&sup5; Zellen bestimmt wurden unter Verwendung der Nylonkugeln als feste Träger, während 4 x 10&sup6; Kugeln bestimmt wurden bei Verwendung der festen Nytranträger. Noch bedeutsamer war, daß die Nytranf ilter wesentlich gefärbt wurden mit den aufgelösten Blutprodukten, während die Nylonkugeln ihre Ausgangsfarbe behielten.The results indicated that in the 30 minute hybridization, 8 x 10⁵ cells were detected using the nylon beads as solid supports, while 4 x 10⁵ beads were detected using the solid nytran supports. More significantly, the nytran filters were significantly stained with the dissolved blood products, while the nylon beads retained their original color.

Beispiel 5Example 5

Beispiel 5 vergleicht die festen Träger, die aus Nytranmernbranen und Nylonkugeln gebildet wurden in einem Sandwich Untersuchungsformat, in dem eine Zielnukleinsäuresequenz sequestriert wird und dann bestimmt wird unter Verwendung eines Chemilumineszenz Untersuchungsformat.Example 5 compares the solid supports formed from nylon membranes and nylon beads in a sandwich assay format in which a target nucleic acid sequence is sequestered and then determined is performed using a chemiluminescence assay format.

3 M GnSCN Lysislösung wurde verwendet, um 1 x 10&sup8; Zellen an Actinobazillus actinomycetemcomitans (Aa), Bakteroides gingivalis (Bg), Bakteroides intermedius (Bi), Eikenella corrodens (Ec), Fusobaktenum nucleatum (Fn) und Wolinella recta (Wr) in 100 Mikroliter Volumen bei 19º C aufzulösen. Die Lysate wurden dann erwärmt auf 65º C für fünf Minuten. Eine biotinylierte 24-Mer Oligonukleotidsonde komplementär zu den konservierten Regionen an bakterieller 165 rRNA (Signalsonde) wurde zugegeben bis zu einer abschließenden Konzentration von 100 Nanogramm pro ml.3 M GnSCN lysis solution was used to solubilize 1 x 108 cells of Actinobacillus actinomycetemcomitans (Aa), Bacteroides gingivalis (Bg), Bacteroides intermedius (Bi), Eikenella corrodens (Ec), Fusobacterium nucleatum (Fn) and Wolinella recta (Wr) in 100 microliter volumes at 19ºC. The lysates were then heated to 65ºC for five minutes. A biotinylated 24-mer oligonucleotide probe complementary to the conserved regions on bacterial 165 rRNA (signal probe) was added to a final concentration of 100 nanograms per ml.

Fünffache Serienverdünnungen der Lysate wurden durchgeführt unter Verwendung von Verdünnungsmitteln in 3 M GuSCN Lysis und Hybridisierungslösung enthaltend die biotinylierten Signaloligonukleotide und 1 x 10&sup8; Gesamtzellen an Aa, Bi, Ek, Fn und Wr. Die Lösungen wurden dann inkubiert 30 Minuten lang bei Raumtemperatur mit Nytranscheiben oder zwei Nylonkugeln, die kovalent daran immobilisiert hatten 0,1 ug an Bg1 spezifischer Oligonukleotidsonde (Einfangsonde). Die festen Träger wurden dann gewaschen mit SDS/FW bei Raumtemperatur, gefolgt von einer Waschung mit 0,5 % Tween 20, 1 mM MgCl2, 0,01 M Tris-HCl pH 8,0 (APB) und dann inkubiert mit 0,4 ug/ml an Streptavidin/Alkaliphosphatase (SA/AP) Konjugat in APB für fünf Minuten bei Raumtemperatur. Die festen Träger wurden dann gewaschen fünfmal mit APB, TMNZ und dann wurde die Gegenwart von Alkaliphosphatase bestimmt durch Inkubieren entweder der Nitranfilter oder der Nylonkugeln mit 200 Mikrolitern an Lumigen (von Lumigen, Inc., Detroit, MI) in 5mm x 40 mm Polypropylenröhrchen. Die Resultate sind in der nachfolgend wiedergegebenen Tabelle gezeigt. Five-fold serial dilutions of the lysates were performed using diluents in 3 M GuSCN Lysis and Hybridization Solution containing the biotinylated signal oligonucleotides and 1 x 10⁸ total cells of Aa, Bi, Ek, Fn and Wr. The solutions were then incubated for 30 minutes at room temperature with Nytran disks or two nylon beads covalently immobilized with 0.1 µg of Bgl specific oligonucleotide probe (capture probe). The solid supports were then washed with SDS/FW at room temperature, followed by a wash with 0.5% Tween 20, 1 mM MgCl2, 0.01 M Tris-HCl pH 8.0 (APB) and then incubated with 0.4 µg/ml of streptavidin/alkaline phosphatase (SA/AP) conjugate in APB for five minutes at room temperature. The solid supports were then washed five times with APB, TMNZ and then the presence of alkaline phosphatase was determined by incubating either the nitrane filters or the nylon beads with 200 microliters of Lumigen (from Lumigen, Inc., Detroit, MI) in 5 mm x 40 mm polypropylene tubes. The results are shown in the table below.

Somit zeigen die Ergebnisse, daß in der 30 Minuten Hybridisierung 3 x 10&sup4; Zellen bestimmt wurden bei Verwendung der Nylonkugeln als feste Träger, während nur 1 x 10&sup8; Zellen bestimmt wurden bei Verwendung der festen Nytranträger. Diese ungefähr 10.000fache Differenz in dem unteren Spiegel der Bestimmung des Ziels war zurückzuführen auf den ernstzunehmenden Hintergrund an nichtspezifischer Bindung der Alkaliphosphatase an die Nytranfilter. Die Nylonkugeln erlaubten es daher sensitiv zu bestimmten die Bg 16s rRNA unter Verwendung eines Signalsystems aus Chemilumineszenzbasis.Thus, the results show that in the 30 minute hybridization, 3 x 10⁴ cells were detected using the nylon beads as solid supports, while only 1 x 10⁴ cells were detected using the Nytran solid supports. This approximately 10,000-fold difference in the lower level of target detection was due to the serious background of nonspecific binding of alkaline phosphatase to the Nytran filters. The nylon beads therefore allowed for sensitive detection of Bg 16s rRNA using a chemiluminescence-based signaling system.

Beispiel 6Example 6

Beispiel 6 beschreibt die Verwendung von 0,23 (3/32 inch) Nylonkugeln immobilisiert in einer nicht porösen Kunststoffkarte zur Bildung einer Multipanelbestimmungs- Zusammensetzung die hierin als Tauchstab bezeichnet wird. Der Tauchstab (oder die Indikatorkarte) der so gebildet wurde besitzt multiple und voneinander verschiedene Stellen die die spezifische Bestimmung multipler Pathogene in einer einzelnen Probe erlauben. In diesem Beispiel wird die spezifische Bestimmung von Bg und Ek demonstriert.Example 6 describes the use of 0.23 (3/32 inch) nylon beads immobilized in a non-porous plastic card to form a multipanel detection composition referred to herein as a dipstick. The dipstick (or indicator card) thus formed has multiple and distinct sites that allow the specific detection of multiple pathogens in a single sample. In this example, the specific detection of Bg and Ek is demonstrated.

Ein Set von sechs identischen Tauchstäben wurde hergestellt, in denen die generelle Konfiguration des Tauchstabs in den Fig. 1 und 2 gezeigt ist. Die fünf Kugeln, jeweils ein unterschiedliches Einfangoligonukleotid besitzend, wurden in den Tauchstab gebracht von links nach rechts in folgender Reihenfolge:A set of six identical dipsticks was prepared, in which the general configuration of the dipstick is shown in Figures 1 and 2. The five beads, each containing a different capture oligonucleotide, were placed in the dipstick from left to right in the following order:

1: PA005 (positive Kontrolle)1: PA005 (positive control)

2: Aa004 (für die Bestimmung von Aa rRNA)2: Aa004 (for the determination of Aa rRNA)

3: 8g002 (für die Bestimmung von Bg rRNA)3: 8g002 (for the determination of Bg rRNA)

10 4: Ek007 (für die Bestimmung von Ek rRNA)10 4: Ek007 (for the determination of Ek rRNA)

5: PA505 (negative Kontrolle)5: PA505 (negative control)

Jeder Tauchstab wurde untersucht in 400 ul Lysis und Hybridisierungslösung wie oben beschrieben enthaltend biotinyliertes UP9A und UP007 mit 500 ng/ml, PA505 mit 5 ng/ml und entweder:Each dipstick was assayed in 400 μl of Lysis and Hybridization Solution as described above containing biotinylated UP9A and UP007 at 500 ng/ml, PA505 at 5 ng/ml and either:

1) 1 x 10&sup8; Bg Zellen.1) 1 x 10⁸ Bg cells.

2) 2 x 10&sup7; Bg Zellen.2) 2 x 10&sup7; Bg cells.

3) 1 x 10&sup8; Ek Zellen.3) 1 x 10&sup8; Ek cells.

4) 2 x 10&sup7; Ek Zellen.4) 2 x 10&sup7; Ek cells.

5) 1 x 10&sup8; Bg Zellen und 1 x 10&sup8; Ek Zellen.5) 1 x 10⁸ Bg cells and 1 x 10⁸ Ek cells.

6) 2 x 10&sup8; Bg Zellen und 2 x 10&sup8; Ek Zellen.6) 2 x 10⁸ Bg cells and 2 x 10⁸ Ek cells.

Die Tauchstäbe wurden nacheinander behandelt durch die folgenden Lösungen mit konstantem Rühren bei 2 Hertz: 10 Minuten in der Hybridisierungslösung, 2 Minuten in SDS/FW, 5 Minuten in SA/HRP Konjugat, 2 Minuten in SDS/FW, 2 Minuten in CAP Puffer, und dann entwickelt 10 Minuten in 4 MN Substratlösung. Die Ergebnisse sind in der nachfolgenden Tabelle beschrieben. Dipsticks were treated sequentially through the following solutions with constant stirring at 2 Hertz: 10 minutes in hybridization solution, 2 minutes in SDS/FW, 5 minutes in SA/HRP conjugate, 2 minutes in SDS/FW, 2 minutes in CAP buffer, and then developed for 10 minutes in 4 MN substrate solution. The results are described in the table below.

Worin ++ anzeigt starkes kolorimetrisches Signal, + anzeigt mittleres kolorimetrisches Signal, - anzeigt kein Signal. Die Resultate zeigen an, daß der Tauchstab in der Lage war spezifisch die Anwesenheit von Bg und Ek zu bestimmen.Where ++ indicates strong colorimetric signal, + indicates medium colorimetric signal, - indicates no signal. The results indicate that the dipstick was able to specifically determine the presence of Bg and Ek.

Claims (13)

1. Zusammensetzung umfassend ein Oligonukleotid, das kovalent an einen festen Träger gebunden ist, der mit einem Amin-haltigen Polymeren beschichtet ist, wobei die kovalente Anbindung auftritt zwischen dem Arnin des Polymer-beschichteten festen Trägers und einem Amin, das mit dem Oligonukleotid verknüpft ist.1. A composition comprising an oligonucleotide covalently linked to a solid support coated with an amine-containing polymer, wherein the covalent linkage occurs between the amine of the polymer-coated solid support and an amine linked to the oligonucleotide. 2. Zusammensetzung nach Anspruch 1, in der das Oligonukleotid aktiviert ist mit einem monofunktionalen oder multifunktionalen Reagenz.2. Composition according to claim 1, in which the oligonucleotide is activated with a monofunctional or multifunctional reagent. 3. Zusammensetzung nach Anspruch 2, in der das Reagenz homotrifunktional ist.3. A composition according to claim 2, wherein the reagent is homotrifunctional. 4. Zusammensetzung nach Anspruch 3, in der das Reagenz Cyanurchlorid ist.4. A composition according to claim 3, wherein the reagent is cyanuric chloride. 5. Zusammensetzung gemäß einem der vorhergehenden Ansprüche, in der der feste Träger, der mit einem Amin-haltigen Polymeren beschichtet ist, eine Nylonkugel ist und eine sphärische Form aufweist.5. Composition according to one of the preceding claims, in which the solid support coated with an amine-containing polymer is a nylon ball and has a spherical shape. 6. Zusammensetzung nach Anspruch 5, in der die Polymerbeschichtete Kugel einen Durchmesser im Bereich von 0,025 bis 1,27 cm (0,01 inch bis 0,5 inch) hat.6. The composition of claim 5, wherein the polymer coated ball has a diameter in the range of 0.025 to 1.27 cm (0.01 inch to 0.5 inch). 7. Zusammensetzung gemäß Anspruch 6, in der die Polymerbeschichtete Kugel einen Durchmesser von 0,15 bis 0,23 cm (0,06 inch bis 0,09 inch) hat.7. The composition of claim 6 wherein the polymer coated ball has a diameter of 0.15 to 0.23 cm (0.06 inch to 0.09 inch). 8. Zusammensetzung gemäß Anspruch 7, in der die Polymerbeschichtete Kugel einen Durchmesser von etwa 0,23 cm (0,09 inch) hat.8. The composition of claim 7, wherein the polymer coated ball has a diameter of about 0.23 cm (0.09 inch). 9. Zusammensetzung gemäß einem der vorhergehenden Ansprüche, in der das Oligonukleotid mit dem polymerbeschichteten festen Träger verknüpft ist über ein Amin, das an das 5- oder 3- Ende des Oligonukleotids angeknüpft ist.9. Composition according to one of the preceding claims, in which the oligonucleotide is combined with the polymer-coated solid support via an amine attached to the 5- or 3-end of the oligonucleotide. 10. Zusammensetzung gemäß einem der Ansprüche 1 bis 8, in der das Oligonukleotid mit dem polymerbeschichteten festen Träger über ein Amin verknüpft wird, das an das Oligonukleotid angeknüpft ist an einer Stelle zwischen den 5- und 3- Enden des Oligonukleotids.10. A composition according to any one of claims 1 to 8, in which the oligonucleotide is linked to the polymer-coated solid support via an amine which is linked to the oligonucleotide at a site between the 5' and 3' ends of the oligonucleotide. 11. Zusammensetzung gemäß einem der vorhergehenden Ansprüche, in der das Polymere Poly (Ethylenimin), Polyvinylamin, Polyallylamin oder Poly (Acylhydrazid) ist.11. Composition according to one of the preceding claims, in which the polymer is poly(ethyleneimine), polyvinylamine, polyallylamine or poly(acylhydrazide). 12. Zusammensetzung gemäß einem der vorhergehenden Ansprüche, in der nicht reagierte Amine des Polymeren blockiert sind.12. Composition according to one of the preceding claims, in which unreacted amines of the polymer are blocked. 13. Verfahren zur Herstellung eines Oligonukleotids, das kovalent an ein Amin-haltiges Polymeres gebunden ist, über ein Amin, das an das 5- Ende oder 3- Ende oder an einer Stelle zwischen dem 5- Ende und dem 3- Ende des Oligonukleotids angeknüpft ist, wobei das Verfahren umfaßt:13. A process for preparing an oligonucleotide covalently linked to an amine-containing polymer via an amine attached to the 5-terminus or 3-terminus or to a site between the 5-terminus and 3-terminus of the oligonucleotide, the process comprising: das Aktivieren eines Aminoalkylsubstituierten Oligonukleotids mit Cyanurchlorid und das konjugieren des aktivierten Oligonukleotids an ein Amin-haltiges Polymer.activating an aminoalkyl-substituted oligonucleotide with cyanuric chloride and conjugating the activated oligonucleotide to an amine-containing polymer.
DE69032425T 1990-05-11 1990-09-04 Immersion test strips for nucleic acid hybridization assays and methods for covalently immobilizing oligonucleotides Expired - Lifetime DE69032425T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52244290A 1990-05-11 1990-05-11

Publications (2)

Publication Number Publication Date
DE69032425D1 DE69032425D1 (en) 1998-07-23
DE69032425T2 true DE69032425T2 (en) 1998-11-26

Family

ID=24080872

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69032425T Expired - Lifetime DE69032425T2 (en) 1990-05-11 1990-09-04 Immersion test strips for nucleic acid hybridization assays and methods for covalently immobilizing oligonucleotides

Country Status (7)

Country Link
US (1) US5514785A (en)
EP (2) EP0455905B1 (en)
JP (1) JPH0420300A (en)
AT (1) ATE167523T1 (en)
DE (1) DE69032425T2 (en)
DK (1) DK0455905T3 (en)
ES (1) ES2116977T3 (en)

Families Citing this family (1021)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
EP0834575B1 (en) * 1990-12-06 2001-11-28 Affymetrix, Inc. (a Delaware Corporation) Identification of nucleic acids in samples
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en) 1991-11-19 2012-04-10 Isis Pharmaceuticals, Inc. Composition and methods for the pulmonary delivery of nucleic acids
US5747244A (en) * 1991-12-23 1998-05-05 Chiron Corporation Nucleic acid probes immobilized on polystyrene surfaces
FI943054A7 (en) * 1991-12-24 1994-08-22 Tepnel Medical Ltd Manipulation of nucleic acid sequences
US6436635B1 (en) 1992-11-06 2002-08-20 Boston University Solid phase sequencing of double-stranded nucleic acids
US5795714A (en) 1992-11-06 1998-08-18 Trustees Of Boston University Method for replicating an array of nucleic acid probes
US6207651B1 (en) * 1996-08-02 2001-03-27 Metabolite Laboratories Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6
AU675251B2 (en) * 1993-01-04 1997-01-30 Becton Dickinson & Company Flow-through hybridization assay for oligonucleotide sequences
US6194144B1 (en) 1993-01-07 2001-02-27 Sequenom, Inc. DNA sequencing by mass spectrometry
US5679510A (en) * 1993-04-27 1997-10-21 Hybridon, Inc. Quantitative detection of specific nucleic acid sequences using lambdoid bacteriophages linked by oligonucleotides to solid support
ATE247128T1 (en) 1993-09-03 2003-08-15 Isis Pharmaceuticals Inc AMINODERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES
DE4409436A1 (en) * 1994-03-19 1995-09-21 Boehringer Mannheim Gmbh Process for processing nucleic acids
ATE220424T1 (en) * 1994-05-28 2002-07-15 Tepnel Medical Ltd PRODUCTION OF NUCLEIC ACID COPIES
US7378236B1 (en) 1994-06-17 2008-05-27 The Board Of Trustees Of The Leland Stanford Junior University Method for analyzing gene expression patterns
US7323298B1 (en) * 1994-06-17 2008-01-29 The Board Of Trustees Of The Leland Stanford Junior University Microarray for determining the relative abundances of polynuceotide sequences
US5807522A (en) * 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5578446A (en) * 1994-07-08 1996-11-26 Becton Dickinson And Company Analytical dipstick for improved mixing and reduced reagent volume
US8236493B2 (en) * 1994-10-21 2012-08-07 Affymetrix, Inc. Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA
US6428955B1 (en) 1995-03-17 2002-08-06 Sequenom, Inc. DNA diagnostics based on mass spectrometry
US7803529B1 (en) 1995-04-11 2010-09-28 Sequenom, Inc. Solid phase sequencing of biopolymers
US6420549B1 (en) 1995-06-06 2002-07-16 Isis Pharmaceuticals, Inc. Oligonucleotide analogs having modified dimers
JP3517031B2 (en) * 1995-06-09 2004-04-05 日清紡績株式会社 Analytical methods for biologically active substances
CA2235762A1 (en) * 1995-11-14 1997-05-22 Genometrix Genomics, Inc. Integrated nucleic acid hybridization devices based upon active surface chemistry
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc Nucleic acid analysis techniques
CA2255599C (en) * 1996-04-25 2006-09-05 Bioarray Solutions, Llc Light-controlled electrokinetic assembly of particles near surfaces
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US20070275921A1 (en) * 1996-06-06 2007-11-29 Isis Pharmaceuticals, Inc. Oligomeric Compounds That Facilitate Risc Loading
US20040266706A1 (en) * 2002-11-05 2004-12-30 Muthiah Manoharan Cross-linked oligomeric compounds and their use in gene modulation
US20080119427A1 (en) * 1996-06-06 2008-05-22 Isis Pharmaceuticals, Inc. Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20030044941A1 (en) 1996-06-06 2003-03-06 Crooke Stanley T. Human RNase III and compositions and uses thereof
DE69737598T2 (en) * 1996-07-29 2007-12-27 Nanosphere Inc., Skokie NANOPARTICLES WITH OLIGONUCLEOTIDES ADDITED TO IT AND THEIR USES
AU2002300406B9 (en) * 1996-11-06 2005-11-03 Sequenom, Inc. Compositions and Methods for Immobilizing Nucleic Acids to Solid Supports
EP1164203B1 (en) 1996-11-06 2007-10-10 Sequenom, Inc. DNA Diagnostics based on mass spectrometry
DE69735112T2 (en) 1996-11-06 2006-09-07 Sequenom, Inc., San Diego Method of analysis and device
US6133436A (en) 1996-11-06 2000-10-17 Sequenom, Inc. Beads bound to a solid support and to nucleic acids
JP2008298785A (en) * 1996-11-06 2008-12-11 Sequenom Inc Compositions and methods for immobilizing nucleic acids on solid supports
WO1998020019A1 (en) * 1996-11-06 1998-05-14 Sequenom, Inc. Compositions and methods for immobilizing nucleic acids to solid supports
US6140053A (en) 1996-11-06 2000-10-31 Sequenom, Inc. DNA sequencing by mass spectrometry via exonuclease degradation
US5900481A (en) * 1996-11-06 1999-05-04 Sequenom, Inc. Bead linkers for immobilizing nucleic acids to solid supports
EP1003908B1 (en) * 1997-04-16 2006-12-06 Applera Corporation Nucleic acid archiving
CA2294988C (en) 1997-07-01 2015-11-24 Isis Pharmaceuticals Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
HUP0003296A3 (en) 1997-07-22 2001-09-28 Qiagen Genomics Inc Bothell Apparatus and methods for arraying solution onto a solid support
US6268131B1 (en) 1997-12-15 2001-07-31 Sequenom, Inc. Mass spectrometric methods for sequencing nucleic acids
CA2321100A1 (en) * 1998-02-19 1999-08-26 Edvotek Articles of manufacture and methods for staining biomolecules
US6013789A (en) * 1998-02-20 2000-01-11 Beckman Coulter, Inc. Covalent attachment of biomolecules to derivatized polypropylene supports
JP2002504678A (en) 1998-02-21 2002-02-12 ビーエーエスエフ アクチェンゲゼルシャフト Use of fluorescent dyes for surface analysis
US20040186071A1 (en) * 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
US7321828B2 (en) 1998-04-13 2008-01-22 Isis Pharmaceuticals, Inc. System of components for preparing oligonucleotides
US6979728B2 (en) * 1998-05-04 2005-12-27 Baylor College Of Medicine Articles of manufacture and methods for array based analysis of biological molecules
US6048695A (en) * 1998-05-04 2000-04-11 Baylor College Of Medicine Chemically modified nucleic acids and methods for coupling nucleic acids to solid support
US6723564B2 (en) 1998-05-07 2004-04-20 Sequenom, Inc. IR MALDI mass spectrometry of nucleic acids using liquid matrices
WO1999060167A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
WO1999060012A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
US6335439B1 (en) 1998-06-11 2002-01-01 Isis Pharmaceuticals, Inc. Method of preparing phosphoramidites
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6225293B1 (en) 1998-09-02 2001-05-01 Isis Pharmaceuticals, Inc. Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
US6077709A (en) 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
BE1012275A3 (en) * 1998-11-12 2000-08-01 Univ Bruxelles Covalent oligonucleotide fixation to nylon surface
DE69929826D1 (en) * 1998-11-23 2006-04-20 Us Gov Sec Army CLEANING METHOD AND DEVICE
US6638760B1 (en) * 1998-11-25 2003-10-28 Pe Corporation (Ny) Method and apparatus for flow-through hybridization
US6300320B1 (en) 1999-01-05 2001-10-09 Isis Pharmaceuticals, Inc. Modulation of c-jun using inhibitors of protein kinase C
US6127124A (en) * 1999-01-20 2000-10-03 Isis Pharmaceuticals, Inc. Fluorescence based nuclease assay
DE19903576C2 (en) 1999-01-29 2001-02-22 Bodenseewerk Perkin Elmer Co Quantitative determination of analytes in a heterogeneous system
WO2000049382A2 (en) * 1999-02-16 2000-08-24 The Perkin-Elmer Corporation Bead dispensing system
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US6268141B1 (en) * 1999-05-12 2001-07-31 Beckman Coulter, Inc. Immobilization of unmodified biopolymers to acyl fluoride activated substrates
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
US6339147B1 (en) 1999-07-29 2002-01-15 Epoch Biosciences, Inc. Attachment of oligonucleotides to solid supports through Schiff base type linkages for capture and detection of nucleic acids
US6147200A (en) * 1999-08-19 2000-11-14 Isis Pharmaceuticals, Inc. 2'-O-acetamido modified monomers and oligomers
US6617442B1 (en) * 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
US7668658B2 (en) * 1999-10-13 2010-02-23 Sequenom, Inc. Methods for generating databases and databases for identifying polymorphic genetic markers
CA2389769A1 (en) * 1999-11-02 2001-05-10 Celine Hu Molecular microarrays and methods for production and use thereof
US7109024B2 (en) * 1999-11-15 2006-09-19 Dr. Chip Biotechnology Inc. Biomolecule-bound substrates
US6261840B1 (en) 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US20020055479A1 (en) 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
AU2000225808A1 (en) * 2000-02-09 2001-08-20 Resq Lab B.V. Packing materials for separation of biomolecules
US20030176385A1 (en) * 2000-02-15 2003-09-18 Jingfang Ju Antisense modulation of protein expression
US6413722B1 (en) 2000-03-22 2002-07-02 Incyte Genomics, Inc. Polymer coated surfaces for microarray applications
US6911535B2 (en) * 2000-03-22 2005-06-28 Solvlink Biosciences Biomolecule/polymer conjugates
ATE452906T1 (en) * 2000-04-13 2010-01-15 Thomas N Wight THERAPEUTIC SUMMARY AND METHODS FOR MODULATING V3, AN ISOFORM OF VERSICAN
US6458589B1 (en) 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
US6680172B1 (en) 2000-05-16 2004-01-20 Regents Of The University Of Michigan Treatments and markers for cancers of the central nervous system
JP2004500867A (en) * 2000-06-07 2004-01-15 ベイラー カレッジ オブ メディシン Novel compositions and methods for array-based nucleic acid hybridization
US20060166227A1 (en) * 2000-06-20 2006-07-27 Stephen Kingsmore Protein expression profiling
US9709559B2 (en) 2000-06-21 2017-07-18 Bioarray Solutions, Ltd. Multianalyte molecular analysis using application-specific random particle arrays
DE60117556T2 (en) 2000-06-21 2006-11-02 Bioarray Solutions Ltd. MULTI-ANALYTIC MOLECULAR ANALYSIS THROUGH THE USE OF APPLICATION SPECIFIC RAPID PARTICLE ARRAYS
US6323009B1 (en) * 2000-06-28 2001-11-27 Molecular Staging, Inc. Multiply-primed amplification of nucleic acid sequences
US6958214B2 (en) 2000-07-10 2005-10-25 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
EP1326892A2 (en) 2000-10-12 2003-07-16 University of Rochester Compositions that inhibit proliferation of cancer cells
US20030045005A1 (en) * 2000-10-17 2003-03-06 Michael Seul Light-controlled electrokinetic assembly of particles near surfaces
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
WO2002061146A1 (en) * 2001-02-01 2002-08-08 The Trustees Of Columbia University In The City Of New York Use of electrical fields to control interactions between proteins and nucleic acid constructions immobilized on solid supports
WO2002072790A2 (en) 2001-03-14 2002-09-19 Myriad Genetics, Inc Tsg101-gag interaction and use thereof
PT2000545E (en) 2001-06-20 2011-12-21 Genentech Inc COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF PULMONARY TUMOR
US20050107595A1 (en) * 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7803915B2 (en) * 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
US7262063B2 (en) 2001-06-21 2007-08-28 Bio Array Solutions, Ltd. Directed assembly of functional heterostructures
EP2221376B1 (en) 2001-06-21 2012-11-21 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
US7297553B2 (en) * 2002-05-28 2007-11-20 Nanosphere, Inc. Method for attachment of silylated molecules to glass surfaces
AU2005241112B2 (en) 2001-07-13 2009-07-30 Nanosphere, Inc. Method for preparing substrates having immobilized molecules and substrates
AU2002322458A1 (en) 2001-07-13 2003-01-29 Nanosphere, Inc. Method for immobilizing molecules onto surfaces
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
US20030096772A1 (en) 2001-07-30 2003-05-22 Crooke Rosanne M. Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
DE60238143D1 (en) 2001-09-18 2010-12-09 Genentech Inc COMPOSITIONS AND METHODS FOR THE DIAGNOSIS OF TUMORS
US7195913B2 (en) 2001-10-05 2007-03-27 Surmodics, Inc. Randomly ordered arrays and methods of making and using
US8158106B2 (en) 2001-10-05 2012-04-17 Surmodics, Inc. Particle immobilized coatings and uses thereof
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
NZ585001A (en) 2001-10-09 2011-08-26 Isis Pharmaceuticals Inc Antisense modulation of insulin-like growth factor binding protein 5 expression
US7439346B2 (en) * 2001-10-12 2008-10-21 Perkinelmer Las Inc. Nucleic acids arrays and methods of use therefor
CA2463725A1 (en) * 2001-10-12 2003-11-06 Spectral Genomics, Inc. Compilations of nucleic acids and arrays and methods of using them
CA2497740C (en) 2001-10-15 2011-06-21 Bioarray Solutions, Ltd. Multiplexed analysis of polymorphic loci by probe elongation-mediated detection
US20030224380A1 (en) * 2001-10-25 2003-12-04 The General Hospital Corporation Genes and polymorphisms on chromosome 10 associated with Alzheimer's disease and other neurodegenerative diseases
AU2002364945A1 (en) * 2001-10-25 2003-07-09 Neurogenetics, Inc. Genes and polymorphisms on chromosome 10 associated with alzheimer's disease and other neurodegenerative diseases
US20030170678A1 (en) * 2001-10-25 2003-09-11 Neurogenetics, Inc. Genetic markers for Alzheimer's disease and methods using the same
DE10154291B4 (en) * 2001-11-05 2005-05-19 Hain Lifescience Gmbh Method for the detection of nucleic acids in the form of a dry rapid test
US20030124599A1 (en) * 2001-11-14 2003-07-03 Shiping Chen Biochemical analysis system with combinatorial chemistry applications
US6927029B2 (en) 2001-12-03 2005-08-09 Agilent Technologies, Inc. Surface with tethered polymeric species for binding biomolecules
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
US8367013B2 (en) * 2001-12-24 2013-02-05 Kimberly-Clark Worldwide, Inc. Reading device, method, and system for conducting lateral flow assays
US20030119203A1 (en) * 2001-12-24 2003-06-26 Kimberly-Clark Worldwide, Inc. Lateral flow assay devices and methods for conducting assays
JP3634307B2 (en) * 2001-12-27 2005-03-30 三菱電機株式会社 Chat management system
US20030124542A1 (en) * 2001-12-28 2003-07-03 Spectral Genomics, Inc. Methods for mapping the chromosomal loci of genes expressed by a cell
AU2002367318B2 (en) 2002-01-02 2007-07-12 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003064679A2 (en) * 2002-01-30 2003-08-07 Id Biomedical Corporation Methods for detecting vancomycin-resistant microorganisms and compositions therefor
AU2003217306A1 (en) * 2002-02-07 2003-09-02 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Diagnostic microarray and method of use thereof
US7553619B2 (en) * 2002-02-08 2009-06-30 Qiagen Gmbh Detection method using dissociated rolling circle amplification
WO2003080649A2 (en) * 2002-03-20 2003-10-02 Regents Of The University Of Minnesota Induction of hepatocyte proliferation in vitro by inhibition of cell cycle inhibitors
US20030180712A1 (en) 2002-03-20 2003-09-25 Biostratum Ab Inhibition of the beta3 subunit of L-type Ca2+ channels
US7169916B2 (en) * 2002-04-01 2007-01-30 Isis Pharmaceuticals, Inc. Chloral-free DCA in oligonucleotide synthesis
JP2005536190A (en) 2002-04-16 2005-12-02 ジェネンテック・インコーポレーテッド Compositions and methods for tumor diagnosis and treatment
WO2003093296A2 (en) * 2002-05-03 2003-11-13 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof, and related methods
US7199107B2 (en) 2002-05-23 2007-04-03 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
AU2003276131A1 (en) * 2002-06-18 2003-12-31 Epigenesis Pharmaceuticals, Inc. A dry powder oligonucleotide formulation, preparation and its uses
JP2004097173A (en) * 2002-07-17 2004-04-02 Toyo Kohan Co Ltd Solid support having electrostatic layer and its use
US20040019000A1 (en) * 2002-07-19 2004-01-29 Muthiah Manoharan Polyalkyleneamine-containing oligomers
EP1575992A4 (en) 2002-08-05 2007-02-21 Univ Rochester CHIMERIC PROTEINS WITH PROTEIN TRANSDUCTION FIELD / DOMAINE DESAMINASE, ASSOCIATED COMPOUNDS AND CORRESPONDING USES
US6878805B2 (en) * 2002-08-16 2005-04-12 Isis Pharmaceuticals, Inc. Peptide-conjugated oligomeric compounds
US7923260B2 (en) 2002-08-20 2011-04-12 Illumina, Inc. Method of reading encoded particles
US7190522B2 (en) * 2002-09-12 2007-03-13 Cyvera Corporation Chemical synthesis using diffraction grating-based encoded optical elements
JP2005536769A (en) * 2002-08-20 2005-12-02 シヴェラ コーポレイション Optical identification elements based on diffraction gratings
US7164533B2 (en) * 2003-01-22 2007-01-16 Cyvera Corporation Hybrid random bead/chip based microarray
US7901630B2 (en) 2002-08-20 2011-03-08 Illumina, Inc. Diffraction grating-based encoded microparticle assay stick
US7872804B2 (en) 2002-08-20 2011-01-18 Illumina, Inc. Encoded particle having a grating with variations in the refractive index
US20040126875A1 (en) * 2002-09-12 2004-07-01 Putnam Martin A. Assay stick
US7399643B2 (en) * 2002-09-12 2008-07-15 Cyvera Corporation Method and apparatus for aligning microbeads in order to interrogate the same
US7508608B2 (en) 2004-11-17 2009-03-24 Illumina, Inc. Lithographically fabricated holographic optical identification element
US7619819B2 (en) 2002-08-20 2009-11-17 Illumina, Inc. Method and apparatus for drug product tracking using encoded optical identification elements
US7900836B2 (en) 2002-08-20 2011-03-08 Illumina, Inc. Optical reader system for substrates having an optically readable code
US7441703B2 (en) 2002-08-20 2008-10-28 Illumina, Inc. Optical reader for diffraction grating-based encoded optical identification elements
WO2004019277A1 (en) * 2002-08-20 2004-03-04 Cyvera Corporation Diffraction grating-based encoded micro-particles for multiplexed experiments
US7285424B2 (en) * 2002-08-27 2007-10-23 Kimberly-Clark Worldwide, Inc. Membrane-based assay devices
US7314763B2 (en) * 2002-08-27 2008-01-01 Kimberly-Clark Worldwide, Inc. Fluidics-based assay devices
US7432105B2 (en) 2002-08-27 2008-10-07 Kimberly-Clark Worldwide, Inc. Self-calibration system for a magnetic binding assay
EP1540591A1 (en) * 2002-09-12 2005-06-15 Cyvera Corporation Diffraction grating-based encoded micro-particles for multiplexed experiments
US7092160B2 (en) 2002-09-12 2006-08-15 Illumina, Inc. Method of manufacturing of diffraction grating-based optical identification element
CA2499037A1 (en) * 2002-09-12 2004-03-25 Cyvera Corporation Method and apparatus for labelling using diffraction grating-based encoded optical identification elements
US20100255603A9 (en) 2002-09-12 2010-10-07 Putnam Martin A Method and apparatus for aligning microbeads in order to interrogate the same
BR0314236A (en) 2002-09-13 2005-08-09 Replicor Inc Oligonucleotide formulation, pharmaceutical composition, kit, antiviral compound, preparation of oligonucleotide and methods for selection of an antiviral oligonucleotide for use as an antiviral agent, for prophylaxis or treatment of a viral infection in a patient, for prophylactic treatment of cancer caused by oncoviruses. for identifying a compound that alters the binding of an oligonucleotide to at least one viral component, for purifying oligonucleotide binding to at least one viral component and for enriching oligonucleotides from an oligonucleotide cluster
AU2003288906C1 (en) 2002-09-20 2010-12-09 Yale University Riboswitches, methods for their use, and compositions for use with riboswitches.
CA2498320A1 (en) * 2002-09-20 2004-04-01 Integrated Dna Technologies, Inc. Anthraquinone quencher dyes, their methods of preparation and use
US7229976B2 (en) 2002-09-26 2007-06-12 Isis Pharmaceuticals, Inc. Modulation of forkhead box O1A expression
EP1560597A4 (en) * 2002-10-29 2007-06-27 Pharmacia Corp DIFFERENTIALLY EXPRESSED GENES INVOLVED IN CANCER, POLYPEPTIDES CODED THEREWITH, AND METHODS OF USING GENES
WO2004041889A2 (en) 2002-11-05 2004-05-21 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US9150605B2 (en) * 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
AU2003291755A1 (en) 2002-11-05 2004-06-07 Isis Pharmaceuticals, Inc. Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
US9150606B2 (en) * 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
CA2504720C (en) 2002-11-05 2013-12-24 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
EP2336318B1 (en) 2002-11-13 2013-04-24 Genzyme Corporation Antisense modulation of apolipoprotein b expression
SI1569695T1 (en) 2002-11-13 2013-08-30 Genzyme Corporation Antisense modulation of apolipoprotein b expression
JP4555089B2 (en) 2002-11-15 2010-09-29 モーフオテク・インコーポレーテツド Method for producing high production amount of antibody from hybridoma created by in vitro immunization
AU2003298655A1 (en) 2002-11-15 2004-06-15 Bioarray Solutions, Ltd. Analysis, secure access to, and transmission of array images
AU2003298650B2 (en) 2002-11-15 2010-03-11 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
EP2410332A1 (en) 2002-11-21 2012-01-25 The University Of Utah Method for identifying purinergic modulators of the olfactory system
US7781172B2 (en) * 2003-11-21 2010-08-24 Kimberly-Clark Worldwide, Inc. Method for extending the dynamic detection range of assay devices
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
US20040121339A1 (en) * 2002-12-19 2004-06-24 Jizhong Zhou Special film-coated substrate for bio-microarray fabrication and use thereof
US20040121334A1 (en) * 2002-12-19 2004-06-24 Kimberly-Clark Worldwide, Inc. Self-calibrated flow-through assay devices
US7247500B2 (en) * 2002-12-19 2007-07-24 Kimberly-Clark Worldwide, Inc. Reduction of the hook effect in membrane-based assay devices
AU2003299694A1 (en) 2002-12-20 2004-07-22 Qiagen Gmbh Nucleic acid amplification
US9487823B2 (en) 2002-12-20 2016-11-08 Qiagen Gmbh Nucleic acid amplification
US6977153B2 (en) * 2002-12-31 2005-12-20 Qiagen Gmbh Rolling circle amplification of RNA
NZ541637A (en) 2003-02-11 2008-07-31 Antisense Therapeutics Pty Ltd Modulation of insulin like growth factor I receptor
US7002006B2 (en) * 2003-02-12 2006-02-21 Isis Pharmaceuticals, Inc. Protection of nucleosides
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20070141570A1 (en) * 2003-03-07 2007-06-21 Sequenom, Inc. Association of polymorphic kinase anchor proteins with cardiac phenotypes and related methods
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
US8043834B2 (en) 2003-03-31 2011-10-25 Qiagen Gmbh Universal reagents for rolling circle amplification and methods of use
US7851209B2 (en) * 2003-04-03 2010-12-14 Kimberly-Clark Worldwide, Inc. Reduction of the hook effect in assay devices
US20040197819A1 (en) * 2003-04-03 2004-10-07 Kimberly-Clark Worldwide, Inc. Assay devices that utilize hollow particles
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
WO2004108081A2 (en) * 2003-06-02 2004-12-16 Isis Pharmaceuticals, Inc. Oligonucleotide synthesis with alternative solvents
JP4579911B2 (en) 2003-06-03 2010-11-10 アイシス・ファーマシューティカルズ・インコーポレイテッド Regulation of survivin expression
AU2004263830B2 (en) 2003-06-13 2008-12-18 Alnylam Pharmaceuticals, Inc. Double-stranded ribonucleic acid with increased effectiveness in an organism
EP1644475A4 (en) * 2003-06-20 2009-06-03 Isis Pharmaceuticals Inc BICATENE COMPOSITIONS COMPRISING A MODIFIED 3'-ENDO CHAIN FOR USE IN GENE MODULATION
US8969314B2 (en) 2003-07-31 2015-03-03 Regulus Therapeutics, Inc. Methods for use in modulating miR-122a
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
US20050053981A1 (en) * 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US20070123480A1 (en) * 2003-09-11 2007-05-31 Replicor Inc. Oligonucleotides targeting prion diseases
CA2538252C (en) * 2003-09-18 2014-02-25 Isis Pharmaceuticals, Inc. 4'-thionucleosides and oligomeric compounds
EP2256201A3 (en) 2003-09-18 2012-07-04 Isis Pharmaceuticals, Inc. Modulation of eIF4E expression
US7927796B2 (en) 2003-09-18 2011-04-19 Bioarray Solutions, Ltd. Number coding for identification of subtypes of coded types of solid phase carriers
CA2539824C (en) 2003-09-22 2015-02-03 Xinwen Wang Surface immobilized polyelectrolyte with multiple functional groups capable of covalently bonding to biomolecules
CA2541438C (en) 2003-10-10 2013-11-26 Meditech Research Limited The modulation of hyaluronan synthesis and degradation in the treatment of disease
CA2544041C (en) 2003-10-28 2015-12-08 Bioarray Solutions Ltd. Optimization of gene expression analysis using immobilized capture probes
CA2544202C (en) 2003-10-29 2012-07-24 Bioarray Solutions Ltd. Multiplexed nucleic acid analysis by fragmentation of double-stranded dna
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
WO2005049849A2 (en) 2003-11-14 2005-06-02 Integrated Dna Technologies, Inc. Fluorescence quenching azo dyes, their methods of preparation and use
DK2295073T3 (en) 2003-11-17 2014-07-28 Genentech Inc ANTIBODY AGAINST CD22 FOR TREATING TUMOR OF HEMATOPOIETIC ORIGIN
US7713748B2 (en) * 2003-11-21 2010-05-11 Kimberly-Clark Worldwide, Inc. Method of reducing the sensitivity of assay devices
US20050112703A1 (en) 2003-11-21 2005-05-26 Kimberly-Clark Worldwide, Inc. Membrane-based lateral flow assay devices that utilize phosphorescent detection
US7943395B2 (en) * 2003-11-21 2011-05-17 Kimberly-Clark Worldwide, Inc. Extension of the dynamic detection range of assay devices
US20050136550A1 (en) * 2003-12-19 2005-06-23 Kimberly-Clark Worldwide, Inc. Flow control of electrochemical-based assay devices
US20050136500A1 (en) * 2003-12-19 2005-06-23 Kimberly-Clark Worldwide; Inc. Flow-through assay devices
US7943089B2 (en) * 2003-12-19 2011-05-17 Kimberly-Clark Worldwide, Inc. Laminated assay devices
EP1711606A2 (en) 2004-01-20 2006-10-18 Isis Pharmaceuticals, Inc. Modulation of glucocorticoid receptor expression
US7468431B2 (en) * 2004-01-22 2008-12-23 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP2 expression
US8778900B2 (en) * 2004-01-22 2014-07-15 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP1 expression
US7433123B2 (en) 2004-02-19 2008-10-07 Illumina, Inc. Optical identification element having non-waveguide photosensitive substrate with diffraction grating therein
US20050191704A1 (en) * 2004-03-01 2005-09-01 Kimberly-Clark Worldwide, Inc. Assay devices utilizing chemichromic dyes
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8790919B2 (en) 2004-03-15 2014-07-29 Isis Pharmaceuticals, Inc. Compositions and methods for optimizing cleavage of RNA by RNase H
JP2007531794A (en) 2004-04-05 2007-11-08 アルニラム ファーマスーティカルズ インコーポレイテッド Methods and reagents used for oligonucleotide synthesis and purification
US20050244869A1 (en) * 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
US20050260755A1 (en) * 2004-04-06 2005-11-24 Isis Pharmaceuticals, Inc. Sequential delivery of oligomeric compounds
US20050260652A1 (en) * 2004-04-15 2005-11-24 The General Hospital Corporation Compositions and methods that modulate RNA interference
AU2005323437B2 (en) 2004-04-30 2011-10-06 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a C5-modified pyrimidine
DK1773872T3 (en) 2004-05-21 2017-05-08 Uab Res Found VARIABLE Lymphocyte Receptors, Associated Polypeptides and Nucleic Acids, and Uses thereof
US20080261904A1 (en) * 2004-06-03 2008-10-23 Balkrishen Bhat Chimeric Gapped Oligomeric Compounds
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7521226B2 (en) 2004-06-30 2009-04-21 Kimberly-Clark Worldwide, Inc. One-step enzymatic and amine detection technique
US7906276B2 (en) 2004-06-30 2011-03-15 Kimberly-Clark Worldwide, Inc. Enzymatic detection techniques
US7094528B2 (en) * 2004-06-30 2006-08-22 Kimberly-Clark Worldwide, Inc. Magnetic enzyme detection techniques
US7848889B2 (en) 2004-08-02 2010-12-07 Bioarray Solutions, Ltd. Automated analysis of multiplexed probe-target interaction patterns: pattern matching and allele identification
US7427675B2 (en) * 2004-08-23 2008-09-23 Isis Pharmaceuticals, Inc. Compounds and methods for the characterization of oligonucleotides
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
CA2989941A1 (en) * 2004-09-23 2006-03-30 Arc Pharmaceuticals, Inc. Pharmaceutical compostions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans
AU2005327506B2 (en) 2004-10-20 2010-07-08 Antisense Therapeutics Ltd Antisense modulation of integrin alpha4 expression
EP2194485B1 (en) 2004-11-16 2012-10-17 Illumina, Inc. Method and apparatus for reading coded microbeads
US7604173B2 (en) 2004-11-16 2009-10-20 Illumina, Inc. Holographically encoded elements for microarray and other tagging labeling applications, and method and apparatus for making and reading the same
WO2006055735A2 (en) 2004-11-16 2006-05-26 Illumina, Inc Scanner having spatial light modulator
US20100256062A1 (en) 2004-12-06 2010-10-07 Howard Tommy E Allelic Variants of Human Factor VIII
ZA200707490B (en) 2005-03-10 2008-12-31 Genentech Inc Methods and compositions for modulatiing vascular integrity
US7476733B2 (en) * 2005-03-25 2009-01-13 The United States Of America As Represented By The Department Of Health And Human Services Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
US8309303B2 (en) 2005-04-01 2012-11-13 Qiagen Gmbh Reverse transcription and amplification of RNA with simultaneous degradation of DNA
WO2006125124A2 (en) * 2005-05-18 2006-11-23 Nanosphere, Inc. Substrate functionalization method for high sensitivity applications
JP2008545659A (en) 2005-05-20 2008-12-18 インテグレイテッド ディーエヌエイ テクノロジーズ インコーポレイテッド Compounds and methods for labeling oligonucleotides
WO2007008300A2 (en) 2005-05-31 2007-01-18 ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE Triblock copolymers for cytoplasmic delivery of gene-based drugs
US8486629B2 (en) 2005-06-01 2013-07-16 Bioarray Solutions, Ltd. Creation of functionalized microparticle libraries by oligonucleotide ligation or elongation
WO2006133022A2 (en) 2005-06-03 2006-12-14 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
WO2006138145A1 (en) 2005-06-14 2006-12-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
EP2239327B1 (en) 2005-08-11 2015-02-25 Synthetic Genomics, Inc. Method for in vitro recombination
EP1915461B1 (en) 2005-08-17 2018-08-01 Dx4U GmbH Composition and method for determination of ck19 expression
EP1931780B1 (en) 2005-08-29 2016-01-06 Regulus Therapeutics Inc. Antisense compounds having enhanced anti-microrna activity
EP1762627A1 (en) 2005-09-09 2007-03-14 Qiagen GmbH Method for the activation of a nucleic acid for performing a polymerase reaction
EP2392645A1 (en) 2005-10-14 2011-12-07 MUSC Foundation For Research Development Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
US8080534B2 (en) * 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
JP5111385B2 (en) * 2005-10-28 2013-01-09 アルナイラム ファーマシューティカルズ, インコーポレイテッド Composition and method for suppressing expression of huntingtin gene
CA2626584A1 (en) * 2005-11-04 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of nav1.8 gene
US20100069461A1 (en) 2005-11-09 2010-03-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor v leiden mutant gene
CA2630602A1 (en) 2005-11-21 2007-05-31 Isis Pharmaceuticals, Inc. Modulation of eif4e-bp2 expression
US7623624B2 (en) 2005-11-22 2009-11-24 Illumina, Inc. Method and apparatus for labeling using optical identification elements characterized by X-ray diffraction
WO2007100412A2 (en) * 2005-12-21 2007-09-07 Yale University Methods and compositions related to the modulation of riboswitches
JP5713377B2 (en) 2005-12-28 2015-05-07 ザ スクリプス リサーチ インスティテュート Natural antisense and non-coding RNA transcripts as drug targets
EP1991677A2 (en) 2006-01-26 2008-11-19 Isis Pharmaceuticals, Inc. Compositions and their uses directed to huntingtin
US7569686B1 (en) 2006-01-27 2009-08-04 Isis Pharmaceuticals, Inc. Compounds and methods for synthesis of bicyclic nucleic acid analogs
AU2007211082B2 (en) 2006-01-27 2012-09-27 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of microRNAs
WO2007090071A2 (en) 2006-01-27 2007-08-09 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
NZ571568A (en) 2006-03-31 2010-11-26 Alnylam Pharmaceuticals Inc Double-stranded RNA molecule compositions and methods for inhibiting expression of Eg5 gene
WO2007114518A1 (en) * 2006-03-31 2007-10-11 Canon Kabushiki Kaisha Probe, probe set, probe-immobilized carrier, and genetic testing method
US7830575B2 (en) 2006-04-10 2010-11-09 Illumina, Inc. Optical scanner with improved scan time
US20070258862A1 (en) * 2006-05-02 2007-11-08 Applera Corporation Variable volume dispenser and method
CN101437943A (en) * 2006-05-03 2009-05-20 波罗的科技发展有限公司 Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
EP2505648A1 (en) 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of PTP1B
JP2009536222A (en) 2006-05-05 2009-10-08 アイシス ファーマシューティカルズ, インコーポレーテッド Compounds and methods for modulating the expression of PCSK9
US7666854B2 (en) * 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
AU2007249349B2 (en) * 2006-05-11 2012-03-08 Isis Pharmaceuticals, Inc. 5'-Modified bicyclic nucleic acid analogs
CN101489566B (en) 2006-05-19 2012-04-18 阿尔尼拉姆医药品有限公司 RNAi regulation of Aha gene and its therapeutic application
WO2007137220A2 (en) 2006-05-22 2007-11-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of ikk-b gene
WO2007137301A2 (en) * 2006-05-23 2007-11-29 Isis Pharmaceuticals, Inc. Modulation of chrebp expression
US20090280188A1 (en) * 2006-06-23 2009-11-12 Northwestern University Asymmetric functionalizated nanoparticles and methods of use
US8198253B2 (en) 2006-07-19 2012-06-12 Isis Pharmaceuticals, Inc. Compositions and their uses directed to HBXIP
US8101585B2 (en) * 2006-08-04 2012-01-24 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of JNK proteins
US20090047673A1 (en) 2006-08-22 2009-02-19 Cary Robert B Miniaturized lateral flow device for rapid and sensitive detection of proteins or nucleic acids
WO2008033866A2 (en) * 2006-09-11 2008-03-20 Yale University Methods and compositions for the use of lysine riboswitches
KR101556798B1 (en) 2006-10-05 2015-10-01 메사츄세츠 인스티튜트 어브 테크놀로지 Multifunctional Encoded Particles for High-Throughput Analysis
ES2526295T5 (en) * 2006-10-18 2021-05-04 Ionis Pharmaceuticals Inc Antisense compounds
US8999317B2 (en) 2006-11-01 2015-04-07 University Of Rochester Methods and compositions related to the structure and function of APOBEC3G
CA2670563A1 (en) * 2006-11-27 2008-06-05 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
BRPI0720038A2 (en) 2006-12-11 2013-12-24 Univ Utah Res Found METHODS TO INHIBIT VASCULAR PERMEABILITY IN TISSUE, TO TRIAL OR EVALUATE AN AGENT THAT INHIBITS VASCULAR PERMEABILITY, TO TREAT OR PREVENT RESPIRATORY ANGUS, SYNDROME TO PREMATULAR DIABETARY RATE, INDIVIDUALS WITH REPULSIVE OR MIMETIC SUGGESTIONS AND TO PROMOTE ANGIOGENESIS IN A FABRIC, ISOLATED POLYPEPTIDE, ISOLATED NUCLEIC ACID, AND, VECTOR
US20100129358A1 (en) 2006-12-22 2010-05-27 University Of Utah Research Foundation Method of detecting ocular diseases and pathologic conditions and treatment of same
WO2009045469A2 (en) 2007-10-02 2009-04-09 Amgen Inc. Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
EP2121987B1 (en) 2007-02-09 2012-06-13 Northwestern University Particles for detecting intracellular targets
CA2679586A1 (en) * 2007-02-27 2008-10-23 Northwestern University Molecule attachment to nanoparticles
MX2009010081A (en) 2007-03-22 2010-01-20 Univ Yale Methods and compositions related to riboswitches that control alternative splicing.
EP2905336A1 (en) 2007-03-29 2015-08-12 Alnylam Pharmaceuticals Inc. Compositions and methods for inhibiting expression of a gene from the ebola
EP2162552A4 (en) 2007-05-11 2010-06-30 Univ Johns Hopkins BIOMARKERS FOR MELANOMES
AU2008260089A1 (en) * 2007-05-29 2008-12-11 Yale University Methods and compositions related to riboswitches that control alternative splicing and RNA processing
EP2164996A4 (en) 2007-05-29 2010-07-14 Univ Yale RIBOREGULATORS AND METHODS AND COMPOSITION FOR THE USE OF AND WITH RIBOREGULATORS
EP2160464B1 (en) 2007-05-30 2014-05-21 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
CA2688321A1 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
US7807372B2 (en) * 2007-06-04 2010-10-05 Northwestern University Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
DK2173760T4 (en) 2007-06-08 2016-02-08 Isis Pharmaceuticals Inc Carbocyclic bicyclic nukleinsyreanaloge
AU2008272918B2 (en) * 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
KR101654007B1 (en) 2007-08-15 2016-09-05 아이오니스 파마수티컬즈, 인코포레이티드 Tetrahydropyran nucleic acid analogs
EP2195331B1 (en) 2007-08-28 2013-11-20 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
WO2009032702A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
US8445217B2 (en) 2007-09-20 2013-05-21 Vanderbilt University Free solution measurement of molecular interactions by backscattering interferometry
US7951785B2 (en) * 2007-09-21 2011-05-31 California Institute Of Technology NFIA in glial fate determination, glioma therapy and astrocytoma treatment
WO2009060124A2 (en) * 2007-11-05 2009-05-14 Baltic Technology Development, Ltd. Use of oligonucleotides with modified bases in hybridization of nucleic acids
US8916531B2 (en) * 2007-11-20 2014-12-23 Isis Pharmaceuticals, Inc. Modulation of CD40 expression
CA2707042A1 (en) 2007-12-10 2009-06-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor vii gene
WO2009086558A1 (en) 2008-01-02 2009-07-09 Tekmira Pharmaceuticals Corporation Improved compositions and methods for the delivery of nucleic acids
WO2009100320A2 (en) * 2008-02-07 2009-08-13 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
US20090215050A1 (en) * 2008-02-22 2009-08-27 Robert Delmar Jenison Systems and methods for point-of-care amplification and detection of polynucleotides
KR101397407B1 (en) 2008-03-05 2014-06-19 알닐람 파마슈티칼스 인코포레이티드 Compositions and methods for inhibiting expression of Eg5 and VEGF genes
WO2009117589A1 (en) * 2008-03-21 2009-09-24 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising tricyclic nucleosides and methods for their use
EP2105145A1 (en) * 2008-03-27 2009-09-30 ETH Zürich Method for muscle-specific delivery lipid-conjugated oligonucleotides
US9290534B2 (en) * 2008-04-04 2016-03-22 Ionis Pharmaceuticals, Inc. Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside
EP2274423A2 (en) * 2008-04-04 2011-01-19 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
CA2721183C (en) 2008-04-11 2019-07-16 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
ES2686708T3 (en) 2008-04-18 2018-10-19 Baxter International Inc. Microsphere-based composition to prevent and / or reverse newly occurring autoimmune diabetes
US8324366B2 (en) 2008-04-29 2012-12-04 Alnylam Pharmaceuticals, Inc. Compositions and methods for delivering RNAI using lipoproteins
US20090274696A1 (en) * 2008-04-29 2009-11-05 Wyeth Methods for treating inflammation
EP2279403B1 (en) 2008-05-05 2016-03-16 Los Alamos National Security, LLC Highly simplified lateral flow-based nucleic acid sample preparation and passive fluid flow control
US8222221B2 (en) 2008-06-04 2012-07-17 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small RNA targeting of gene promoters
CA2732343C (en) 2008-07-29 2017-05-09 The Board Of Regents Of The University Of Texas System Selective inhibition of polyglutamine protein expression
EP2323667A4 (en) * 2008-08-07 2012-07-25 Isis Pharmaceuticals Inc MODULATION OF TRANSTHYRETIN EXPRESSION FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) DISORDERS
WO2010027831A1 (en) 2008-08-25 2010-03-11 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to ctgf
NZ601660A (en) 2008-08-25 2014-05-30 Excaliard Pharmaceuticals Inc Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
WO2010028054A1 (en) 2008-09-02 2010-03-11 Alnylam Europe Ag. Compositions and methods for inhibiting expression of mutant egfr gene
AU2009298802A1 (en) 2008-09-23 2010-04-08 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
DK2361256T3 (en) * 2008-09-24 2013-07-01 Isis Pharmaceuticals Inc Cyclohexenyl-nucleic acid analogues
DK2356129T3 (en) * 2008-09-24 2013-05-13 Isis Pharmaceuticals Inc Substituted alpha-L bicyclic nucleosides
AU2009296395A1 (en) 2008-09-25 2010-04-01 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene
CA2740000C (en) 2008-10-09 2017-12-12 Tekmira Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
KR101773551B1 (en) 2008-10-15 2017-08-31 아이오니스 파마수티컬즈, 인코포레이티드 Modulation of factor 11 expression
MX360460B (en) 2008-10-20 2018-11-05 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of transthyretin.
US20120059045A1 (en) 2008-10-24 2012-03-08 Isis Pharmaceuticals, Inc. Methods of using oligomeric compounds comprising 2'-substituted nucleosides
EP2447274B1 (en) 2008-10-24 2017-10-04 Ionis Pharmaceuticals, Inc. Oligomeric compounds and methods
CN111808084A (en) 2008-11-10 2020-10-23 阿布特斯生物制药公司 Novel lipids and compositions for delivery of therapeutic agents
EP2365803B1 (en) 2008-11-24 2017-11-01 Northwestern University Polyvalent rna-nanoparticle compositions
US20110294870A1 (en) 2008-12-04 2011-12-01 Opko Curna, Llc Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
ES2629630T3 (en) 2008-12-04 2017-08-11 Curna, Inc. Treatment of diseases related to erythropoietin (EPO) by inhibiting the natural antisense transcript to EPO
US20110237649A1 (en) 2008-12-04 2011-09-29 Opko Curna, Llc Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
CA2746514C (en) 2008-12-10 2018-11-27 Alnylam Pharmaceuticals, Inc. Gnaq targeted dsrna compositions and methods for inhibiting expression
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
AU2010203474B2 (en) * 2009-01-08 2015-11-19 Northwestern University Inhibition of bacterial protein production by polyvalent oligonucleotide modified nanoparticle conjugates
KR101546673B1 (en) * 2009-01-15 2015-08-25 삼성전자주식회사 Toner for electrophotographic and process for preparing the same
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
US20120021515A1 (en) 2009-02-06 2012-01-26 Swayze Eric E Oligomeric compounds and methods
US8536320B2 (en) 2009-02-06 2013-09-17 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
CN102439149B (en) 2009-02-12 2018-01-02 库尔纳公司 By suppressing to treat the related diseases of GDNF for the natural antisense transcript of the glial derived neurotrophic factor (GDNF)
ES2762610T3 (en) 2009-02-12 2020-05-25 Curna Inc Treatment of diseases related to brain-derived neurotrophic factor (BDNF) by inhibition of natural antisense transcript for BDNF
WO2010099341A1 (en) 2009-02-26 2010-09-02 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of mig-12 gene
AU2010221419B2 (en) 2009-03-02 2015-10-01 Alnylam Pharmaceuticals, Inc. Nucleic acid chemical modifications
WO2010102058A2 (en) 2009-03-04 2010-09-10 Curna, Inc. Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
AU2010223967B2 (en) 2009-03-12 2015-07-30 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
CN102482677B (en) 2009-03-16 2017-10-17 库尔纳公司 Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2)-associated diseases by inhibiting the natural antisense transcript of NRF2
WO2010107740A2 (en) 2009-03-17 2010-09-23 Curna, Inc. Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
CN102449170A (en) 2009-04-15 2012-05-09 西北大学 Delivery of oligonucleotide-functionalized nanoparticles
EP3248618A1 (en) 2009-04-22 2017-11-29 Massachusetts Institute Of Technology Innate immune suppression enables repeated delivery of long rna molecules
WO2010124231A2 (en) 2009-04-24 2010-10-28 The Board Of Regents Of The University Of Texas System Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
EP2424987B1 (en) 2009-05-01 2017-11-15 CuRNA, Inc. Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg
CA3045126A1 (en) 2009-05-05 2010-11-11 Arbutus Biopharma Corporation Methods of delivering oligonucleotides to immune cells
SG10201911942UA (en) 2009-05-05 2020-02-27 Muthiah Manoharan Lipid compositions
CN103223177B (en) 2009-05-06 2016-08-10 库尔纳公司 By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene
ES2609655T3 (en) 2009-05-06 2017-04-21 Curna, Inc. Treatment of diseases related to tristetraproline (TTP) by inhibition of natural antisense transcript for TTP
WO2010132665A1 (en) 2009-05-15 2010-11-18 Yale University Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
DK2432881T3 (en) 2009-05-18 2018-02-26 Curna Inc TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
CA2762987A1 (en) 2009-05-22 2010-11-25 Joseph Collard Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
KR101704988B1 (en) 2009-05-28 2017-02-08 큐알엔에이, 인크. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
KR101766408B1 (en) 2009-06-10 2017-08-10 알닐람 파마슈티칼스 인코포레이티드 Improved lipid formulation
US8951981B2 (en) 2009-06-16 2015-02-10 Curna, Inc. Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1
WO2010148050A2 (en) 2009-06-16 2010-12-23 Curna, Inc. Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
ES2699827T3 (en) 2009-06-17 2019-02-13 Biogen Ma Inc Compositions and methods for SMN2 splicing modulation in a subject
WO2010151671A2 (en) 2009-06-24 2010-12-29 Curna, Inc. Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
EP2446037B1 (en) 2009-06-26 2016-04-20 CuRNA, Inc. Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
CN102762731B (en) 2009-08-05 2018-06-22 库尔纳公司 By inhibiting to treat insulin gene (INS) relevant disease for the natural antisense transcript of insulin gene (INS)
US9012421B2 (en) 2009-08-06 2015-04-21 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
AP2015008874A0 (en) 2009-08-14 2015-11-30 Alnylam Pharmaceuticals Inc Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
WO2011022420A1 (en) 2009-08-17 2011-02-24 Yale University Methylation biomarkers and methods of use
CA2771172C (en) 2009-08-25 2021-11-30 Opko Curna, Llc Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
CA2772715C (en) 2009-09-02 2019-03-26 Genentech, Inc. Mutant smoothened and methods of using the same
JP5819308B2 (en) 2009-10-22 2015-11-24 ジェネンテック, インコーポレイテッド Methods and compositions for modulating macrophage stimulating protein hepsin activation
WO2011056687A2 (en) 2009-10-27 2011-05-12 Swift Biosciences, Inc. Polynucleotide primers and probes
CA2779099C (en) 2009-10-30 2021-08-10 Northwestern University Templated nanoconjugates
US20110110860A1 (en) 2009-11-02 2011-05-12 The Board Of Regents Of The University Of Texas System Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
EP2496716A1 (en) 2009-11-03 2012-09-12 University Of Virginia Patent Foundation Versatile, visible method for detecting polymeric analytes
WO2011063403A1 (en) 2009-11-23 2011-05-26 Swift Biosciences, Inc. Devices to extend single stranded target molecules
PH12012500982A1 (en) 2009-11-30 2019-07-10 Genentech Inc Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211=seqid2)
EP3296398A1 (en) 2009-12-07 2018-03-21 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
JP6025567B2 (en) 2009-12-16 2016-11-16 カッパーアールエヌエー,インコーポレイテッド Treatment of MBTPS1-related diseases by inhibition of the natural antisense transcript against the membrane-bound transcription factor peptidase, site 1 (MBTPS1)
EP3494963A1 (en) 2009-12-18 2019-06-12 The University of British Columbia Methods and compositions for delivery of nucleic acids
CN102869776B (en) 2009-12-23 2017-06-23 库尔纳公司 HGF relevant diseases are treated by suppressing the natural antisense transcript of HGF (HGF)
RU2619185C2 (en) 2009-12-23 2017-05-12 Курна, Инк. Treatment of diseases associated with uncoupling proteins 2 (ucp2), by inhibiting of natural antisense transcript to ucp2
ES2585829T3 (en) 2009-12-29 2016-10-10 Curna, Inc. Treatment of diseases related to tumor protein 63 (p63) by inhibition of natural antisense transcription to p63
EP2519633B1 (en) 2009-12-29 2017-10-25 CuRNA, Inc. Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
CA2785832A1 (en) 2010-01-04 2011-07-07 Curna, Inc. Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
KR101853509B1 (en) 2010-01-06 2018-04-30 큐알엔에이, 인크. Treatment of Pancreatic Developmental Gene Related Diseases By Inhibition of Natural Antisense Transcript to A Pancreatic Developmental Gene
JP6027893B2 (en) 2010-01-11 2016-11-16 カッパーアールエヌエー,インコーポレイテッド Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcripts against sex hormone binding globulin (SHBG)
WO2011085102A1 (en) 2010-01-11 2011-07-14 Isis Pharmaceuticals, Inc. Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2524042A2 (en) 2010-01-12 2012-11-21 Yale University Structured rna motifs and compounds and methods for their use
EP2524054A2 (en) * 2010-01-14 2012-11-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
EP2529015B1 (en) 2010-01-25 2017-11-15 CuRNA, Inc. Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
WO2011094580A2 (en) 2010-01-28 2011-08-04 Alnylam Pharmaceuticals, Inc. Chelated copper for use in the preparation of conjugated oligonucleotides
US9198972B2 (en) 2010-01-28 2015-12-01 Alnylam Pharmaceuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
WO2011097388A1 (en) 2010-02-03 2011-08-11 Alnylam Pharmaceuticals, Inc. Selective inhibition of polyglutamine protein expression
US20130028889A1 (en) 2010-02-04 2013-01-31 Ico Therapeutics Inc. Dosing regimens for treating and preventing ocular disorders using c-raf antisense
CN102844435B (en) 2010-02-22 2017-05-10 库尔纳公司 Treatment of PYCR1-associated diseases by inhibiting the natural antisense transcript of pyrroline-5-carboxylate reductase 1 (PYCR1)
WO2011105901A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 9 (c9) and uses thereof
WO2011105902A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-beta (c8-beta) and uses thereof
MA34057B1 (en) 2010-02-23 2013-03-05 Genentech Inc Formulations and methods for the diagnosis and treatment of tumor
WO2011105900A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011112516A1 (en) 2010-03-08 2011-09-15 Ico Therapeutics Inc. Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
US20130101512A1 (en) 2010-03-12 2013-04-25 Chad A. Mirkin Crosslinked polynucleotide structure
EP3210611B1 (en) 2010-03-12 2019-08-21 The Brigham and Women's Hospital, Inc. Methods of treating vascular inflammatory disorders
US9193752B2 (en) 2010-03-17 2015-11-24 Isis Pharmaceuticals, Inc. 5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
US8889350B2 (en) 2010-03-26 2014-11-18 Swift Biosciences, Inc. Methods and compositions for isolating polynucleotides
EP2553123B1 (en) 2010-03-26 2016-08-24 Integrated DNA Technologies, Inc. Methods for enhancing nucleic acid hybridization
US9506057B2 (en) 2010-03-26 2016-11-29 Integrated Dna Technologies, Inc. Modifications for antisense compounds
AU2011235276B2 (en) 2010-03-29 2015-09-03 Alnylam Pharmaceuticals, Inc. SiRNA therapy for transthyretin (TTR) related ocular amyloidosis
US9102938B2 (en) 2010-04-01 2015-08-11 Alnylam Pharmaceuticals, Inc. 2′ and 5′ modified monomers and oligonucleotides
EP2555778A4 (en) 2010-04-06 2014-05-21 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITING CD274 / PD-L1 GENE EXPRESSION
WO2011127337A2 (en) 2010-04-09 2011-10-13 Opko Curna Llc Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
US20110269194A1 (en) 2010-04-20 2011-11-03 Swift Biosciences, Inc. Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
WO2011133868A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Conformationally restricted dinucleotide monomers and oligonucleotides
US10913767B2 (en) 2010-04-22 2021-02-09 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
EP2601204B1 (en) 2010-04-28 2016-09-07 Ionis Pharmaceuticals, Inc. Modified nucleosides and oligomeric compounds prepared therefrom
US9156873B2 (en) 2010-04-28 2015-10-13 Isis Pharmaceuticals, Inc. Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom
WO2011139699A2 (en) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. 5' modified nucleosides and oligomeric compounds prepared therefrom
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
PL2563920T3 (en) 2010-04-29 2017-08-31 Ionis Pharmaceuticals, Inc. Modulation of transthyretin expression
WO2011139387A1 (en) 2010-05-03 2011-11-10 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
SG185027A1 (en) 2010-05-03 2012-11-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
TWI531370B (en) 2010-05-14 2016-05-01 可娜公司 Treatment of PAR4-related diseases by inhibiting PAR4 natural anti-strand transcript
WO2011150226A1 (en) 2010-05-26 2011-12-01 Landers James P Method for detecting nucleic acids based on aggregate formation
US8895528B2 (en) 2010-05-26 2014-11-25 Curna, Inc. Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
CA3102008A1 (en) 2010-06-02 2011-12-08 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
US8957200B2 (en) 2010-06-07 2015-02-17 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
KR101932628B1 (en) 2010-06-07 2018-12-27 파이어플라이 바이오웍스, 인코포레이티드 Nucleic acid detection and quantification by post-hybridization labeling and universal encoding
EP2580228B1 (en) 2010-06-08 2016-03-23 Ionis Pharmaceuticals, Inc. Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
US9638632B2 (en) 2010-06-11 2017-05-02 Vanderbilt University Multiplexed interferometric detection system and method
US20130236968A1 (en) 2010-06-21 2013-09-12 Alnylam Pharmaceuticals, Inc. Multifunctional copolymers for nucleic acid delivery
US9168297B2 (en) 2010-06-23 2015-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Regulation of skin pigmentation by neuregulin-1 (NRG-1)
JP5998131B2 (en) 2010-07-14 2016-09-28 カッパーアールエヌエー,インコーポレイテッド DISCSLARGEHOMOLOG (DLG) Treatment of DLG-related diseases by inhibition of natural antisense transcripts on DLG1
EP2595663A4 (en) 2010-07-19 2014-03-05 Isis Pharmaceuticals Inc MODULATION OF THE EXPRESSION OF MYOTONIC DYSTROPHIC PROTEIN KINASE (DMPK)
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012021554A1 (en) 2010-08-09 2012-02-16 Yale University Cyclic di-gmp-ii riboswitches, motifs, and compounds, and methods for their use
AU2011299233B2 (en) 2010-09-07 2016-09-15 Integrated Dna Technologies, Inc. Modifications for antisense compounds
WO2012044992A2 (en) 2010-09-30 2012-04-05 Agency For Science, Technology And Research (A*Star) Methods and reagents for detection and treatment of esophageal metaplasia
DK2625197T3 (en) 2010-10-05 2016-10-03 Genentech Inc Smoothened MUTANT AND METHODS OF USING THE SAME
CN103210086B (en) 2010-10-06 2017-06-09 库尔纳公司 Treatment of NEU4-associated diseases by inhibiting the natural antisense transcript of sialidase 4 (NEU4)
EP2625292B1 (en) 2010-10-07 2018-12-05 The General Hospital Corporation Biomarkers of cancer
KR101865433B1 (en) 2010-10-22 2018-07-13 큐알엔에이, 인크. Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
KR101913232B1 (en) 2010-10-27 2018-10-30 큐알엔에이, 인크. Treatment of interferon-related developmental regulator 1(ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1
WO2012064824A1 (en) 2010-11-09 2012-05-18 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
CA2817256A1 (en) 2010-11-12 2012-05-18 The General Hospital Corporation Polycomb-associated non-coding rnas
CA2817960C (en) 2010-11-17 2020-06-09 Ionis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
WO2012071238A2 (en) 2010-11-23 2012-05-31 Opko Curna Llc Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
US9150926B2 (en) 2010-12-06 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diagnosis and treatment of adrenocortical tumors using human microRNA-483
EP2648763A4 (en) 2010-12-10 2014-05-14 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
EP2649182A4 (en) 2010-12-10 2015-05-06 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHOD FOR INCREASING AN ERYTHROPOIETIN (EPO) PREPARATION
CA2824526C (en) 2011-01-11 2020-07-07 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
EP2663323B1 (en) 2011-01-14 2017-08-16 The General Hospital Corporation Methods targeting mir-128 for regulating cholesterol/lipid metabolism
DK2670404T3 (en) 2011-02-02 2018-11-19 Univ Princeton CIRCUIT MODULATORS AS VIRUS PRODUCTION MODULATORS
PT2670411T (en) 2011-02-02 2019-06-18 Excaliard Pharmaceuticals Inc Antisense compounds targeting connective tissue growth factor (ctgf) for use in a method of treating keloids or hypertrophic scars
JP2014506789A (en) 2011-02-03 2014-03-20 マーナ セラピューティクス インコーポレイテッド miR-124 synthetic mimics
SG10201600836PA (en) 2011-02-03 2016-03-30 Mirna Therapeutics Inc Synthetic mimics of mir-34
EP2673361B1 (en) 2011-02-08 2016-04-13 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
EP2678026B1 (en) 2011-02-21 2016-05-18 The University of Zurich Ankyrin g for use in the treatment of neurodegenerative disorders
US9562853B2 (en) 2011-02-22 2017-02-07 Vanderbilt University Nonaqueous backscattering interferometric methods
PH12013501969B1 (en) 2011-03-29 2018-08-31 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of tmprss6 gene
EP3460064B8 (en) 2011-04-03 2024-03-20 The General Hospital Corporation d/b/a Massachusetts General Hospital Efficient protein expression in vivo using modified rna (mod-rna)
CN103608467B (en) 2011-04-20 2017-07-21 美飒生物技术公司 Vibration amplified reaction for nucleic acid
WO2012149154A1 (en) 2011-04-26 2012-11-01 Swift Biosciences, Inc. Polynucleotide primers and probes
WO2012151268A1 (en) 2011-05-02 2012-11-08 University Of Virginia Patent Foundation Method and system for high throughput optical and label free detection of analytes
WO2012151289A2 (en) 2011-05-02 2012-11-08 University Of Virginia Patent Foundation Method and system to detect aggregate formation on a substrate
KR102043422B1 (en) 2011-06-09 2019-11-11 큐알엔에이, 인크. Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
WO2012170347A1 (en) 2011-06-09 2012-12-13 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
EP3320922A1 (en) 2011-06-10 2018-05-16 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
MX390699B (en) 2011-06-21 2025-03-21 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITION OF APOLIPOPROTEIN C-III (APOC3) GENES.
EP2723758B1 (en) 2011-06-21 2018-06-20 Alnylam Pharmaceuticals, Inc. Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof
EP3388068A1 (en) 2011-06-21 2018-10-17 Alnylam Pharmaceuticals, Inc. Composition and methods for inhibition of expression of protein c (proc) genes
WO2012178033A2 (en) 2011-06-23 2012-12-27 Alnylam Pharmaceuticals, Inc. Serpina1 sirnas: compositions of matter and methods of treatment
US9322021B2 (en) 2011-06-29 2016-04-26 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (KLKB1) expression
EP2739735A2 (en) 2011-08-01 2014-06-11 Alnylam Pharmaceuticals, Inc. Method for improving the success rate of hematopoietic stem cell transplants
US10202599B2 (en) 2011-08-11 2019-02-12 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
AU2012308302A1 (en) 2011-09-14 2014-03-20 Northwestern University Nanoconjugates able to cross the blood-brain barrier
AU2012308320C1 (en) 2011-09-14 2018-08-23 Translate Bio Ma, Inc. Multimeric oligonucleotide compounds
US9580713B2 (en) 2011-09-17 2017-02-28 Yale University Fluoride-responsive riboswitches, fluoride transporters, and methods of use
EP3456317B1 (en) 2011-09-27 2025-09-24 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
US10184151B2 (en) 2011-10-11 2019-01-22 The Brigham And Women's Hospital, Inc. Micrornas in neurodegenerative disorders
BR112014008862A2 (en) 2011-10-14 2018-08-07 Genentech Inc isolated antibody that binds to htra1, isolated nucleic acid, host cell, immunoconjugate, pharmaceutical formulation, methods and uses
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
JP2015502365A (en) 2011-12-12 2015-01-22 オンコイミューニン,インコーポレイティド In vivo delivery of oligonucleotides
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
AU2012358238B2 (en) 2011-12-22 2017-12-07 C. Frank Bennett Methods for modulating Metastasis-Associated-in-Lung-Adenocarcinoma-Transcript-1(MALAT-1) expression
WO2013120003A1 (en) 2012-02-08 2013-08-15 Isis Pharmaceuticals, Inc. Modulation of rna by repeat targeting
LT2825672T (en) 2012-03-13 2019-06-10 Swift Biosciences, Inc. Methods and compositions for size-controlled homopolymer tailing of substrate polynucleotides by a nucleic acid polymerase
HK1210211A1 (en) 2012-03-15 2016-04-15 科纳公司 Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
CA2907072A1 (en) 2012-03-16 2013-09-19 Valerion Therapeutics, Llc Antisense conjugates for decreasing expression of dmpk
US9340784B2 (en) 2012-03-19 2016-05-17 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating alpha-1-antitrypsin expression
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
CN104411338A (en) 2012-04-02 2015-03-11 现代治疗公司 Modified polynucleotides for the production of biologics and proteins associated with human disease
EP2850092B1 (en) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
WO2013154799A1 (en) 2012-04-09 2013-10-17 Isis Pharmaceuticals, Inc. Tricyclic nucleosides and oligomeric compounds prepared therefrom
US9133461B2 (en) 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
CN104704122A (en) 2012-04-20 2015-06-10 艾珀特玛治疗公司 miRNA modulators of thermogenesis
WO2013159108A2 (en) 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
WO2013163628A2 (en) 2012-04-27 2013-10-31 Duke University Genetic correction of mutated genes
US9273949B2 (en) 2012-05-11 2016-03-01 Vanderbilt University Backscattering interferometric methods
SG11201407483YA (en) 2012-05-16 2014-12-30 Rana Therapeutics Inc Compositions and methods for modulating smn gene family expression
WO2013173652A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating gene expression
WO2013177248A2 (en) 2012-05-22 2013-11-28 Isis Pharmaceuticals, Inc. Modulation of enhancer rna mediated gene expression
WO2014004572A2 (en) 2012-06-25 2014-01-03 Isis Pharmaceuticals, Inc. Modulation of ube3a-ats expression
US20140038182A1 (en) 2012-07-17 2014-02-06 Dna Logix, Inc. Cooperative primers, probes, and applications thereof
WO2014018930A1 (en) 2012-07-27 2014-01-30 Isis Pharmaceuticals. Inc. Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
WO2014022852A1 (en) 2012-08-03 2014-02-06 Aptamir Therapeutics, Inc. Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
CN104736551B (en) 2012-08-15 2017-07-28 Ionis制药公司 The method for preparing oligomeric compounds using improved end-blocking scheme
WO2014045126A2 (en) 2012-09-18 2014-03-27 Uti Limited Partnership Treatment of pain by inhibition of usp5 de-ubiquitinase
EP4052709A1 (en) 2012-10-11 2022-09-07 Ionis Pharmaceuticals, Inc. Methods of treating kennedy's disease
AR092982A1 (en) 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc MODULATION OF THE EXPRESSION OF ANDROGEN RECEIVERS
US9695418B2 (en) 2012-10-11 2017-07-04 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleosides and uses thereof
US9029335B2 (en) 2012-10-16 2015-05-12 Isis Pharmaceuticals, Inc. Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
CA3201145A1 (en) 2012-10-26 2014-05-01 Geron Corporation C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
US11230589B2 (en) 2012-11-05 2022-01-25 Foundation Medicine, Inc. Fusion molecules and uses thereof
EP2914621B1 (en) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
PL2922554T3 (en) 2012-11-26 2022-06-20 Modernatx, Inc. Terminally modified rna
EP2928303A4 (en) 2012-12-07 2016-07-13 Haplomics Inc REPAIR OF FACTOR VIII MUTATION AND INDUCTION OF TOLERANCE
AU2013374345A1 (en) 2013-01-17 2015-08-06 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
CA3150658A1 (en) 2013-01-18 2014-07-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
DK2951191T3 (en) 2013-01-31 2019-01-14 Ionis Pharmaceuticals Inc PROCEDURE FOR MANUFACTURING OLIGOMERIC COMPOUNDS USING MODIFIED CLUTCH PROTOCOLS
DK2956176T3 (en) 2013-02-14 2018-08-27 Ionis Pharmaceuticals Inc MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS
WO2014130922A1 (en) 2013-02-25 2014-08-28 Trustees Of Boston University Compositions and methods for treating fungal infections
WO2014134179A1 (en) 2013-02-28 2014-09-04 The Board Of Regents Of The University Of Texas System Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
IL288931B2 (en) 2013-03-14 2025-05-01 Alnylam Pharmaceuticals Inc Complement component c5 irna compositions and methods of use thereof
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
US9937231B2 (en) 2013-03-27 2018-04-10 The General Hospital Corporation Methods and agents for treating Alzheimer's disease
EP4286517A3 (en) 2013-04-04 2024-03-13 President and Fellows of Harvard College Therapeutic uses of genome editing with crispr/cas systems
US10590412B2 (en) 2013-04-19 2020-03-17 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation nucleic acids through nonsense mediated decay
DK2992098T3 (en) 2013-05-01 2019-06-17 Ionis Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR MODULATION OF HBV AND TTR EXPRESSION
EA038792B1 (en) 2013-05-22 2021-10-20 Элнилэм Фармасьютикалз, Инк. SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
KR102234623B1 (en) 2013-05-22 2021-04-02 알닐람 파마슈티칼스 인코포레이티드 Tmprss6 compositions and methods of use thereof
EP3004396B1 (en) 2013-06-06 2019-10-16 The General Hospital Corporation Compositions for the treatment of cancer
JP6869720B2 (en) 2013-06-13 2021-05-12 アンチセンス セラピューティクス リミテッド Combination therapy
EP3011026B1 (en) 2013-06-21 2019-12-18 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile
CA2917229A1 (en) 2013-07-02 2015-01-08 Isis Pharmaceuticals, Inc. Modulators of growth hormone receptor
CA2917348A1 (en) 2013-07-11 2015-01-15 Moderna Therapeutics, Inc. Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
WO2015017694A1 (en) * 2013-07-31 2015-02-05 Regents Of The University Of California Dna double-write/double binding identity
HRP20200250T1 (en) 2013-08-08 2020-05-29 The Scripps Research Institute SITE-SPECIFIC ENZYME MARKING OF NUCLEIC ACIDS AND IN VITRO IMPLEMENTATION OF NON-NATURAL NUCLEOTIDS
TW201536329A (en) 2013-08-09 2015-10-01 Isis Pharmaceuticals Inc Compound and method for regulating the manifestation of dystrophic myotonic protein kinase (DMPK)
KR102365486B1 (en) 2013-08-28 2022-02-18 아이오니스 파마수티컬즈, 인코포레이티드 Modulation of prekallikrein (pkk) expression
EP3041934A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
MY181251A (en) 2013-09-13 2020-12-21 Ionis Pharmaceuticals Inc Modulators of complement factor b
CA2925107A1 (en) 2013-10-02 2015-04-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the lect2 gene
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
LT3052628T (en) 2013-10-04 2020-09-10 Alnylam Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR SUPPRESSION OF ALAS1 GENE EXPRESSION
US10584387B2 (en) 2013-10-09 2020-03-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Detection of hepatitis delta virus (HDV) for the diagnosis and treatment of Sjögren's syndrome and lymphoma
US11162096B2 (en) 2013-10-14 2021-11-02 Ionis Pharmaceuticals, Inc Methods for modulating expression of C9ORF72 antisense transcript
WO2015061246A1 (en) 2013-10-21 2015-04-30 Isis Pharmaceuticals, Inc. Method for solution phase detritylation of oligomeric compounds
EP3683321B1 (en) 2013-10-21 2021-12-08 The General Hospital Corporation Methods relating to circulating tumor cell clusters and the treatment of cancer
US10301622B2 (en) 2013-11-04 2019-05-28 Northwestern University Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (SNA)
SI3071696T1 (en) 2013-11-22 2019-11-29 Mina Therapeutics Ltd C / EBP alpha short-acting RNA compositions and application processes
US10182988B2 (en) 2013-12-03 2019-01-22 Northwestern University Liposomal particles, methods of making same and uses thereof
CA2844640A1 (en) 2013-12-06 2015-06-06 The University Of British Columbia Method for treatment of castration-resistant prostate cancer
US10385388B2 (en) 2013-12-06 2019-08-20 Swift Biosciences, Inc. Cleavable competitor polynucleotides
SG10201804960RA (en) 2013-12-12 2018-07-30 Alnylam Pharmaceuticals Inc Complement component irna compositions and methods of use thereof
CN111729090A (en) 2013-12-20 2020-10-02 通用医疗公司 Methods and Assays Related to Circulating Tumor Cells
PT3087183T (en) 2013-12-24 2020-10-08 Ionis Pharmaceuticals Inc Modulation of angiopoietin-like 3 expression
ES2694857T3 (en) 2014-02-04 2018-12-27 Genentech, Inc. Smoothened mutant and methods of using it
CN113057959B (en) 2014-02-11 2024-07-16 阿尔尼拉姆医药品有限公司 Ketohexokinase (KHK) iRNA compositions and methods of use thereof
EP3119789B1 (en) 2014-03-17 2020-04-22 Ionis Pharmaceuticals, Inc. Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
EP3119888B1 (en) 2014-03-19 2021-07-28 Ionis Pharmaceuticals, Inc. Compositions for modulating ataxin 2 expression
US10006027B2 (en) 2014-03-19 2018-06-26 Ionis Pharmaceuticals, Inc. Methods for modulating Ataxin 2 expression
HUE050704T2 (en) 2014-04-01 2020-12-28 Biogen Ma Inc Compositions for modulating sod-1 expression
TWI638047B (en) 2014-04-09 2018-10-11 史基普研究協會 Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
EP3797780B1 (en) 2014-04-17 2022-09-14 Biogen MA Inc. Compositions and methods for modulation of smn2 splicing in a subject
WO2015164693A1 (en) 2014-04-24 2015-10-29 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising alpha-beta-constrained nucleic acid
HUE052709T2 (en) 2014-05-01 2021-05-28 Ionis Pharmaceuticals Inc Conjugates of modified antisense oligonucleotides and their use to modify PKK expression
BR112016022742B1 (en) 2014-05-01 2022-06-14 Ionis Pharmaceuticals, Inc CHEMICAL COMPOUND, COMPOSITION INCLUDING COMPOUND AND USE THEREOF
EA036496B1 (en) 2014-05-01 2020-11-17 Ионис Фармасьютикалз, Инк. Conjugated oligonucleotides for modulating complement factor b expression
US10098959B2 (en) 2014-05-01 2018-10-16 Ionis Pharmaceuticals, Inc. Method for synthesis of reactive conjugate clusters
US9382540B2 (en) 2014-05-01 2016-07-05 Isis Pharmaceuticals, Inc Compositions and methods for modulating angiopoietin-like 3 expression
WO2015171918A2 (en) 2014-05-07 2015-11-12 Louisiana State University And Agricultural And Mechanical College Compositions and uses for treatment thereof
TW201607559A (en) 2014-05-12 2016-03-01 阿尼拉製藥公司 Methods and compositions for treating a SERPINC1-associated disorder
AU2015264038B2 (en) 2014-05-22 2021-02-11 Alnylam Pharmaceuticals, Inc. Angiotensinogen (AGT) iRNA compositions and methods of use thereof
EP3148564B1 (en) 2014-06-02 2020-01-08 Children's Medical Center Corporation Methods and compositions for immunomodulation
KR102524543B1 (en) 2014-06-10 2023-04-20 에라스무스 유니버시티 메디컬 센터 로테르담 Antisense oligonucleotides useful in treatment of Pompe Disease
EP3161159B1 (en) 2014-06-25 2020-08-05 The General Hospital Corporation Targeting human satellite ii (hsatii)
US20170204152A1 (en) 2014-07-16 2017-07-20 Moderna Therapeutics, Inc. Chimeric polynucleotides
US9951327B1 (en) 2014-07-17 2018-04-24 Integrated Dna Technologies, Inc. Efficient and rapid method for assembling and cloning double-stranded DNA fragments
EP3171895A1 (en) 2014-07-23 2017-05-31 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
WO2016018665A1 (en) 2014-07-31 2016-02-04 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
WO2016028940A1 (en) 2014-08-19 2016-02-25 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
CN107106704A (en) 2014-08-29 2017-08-29 儿童医疗中心有限公司 Method and composition for treating cancer
CN113599539A (en) 2014-08-29 2021-11-05 阿尔尼拉姆医药品有限公司 Methods of Treating Transthyretin (TTR) -mediated amyloidosis
WO2016040589A1 (en) 2014-09-12 2016-03-17 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
US10436802B2 (en) 2014-09-12 2019-10-08 Biogen Ma Inc. Methods for treating spinal muscular atrophy
US10533172B2 (en) 2014-09-18 2020-01-14 The University Of British Columbia Allele-specific therapy for huntington disease haplotypes
EP3663403A1 (en) 2014-09-26 2020-06-10 University of Massachusetts Rna-modulating agents
TW202503057A (en) 2014-10-10 2025-01-16 美商艾爾妮蘭製藥公司 Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
WO2016061487A1 (en) 2014-10-17 2016-04-21 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
EP3212794B1 (en) 2014-10-30 2021-04-07 Genzyme Corporation Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
SG11201703645XA (en) 2014-11-10 2017-06-29 Glaxosmithkline Intellectual Property (No 2) Ltd Long acting pharmaceutical compositions for hepatitis c
KR102545316B1 (en) 2014-11-10 2023-06-22 알닐람 파마슈티칼스 인코포레이티드 Hepatitis b virus (hbv) irna compositions and methods of use thereof
KR20170081257A (en) 2014-11-10 2017-07-11 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Combination long acting compositions and methods for hepatitis c
JP2017535552A (en) 2014-11-17 2017-11-30 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. Apolipoprotein C3 (APOC3) iRNA composition and methods of use thereof
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US10400243B2 (en) 2014-11-25 2019-09-03 Ionis Pharmaceuticals, Inc. Modulation of UBE3A-ATS expression
WO2016094342A1 (en) 2014-12-08 2016-06-16 The Board Of Regents Of The University Of Texas System Lipocationic polymers and uses thereof
JP2018504380A (en) 2014-12-18 2018-02-15 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. REVERSIR ™ compounds
US9688707B2 (en) 2014-12-30 2017-06-27 Ionis Pharmaceuticals, Inc. Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
US10793855B2 (en) 2015-01-06 2020-10-06 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of C9ORF72 antisense transcript
US10538763B2 (en) 2015-01-16 2020-01-21 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of DUX4
EP3247988A4 (en) 2015-01-23 2018-12-19 Vanderbilt University A robust interferometer and methods of using same
WO2016130600A2 (en) 2015-02-09 2016-08-18 Duke University Compositions and methods for epigenome editing
CA2976445A1 (en) 2015-02-13 2016-08-18 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
EP3262181B1 (en) 2015-02-23 2024-04-10 Ionis Pharmaceuticals, Inc. Method for solution phase detritylation of oligomeric compounds
WO2016135559A2 (en) 2015-02-23 2016-09-01 Crispr Therapeutics Ag Materials and methods for treatment of human genetic diseases including hemoglobinopathies
AU2016222546B2 (en) 2015-02-26 2020-01-23 Ionis Pharmaceuticals, Inc. Allele specific modulators of P23H rhodopsin
US11129844B2 (en) 2015-03-03 2021-09-28 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating MECP2 expression
AU2016243583B2 (en) 2015-03-27 2022-03-10 President And Fellows Of Harvard College Modified T cells and methods of making and using the same
MX2017012426A (en) 2015-04-03 2018-01-26 Ionis Pharmaceuticals Inc Compounds and methods for modulating tmprss6 expression.
US10961532B2 (en) 2015-04-07 2021-03-30 The General Hospital Corporation Methods for reactivating genes on the inactive X chromosome
US10745702B2 (en) 2015-04-08 2020-08-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the LECT2 gene
US10407678B2 (en) 2015-04-16 2019-09-10 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of C9ORF72 antisense transcript
RS60230B1 (en) 2015-04-16 2020-06-30 Ionis Pharmaceuticals Inc Compositions for modulating c9orf72 expression
EP3286546B1 (en) 2015-04-24 2023-07-19 Mesa Biotech, Inc. Fluidic test cassette
WO2016201301A1 (en) 2015-06-12 2016-12-15 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
EP3310918B1 (en) 2015-06-18 2020-08-05 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
WO2016209862A1 (en) 2015-06-23 2016-12-29 Alnylam Pharmaceuticals, Inc. Glucokinase (gck) irna compositions and methods of use thereof
CN108139375A (en) 2015-06-26 2018-06-08 贝斯以色列女执事医疗中心股份有限公司 Cancer therapy targeting tetraspanin 33 (TSPAN33) in myeloid-derived suppressor cells
EP3314027A4 (en) 2015-06-29 2019-07-03 Caris Science, Inc. THERAPEUTIC OLIGONUCLEOTIDES
WO2017011286A1 (en) 2015-07-10 2017-01-19 Alnylam Pharmaceuticals, Inc. Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
CA3205381A1 (en) 2015-07-17 2017-01-26 Alnylam Pharmaceuticals, Inc. Multi-targeted single entity conjugates
US10941176B2 (en) 2015-07-28 2021-03-09 Caris Science, Inc. Therapeutic oligonucleotides
WO2017021961A1 (en) 2015-08-04 2017-02-09 Yeda Research And Development Co. Ltd. Methods of screening for riboswitches and attenuators
CA2996873A1 (en) 2015-09-02 2017-03-09 Alnylam Pharmaceuticals, Inc. Programmed cell death 1 ligand 1 (pd-l1) irna compositions and methods of use thereof
WO2017048789A1 (en) 2015-09-14 2017-03-23 The Board Of Regents Of The University Of Texas System Lipocationic dendrimers and uses thereof
US20190048340A1 (en) 2015-09-24 2019-02-14 Crispr Therapeutics Ag Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
EP4285912A3 (en) 2015-09-25 2024-07-10 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating ataxin 3 expression
CN113817735A (en) 2015-10-08 2021-12-21 Ionis制药公司 Compounds and methods for modulating angiotensinogen expression
EP4089175A1 (en) 2015-10-13 2022-11-16 Duke University Genome engineering with type i crispr systems in eukaryotic cells
AU2016344609B2 (en) 2015-10-28 2022-05-12 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of duchenne muscular dystrophy
MY196448A (en) 2015-10-30 2023-04-12 Genentech Inc Anti-Htra1 Antibodies and Methods of use Thereof
EP3370734B1 (en) 2015-11-05 2023-01-04 Children's Hospital Los Angeles Antisense oligo for use in treating acute myeloid leukemia
KR20250078597A (en) 2015-11-06 2025-06-02 아이오니스 파마수티컬즈, 인코포레이티드 MODULATING APOLIPOPROTEIN (a) EXPRESSION
BR112018008971A2 (en) 2015-11-06 2018-11-27 Crispr Therapeutics Ag Materials and Methods for Treatment of Type 1a Glycogen Storage Disease
AU2016355178B9 (en) 2015-11-19 2019-05-30 Massachusetts Institute Of Technology Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
KR102787119B1 (en) 2015-11-30 2025-03-27 듀크 유니버시티 Therapeutic targets and methods for correcting the human dystrophin gene by gene editing
CN109715801B (en) 2015-12-01 2022-11-01 克里斯普治疗股份公司 Materials and methods for treating alpha 1 antitrypsin deficiency
EP3389670A4 (en) 2015-12-04 2020-01-08 Ionis Pharmaceuticals, Inc. Methods of treating breast cancer
WO2017099579A1 (en) 2015-12-07 2017-06-15 Erasmus University Medical Center Rotterdam Enzymatic replacement therapy and antisense therapy for pompe disease
KR20180095843A (en) 2015-12-07 2018-08-28 젠자임 코포레이션 Methods and compositions for the treatment of Serpinc1-related disorders
WO2017106767A1 (en) 2015-12-18 2017-06-22 The Scripps Research Institute Production of unnatural nucleotides using a crispr/cas9 system
KR20180118111A (en) 2015-12-23 2018-10-30 크리스퍼 테라퓨틱스 아게 Materials and methods for the treatment of amyotrophic lateral sclerosis and/or frontotemporal lobe degeneration
AU2016381174A1 (en) 2015-12-31 2018-05-31 Ionis Pharmaceuticals, Inc. Methods for reducing Ataxin-2 expression
CA3006599A1 (en) 2016-01-05 2017-07-13 Ionis Pharmaceuticals, Inc. Methods for reducing lrrk2 expression
EP3408649B1 (en) 2016-01-29 2023-06-14 Vanderbilt University Free-solution response function interferometry
US20190038771A1 (en) 2016-02-02 2019-02-07 Crispr Therapeutics Ag Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
EP3411396A1 (en) 2016-02-04 2018-12-12 Curis, Inc. Mutant smoothened and methods of using the same
EP3416689B1 (en) 2016-02-18 2023-01-18 CRISPR Therapeutics AG Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
JP7033072B2 (en) 2016-02-25 2022-03-09 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド Treatment for fibrosis targeting SMOC2
EP3429690A4 (en) 2016-03-16 2019-10-23 Ionis Pharmaceuticals, Inc. METHODS FOR MODULATING KEAP1
WO2017161168A1 (en) 2016-03-16 2017-09-21 Ionis Pharmaceuticals, Inc. Modulation of dyrk1b expression
EP3429632B1 (en) 2016-03-16 2023-01-04 CRISPR Therapeutics AG Materials and methods for treatment of hereditary haemochromatosis
US10731166B2 (en) 2016-03-18 2020-08-04 Caris Science, Inc. Oligonucleotide probes and uses thereof
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
AU2017252023B2 (en) 2016-04-18 2024-05-02 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
WO2017184689A1 (en) 2016-04-19 2017-10-26 Alnylam Pharmaceuticals, Inc. High density lipoprotein binding protein (hdlbp/vigilin) irna compositions and methods of use thereof
WO2017191503A1 (en) 2016-05-05 2017-11-09 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
CN109414408B (en) 2016-05-16 2022-03-29 得克萨斯州大学系统董事会 Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
WO2017205686A1 (en) 2016-05-25 2017-11-30 Caris Science, Inc. Oligonucleotide probes and uses thereof
EP3469083A1 (en) 2016-06-10 2019-04-17 Alnylam Pharmaceuticals, Inc. COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
AU2017286811A1 (en) 2016-06-17 2018-11-22 Ionis Pharmaceuticals, Inc. Modulation of gys1 expression
US20190218257A1 (en) 2016-06-24 2019-07-18 The Scripps Research Institute Novel nucleoside triphosphate transporter and uses thereof
US11174469B2 (en) 2016-06-29 2021-11-16 Crispr Therapeutics Ag Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders
EP4484443A3 (en) 2016-06-29 2025-03-26 CRISPR Therapeutics AG Materials and methods for treatment of friedreich ataxia and other related disorders
US11427838B2 (en) 2016-06-29 2022-08-30 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
CN109843914B (en) 2016-07-06 2024-03-15 沃泰克斯药物股份有限公司 Materials and methods for treating pain-related conditions
JP7305534B2 (en) 2016-07-06 2023-07-10 バーテックス ファーマシューティカルズ インコーポレイテッド Materials and methods for treating pain-related disorders
WO2018007871A1 (en) 2016-07-08 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of transthyretin amyloidosis
WO2018013525A1 (en) 2016-07-11 2018-01-18 Translate Bio Ma, Inc. Nucleic acid conjugates and uses thereof
JP7490211B2 (en) 2016-07-19 2024-05-27 デューク ユニバーシティ Therapeutic Applications of CPF1-Based Genome Editing
KR20190031306A (en) 2016-07-21 2019-03-25 맥스시티 인코포레이티드 Methods and compositions for altering genomic DNA
WO2018020323A2 (en) 2016-07-25 2018-02-01 Crispr Therapeutics Ag Materials and methods for treatment of fatty acid disorders
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
NL2017295B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Antisense oligomeric compound for Pompe disease
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018055577A1 (en) 2016-09-23 2018-03-29 Synthena Ag Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
US11400161B2 (en) 2016-10-06 2022-08-02 Ionis Pharmaceuticals, Inc. Method of conjugating oligomeric compounds
US11459568B2 (en) 2016-10-31 2022-10-04 University Of Massachusetts Targeting microRNA-101-3p in cancer therapy
JOP20190104A1 (en) 2016-11-10 2019-05-07 Ionis Pharmaceuticals Inc Compounds and methods for reducing atxn3 expression
TWI788312B (en) 2016-11-23 2023-01-01 美商阿尼拉製藥公司 SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2018102745A1 (en) 2016-12-02 2018-06-07 Cold Spring Harbor Laboratory Modulation of lnc05 expression
CN110191955B (en) 2016-12-13 2024-05-31 西雅图儿童医院(Dba西雅图儿童研究所) Methods for exogenous drug activation of chemically induced signaling complexes expressed in engineered cells in vitro and in vivo
WO2018112320A1 (en) 2016-12-16 2018-06-21 Alnylam Pharmaceuticals, Inc. Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
RU2019126483A (en) 2017-01-23 2021-02-24 Ридженерон Фармасьютикалз, Инк. VARIANTS OF 17-BETA-HYDROXYSTEROID DEHYDROGENASE 13 (HSD17B13) AND THEIR APPLICATION
EP3585895A1 (en) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Compositions and methods for gene editing
EP3585898A1 (en) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
EP3585807A1 (en) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
EP3585900B1 (en) 2017-02-22 2022-12-21 CRISPR Therapeutics AG Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
WO2018154459A1 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
US11180756B2 (en) 2017-03-09 2021-11-23 Ionis Pharmaceuticals Morpholino modified oligomeric compounds
WO2018183969A1 (en) 2017-03-30 2018-10-04 California Institute Of Technology Barcoded rapid assay platform for efficient analysis of candidate molecules and methods of making and using the platform
EP3609521A4 (en) 2017-04-14 2021-06-16 University of Massachusetts TARGETING OF TROPISM CELL RECEPTORS TO INHIBIT CYTOMEGALOVIRUS INFECTION
CA3059446A1 (en) 2017-04-18 2018-10-25 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
WO2018193428A1 (en) 2017-04-20 2018-10-25 Synthena Ag Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
EP4036101A1 (en) 2017-04-20 2022-08-03 Synthena AG Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
US12208140B2 (en) 2017-04-21 2025-01-28 The Broad Institute, Inc. Targeted delivery to beta cells
MX2019013514A (en) 2017-05-12 2020-01-20 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology.
TW202434265A (en) 2017-07-10 2024-09-01 美商健贊公司 Methods and compositions for treating a bleeding event in a subject having hemophilia
JP7325341B2 (en) 2017-07-11 2023-08-14 シンソークス,インク. Incorporation of non-natural nucleotides and method thereof
MX2020000387A (en) 2017-07-13 2020-08-17 Univ Northwestern General and direct method for preparing oligonucleotide-functiona lized metal-organic framework nanoparticles.
EP3652317A1 (en) 2017-07-13 2020-05-20 Alnylam Pharmaceuticals, Inc. Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof
KR20240141853A (en) 2017-08-03 2024-09-27 신톡스, 인크. Cytokine conjugates for the treatment of autoimmune diseases
WO2019036613A1 (en) 2017-08-18 2019-02-21 Ionis Pharmaceuticals, Inc. Modulation of the notch signaling pathway for treatment of respiratory disorders
WO2019048632A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
US20200208152A1 (en) 2017-09-08 2020-07-02 Mina Therapeutics Limited Stabilized sarna compositions and methods of use
US10517889B2 (en) 2017-09-08 2019-12-31 Ionis Pharmaceuticals, Inc. Modulators of SMAD7 expression
US11999953B2 (en) 2017-09-13 2024-06-04 The Children's Medical Center Corporation Compositions and methods for treating transposon associated diseases
BR112020005230A2 (en) 2017-09-19 2020-09-24 Alnylam Pharmaceuticals, Inc. compositions and methods for the treatment of transthyretin-mediated amyloidosis (ttr)
MA50833A (en) 2017-10-17 2020-08-26 Bayer Healthcare Llc COMPOSITIONS AND METHODS FOR GENE EDITING FOR HEMOPHILIA A
MA50849A (en) 2017-10-26 2020-09-02 Vertex Pharma SUBSTANCES AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
SG11202002940QA (en) 2017-11-01 2020-04-29 Alnylam Pharmaceuticals Inc Complement component c3 irna compositions and methods of use thereof
EP3707155A2 (en) 2017-11-09 2020-09-16 Vertex Pharmaceuticals Incorporated Crispr/cas systems for treatment of dmd
TWI809004B (en) 2017-11-09 2023-07-21 美商Ionis製藥公司 Compounds and methods for reducing snca expression
US20200385719A1 (en) 2017-11-16 2020-12-10 Alnylam Pharmaceuticals, Inc. Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
WO2019100039A1 (en) 2017-11-20 2019-05-23 Alnylam Pharmaceuticals, Inc. Serum amyloid p component (apcs) irna compositions and methods of use thereof
CA3082450A1 (en) 2017-11-21 2019-05-31 Crispr Therapeutics Ag Materials and methods for treatment of autosomal dominant retinitis pigmentosa
WO2019104155A2 (en) 2017-11-22 2019-05-31 The University Of Chicago Chemical probe-dependent evaluation of protein activity and uses thereof
AU2018378479B2 (en) 2017-12-05 2025-03-13 Vertex Pharmaceuticals Incorporated CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereof
JP2021506251A (en) 2017-12-14 2021-02-22 クリスパー セラピューティクス アーゲー New RNA programmable endonuclease system, as well as its use in genome editing and other applications
EP3728593A1 (en) 2017-12-18 2020-10-28 Alnylam Pharmaceuticals, Inc. High mobility group box-1 (hmgb1) irna compositions and methods of use thereof
US11459564B2 (en) 2017-12-21 2022-10-04 Ionis Pharmaceuticals, Inc. Modulation of frataxin expression
WO2019123430A1 (en) 2017-12-21 2019-06-27 Casebia Therapeutics Llp Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
AU2018393050A1 (en) 2017-12-21 2020-06-18 Bayer Healthcare Llc Materials and methods for treatment of Usher Syndrome Type 2A
SG11202006101WA (en) 2017-12-29 2020-07-29 Scripps Research Inst Unnatural base pair compositions and methods of use
WO2019140102A1 (en) 2018-01-10 2019-07-18 Translate Bio Ma, Inc. Compositions and methods for facilitating delivery of synthetic nucleic acids to cells
CA3088180A1 (en) 2018-01-12 2019-07-18 Crispr Therapeutics Ag Compositions and methods for gene editing by targeting transferrin
AU2019206731A1 (en) 2018-01-15 2020-07-30 Ionis Pharmaceuticals, Inc. Modulators of DNM2 expression
EP3740580A4 (en) 2018-01-19 2021-10-20 Duke University GENOMIC ENGINEERING WITH CRISPR-CAS SYSTEMS IN EUKARYOTES
WO2019147743A1 (en) 2018-01-26 2019-08-01 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
US11566236B2 (en) 2018-02-05 2023-01-31 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
US11268077B2 (en) 2018-02-05 2022-03-08 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
MA51869A (en) 2018-02-16 2020-12-23 Bayer Healthcare Llc COMPOSITIONS AND METHODS FOR TARGETING GENE EDITING OF FIBRINOGEN-ALPHA
CN112004547A (en) 2018-02-26 2020-11-27 新索思股份有限公司 IL-15 conjugates and uses thereof
US11732260B2 (en) 2018-03-02 2023-08-22 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of amyloid-β precursor protein
TWI840345B (en) 2018-03-02 2024-05-01 美商Ionis製藥公司 Modulators of irf4 expression
MA52074A (en) 2018-03-19 2021-01-27 Bayer Healthcare Llc NEW PROGRAMMABLE RNA ENDONUCLEASE SYSTEMS AND THEIR USES
WO2019183440A1 (en) 2018-03-22 2019-09-26 Ionis Pharmaceuticals, Inc. Methods for modulating fmr1 expression
EP3775258A4 (en) 2018-03-28 2022-01-26 Board of Regents, The University of Texas System IDENTIFICATION OF EPIGENETIC ALTERATIONS IN DNA ISOLATED FROM EXOSOMES
WO2019186514A2 (en) 2018-03-30 2019-10-03 Rheinische Friedrich-Wilhelms-Universitat Bonn Aptamers for targeted activaton of t cell-mediated immunity
JP7522038B2 (en) 2018-04-06 2024-07-24 ザ チルドレンズ メディカル センター コーポレーション Compositions and methods for modulating somatic cell reprogramming and imprinting - Patents.com
SG11202008660TA (en) 2018-04-11 2020-10-29 Ionis Pharmaceuticals Inc Modulators of ezh2 expression
EP3775211B1 (en) 2018-04-12 2023-04-05 MiNA Therapeutics Limited Sirt1-sarna compositions and methods of use
WO2019204668A1 (en) 2018-04-18 2019-10-24 Casebia Therapeutics Limited Liability Partnership Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
WO2019210057A1 (en) 2018-04-27 2019-10-31 Seattle Children's Hospital (dba Seattle Children's Research Institute) Rapamycin resistant cells
MX2020011570A (en) 2018-05-07 2020-11-24 Alnylam Pharmaceuticals Inc Extrahepatic delivery.
CU20200082A7 (en) 2018-05-09 2021-06-08 Ionis Pharmaceuticals Inc COMPOUNDS AND METHODS FOR REDUCING THE EXPRESSION OF FXI
EP4663758A3 (en) 2018-05-09 2026-04-29 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing atxn3 expression
US12582702B2 (en) 2018-05-11 2026-03-24 University Of Massachusetts Methods for improving leptin sensitivity for the treatment of obesity and diabetes
TWI851574B (en) 2018-05-14 2024-08-11 美商阿尼拉製藥公司 ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
CA3103429A1 (en) 2018-06-14 2019-12-19 Don W. Cleveland Compounds and methods for increasing stmn2 expression
TWI833770B (en) 2018-06-27 2024-03-01 美商Ionis製藥公司 Compounds and methods for reducing lrrk2 expression
US12496311B2 (en) 2018-07-17 2025-12-16 Aronora, Inc. Methods for safely reducing thrombopoietin
AR115847A1 (en) 2018-07-25 2021-03-03 Ionis Pharmaceuticals Inc COMPOUNDS AND METHODS TO REDUCE THE EXPRESSION OF ATXN2
JP7625512B2 (en) 2018-08-13 2025-02-03 アルナイラム ファーマシューティカルズ, インコーポレイテッド Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof
TW202020157A (en) 2018-08-16 2020-06-01 美商艾爾妮蘭製藥公司 Compositions and methods for inhibiting expression of the lect2 gene
CA3110661A1 (en) 2018-08-29 2020-03-05 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
JP7535310B2 (en) 2018-09-14 2024-08-16 ノースウェスタン ユニバーシティ Programming protein polymerization with DNA
US20210332367A1 (en) 2018-09-18 2021-10-28 Alnylam Pharmaceuticals, Inc. KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP3856931B1 (en) 2018-09-25 2023-10-11 Co-Diagnostics, Inc. Allele-specific design of cooperative primers for improved nucleic acid variant genotyping
WO2020069055A1 (en) 2018-09-28 2020-04-02 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
JP7520826B2 (en) 2018-10-17 2024-07-23 クリスパー・セラピューティクス・アクチェンゲゼルシャフト Compositions and methods for transgene delivery
US10913951B2 (en) 2018-10-31 2021-02-09 University of Pittsburgh—of the Commonwealth System of Higher Education Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
SG11202102930YA (en) 2018-11-08 2021-04-29 Synthorx Inc Interleukin 10 conjugates and uses thereof
TW202028222A (en) 2018-11-14 2020-08-01 美商Ionis製藥公司 Modulators of foxp3 expression
CR20210311A (en) 2018-11-15 2021-07-22 Ionis Pharmaceuticals Inc Modulators of irf5 expression
US12281305B2 (en) 2018-11-21 2025-04-22 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing prion expression
CN113710799B (en) 2018-11-28 2024-11-12 克里斯珀医疗股份公司 Optimized mRNA encoding Cas9 for use in LNPs
WO2020117706A1 (en) 2018-12-03 2020-06-11 Triplet Therapeutics, Inc. Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh3 activity
US20210332495A1 (en) 2018-12-06 2021-10-28 Northwestern University Protein Crystal Engineering Through DNA Hybridization Interactions
RS67553B1 (en) 2018-12-20 2026-01-30 Humabs Biomed Sa Combination hbv therapy
AU2019406186A1 (en) 2018-12-20 2021-07-15 Praxis Precision Medicines, Inc. Compositions and methods for the treatment of KCNT1 related disorders
MX2021008628A (en) 2019-01-16 2021-11-17 Genzyme Corp Serpinc1 irna compositions and methods of use thereof.
BR112021013369A2 (en) 2019-01-31 2021-09-21 Ionis Pharmaceuticals, Inc. YAP1 EXPRESSION MODULATORS
EP3923974A4 (en) 2019-02-06 2023-02-08 Synthorx, Inc. IL-2 CONJUGATES AND METHODS OF USE THEREOF
SG11202108357PA (en) 2019-02-15 2021-08-30 Crispr Therapeutics Ag Gene editing for hemophilia a with improved factor viii expression
WO2020171889A1 (en) 2019-02-19 2020-08-27 University Of Rochester Blocking lipid accumulation or inflammation in thyroid eye disease
AU2020227824B2 (en) 2019-02-27 2025-07-10 Ionis Pharmaceuticals, Inc. Modulators of MALAT1 expression
SG11202109741VA (en) 2019-03-12 2021-10-28 Crispr Therapeutics Ag Novel high fidelity rna-programmable endonuclease systems and uses thereof
WO2020191177A1 (en) 2019-03-21 2020-09-24 Sudhir Agrawal Antisense oligonucleotides for allele specificity
WO2020203880A1 (en) 2019-03-29 2020-10-08 田辺三菱製薬株式会社 Compound, method and pharmaceutical composition for dux4 expression adjustment
PT3947684T (en) 2019-03-29 2025-05-19 Ionis Pharmaceuticals Inc Compounds and methods for modulating ube3a-ats
EP3953473A1 (en) 2019-04-12 2022-02-16 MiNA Therapeutics Limited Sirt1-sarna compositions and methods of use
PH12021552870A1 (en) 2019-05-13 2022-03-21 Vir Biotechnology Inc Compositions and methods for treating hepatitis b virus (hbv) infection
AU2020279101B2 (en) 2019-05-17 2025-07-24 Alnylam Pharmaceuticals, Inc. Oral delivery of oligonucleotides
AU2020291535A1 (en) 2019-06-14 2022-01-20 The Scripps Research Institute Reagents and methods for replication, transcription, and translation in semi-synthetic organisms
WO2021021673A1 (en) 2019-07-26 2021-02-04 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating gfap
EP4007812A1 (en) 2019-08-01 2022-06-08 Alnylam Pharmaceuticals, Inc. Serpin family f member 2 (serpinf2) irna compositions and methods of use thereof
EP4007811A2 (en) 2019-08-01 2022-06-08 Alnylam Pharmaceuticals, Inc. Carboxypeptidase b2 (cpb2) irna compositions and methods of use thereof
EP4013870A1 (en) 2019-08-13 2022-06-22 Alnylam Pharmaceuticals, Inc. Small ribosomal protein subunit 25 (rps25) irna agent compositions and methods of use thereof
KR20220062517A (en) 2019-08-15 2022-05-17 아이오니스 파마수티컬즈, 인코포레이티드 Linkage-modified oligomeric compounds and uses thereof
CN114555128A (en) 2019-08-15 2022-05-27 新索思股份有限公司 Combination immunooncology therapy with IL-2 conjugates
US20220281911A1 (en) 2019-08-19 2022-09-08 Mina Therapeutics Limited Oligonucleotide conjugate compositions and methods of use
EP4017540A1 (en) 2019-08-23 2022-06-29 Synthorx, Inc. Il-15 conjugates and uses thereof
BR112022003860A2 (en) 2019-09-03 2022-08-16 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE LECT2 GENE
US12234271B2 (en) 2019-09-10 2025-02-25 Synthorx, Inc. Il-2 conjugates and methods of use to treat autoimmune diseases
US12319711B2 (en) 2019-09-20 2025-06-03 Northwestern University Spherical nucleic acids with tailored and active protein coronae
US12503699B2 (en) 2019-10-04 2025-12-23 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing UGT1a1 gene expression
EP4045652A1 (en) 2019-10-18 2022-08-24 Alnylam Pharmaceuticals, Inc. Solute carrier family member irna compositions and methods of use thereof
WO2021081026A1 (en) 2019-10-22 2021-04-29 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
US12378560B2 (en) 2019-10-29 2025-08-05 Northwestern University Sequence multiplicity within spherical nucleic acids
US20230040920A1 (en) 2019-11-01 2023-02-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajb1-prkaca fusion gene expression
EP4051795A1 (en) 2019-11-01 2022-09-07 Alnylam Pharmaceuticals, Inc. Huntingtin (htt) irna agent compositions and methods of use thereof
WO2021091986A1 (en) 2019-11-04 2021-05-14 Synthorx, Inc. Interleukin 10 conjugates and uses thereof
WO2021092145A1 (en) 2019-11-06 2021-05-14 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna composition and methods of use thereof for treating or preventing ttr-associated ocular diseases
BR112022007795A2 (en) 2019-11-06 2022-07-05 Alnylam Pharmaceuticals Inc EXTRAHEPATIC ADMINISTRATION
BR112022009216A2 (en) 2019-11-13 2022-08-02 Alnylam Pharmaceuticals Inc METHODS AND COMPOSITIONS TO TREAT AN ANGIOTENSINOGEN-ASSOCIATED DISORDER (AGT)
US12565653B2 (en) 2019-11-22 2026-03-03 Alnylam Pharmaceuticals, Inc. ATAXIN3 (ATXN3) RNAi agent compositions and methods of use thereof
KR20220115995A (en) 2019-12-13 2022-08-19 알닐람 파마슈티칼스 인코포레이티드 Human chromosome 9 open reading frame 72 (C9orf72) iRNA preparation compositions and methods of using the same
WO2021126734A1 (en) 2019-12-16 2021-06-24 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
WO2021122944A1 (en) 2019-12-18 2021-06-24 Alia Therapeutics Srl Compositions and methods for treating retinitis pigmentosa
EP4058032A4 (en) 2019-12-19 2024-01-10 Entrada Therapeutics, Inc. COMPOSITIONS FOR ADMINISTRATION OF ANTISENSE COMPOUNDS
WO2021154705A1 (en) 2020-01-27 2021-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
WO2021154941A1 (en) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
IL295445A (en) 2020-02-10 2022-10-01 Alnylam Pharmaceuticals Inc Compositions and methods for silencing vegf-a expression
JP7735288B2 (en) 2020-02-18 2025-09-08 アルナイラム ファーマシューティカルズ, インコーポレイテッド Apolipoprotein C3 (APOC3) iRNA Compositions and Methods of Use Thereof
CN120505310A (en) 2020-02-28 2025-08-19 Ionis制药公司 Compounds and methods for modulating SMN2
GB2613225B (en) 2020-03-04 2024-01-03 Verve Therapeutics Inc Compositions and methods for targeted RNA delivery
EP4114947A1 (en) 2020-03-05 2023-01-11 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
BR112022017822A2 (en) 2020-03-06 2022-11-08 Alnylam Pharmaceuticals Inc KETEXOCINASE (KHK) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
CN115461460A (en) 2020-03-06 2022-12-09 阿尔尼拉姆医药品有限公司 Compositions and methods for inhibiting the expression of transthyretin (TTR)
EP4121534A1 (en) 2020-03-18 2023-01-25 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
TW202204615A (en) 2020-03-26 2022-02-01 美商阿尼拉製藥公司 Coronavirus irna compositions and methods of use thereof
US20230190785A1 (en) 2020-03-30 2023-06-22 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajc15 gene expression
US12534731B2 (en) 2020-04-01 2026-01-27 Alnylam Pharmaceuticals, Inc. Alpha-2A adrenergic receptor (ADRA2A) iRNA agent compositions and methods of use thereof
KR20230008729A (en) 2020-04-06 2023-01-16 알닐람 파마슈티칼스 인코포레이티드 Compositions and methods for silencing MYOC expression
EP4133076A1 (en) 2020-04-07 2023-02-15 Alnylam Pharmaceuticals, Inc. Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof
JP2023521094A (en) 2020-04-07 2023-05-23 アルナイラム ファーマシューティカルズ, インコーポレイテッド Compositions and methods for silencing SCN9A expression
EP4133077A1 (en) 2020-04-07 2023-02-15 Alnylam Pharmaceuticals, Inc. Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
IL297702A (en) 2020-04-27 2022-12-01 Alnylam Pharmaceuticals Inc Compositions of apolipoprotein e (apoe) RNA material and methods of using them
JP2023523790A (en) 2020-04-30 2023-06-07 アルナイラム ファーマシューティカルズ, インコーポレイテッド COMPLEMENT FACTOR B (CFB) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
TWI901676B (en) 2020-05-01 2025-10-21 美商Ionis製藥公司 Compounds and methods for modulating atxn1
JP7776420B2 (en) 2020-05-12 2025-11-26 田辺三菱製薬株式会社 Compounds, methods and pharmaceutical compositions for modulating ataxin 3 expression
WO2021231673A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
WO2021231691A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
EP4150090A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of otoferlin (otof)
WO2021231685A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
WO2021231698A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
WO2021231675A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
WO2021231680A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
EP4150087A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
US20230183707A1 (en) 2020-05-21 2023-06-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting marc1 gene expression
MX2022014606A (en) 2020-05-22 2023-03-08 Wave Life Sciences Ltd Double stranded oligonucleotide compositions and methods relating thereto.
AR122534A1 (en) 2020-06-03 2022-09-21 Triplet Therapeutics Inc METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY
JP2023530234A (en) 2020-06-05 2023-07-14 ザ・ブロード・インスティテュート・インコーポレイテッド Compositions and methods for treating neoplasms
EP4162050A1 (en) 2020-06-09 2023-04-12 Alnylam Pharmaceuticals, Inc. Rnai compositions and methods of use thereof for delivery by inhalation
WO2021252649A2 (en) 2020-06-09 2021-12-16 Alnylam Pharmaceuticals, Inc. Sirna compositions and methods for silencing gpam (glycerol-3-phosphate acyltransferase 1, mitochondrial) expression
WO2021257782A1 (en) 2020-06-18 2021-12-23 Alnylam Pharmaceuticals, Inc. XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
PH12022553569A1 (en) 2020-06-24 2023-04-12 Humabs Biomed Sa Engineered hepatitis b virus neutralizing antibodies and uses thereof
IL299074A (en) 2020-06-25 2023-02-01 Synthorx Inc Immuno oncology combination therapy with il-2 conjugates and anti-egfr antibodies
EP4172338A4 (en) 2020-06-29 2025-06-11 Ionis Pharmaceuticals, Inc. COMPOUNDS AND METHODS FOR MODULATING PLP1
WO2022011214A1 (en) 2020-07-10 2022-01-13 Alnylam Pharmaceuticals, Inc. Circular sirnas
KR20230050336A (en) 2020-07-10 2023-04-14 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) Methods and compositions for treating epilepsy
CA3189922A1 (en) 2020-07-28 2022-02-03 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing app expression
IL300258A (en) 2020-08-07 2023-03-01 Ionis Pharmaceuticals Inc Compounds and methods for modulating scn2a
EP4208549A4 (en) 2020-09-04 2025-04-16 Verve Therapeutics, Inc. Compositions and methods for capping rnas
WO2022066847A1 (en) 2020-09-24 2022-03-31 Alnylam Pharmaceuticals, Inc. Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
EP4222264A1 (en) 2020-09-30 2023-08-09 CRISPR Therapeutics AG Materials and methods for treatment of amyotrophic lateral sclerosis
EP4225917A1 (en) 2020-10-05 2023-08-16 Alnylam Pharmaceuticals, Inc. G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
EP3978608A1 (en) 2020-10-05 2022-04-06 SQY Therapeutics Oligomeric compound for dystrophin rescue in dmd patients throughout skipping of exon-51
JP2023546010A (en) 2020-10-09 2023-11-01 シンソークス, インコーポレイテッド Immuno-oncology therapy using IL-2 conjugates
IL301611A (en) 2020-10-09 2023-05-01 Synthorx Inc Combined immuno-oncology treatment with pairs of IL-2 and pembrolizumab
CA3198823A1 (en) 2020-10-21 2022-04-28 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating primary hyperoxaluria
CN116761885A (en) 2020-10-23 2023-09-15 斯克利普斯研究所 Reverse transcription of polynucleotides comprising unnatural nucleotides
EP4232582A1 (en) 2020-10-23 2023-08-30 Alnylam Pharmaceuticals, Inc. Mucin 5b (muc5b) irna compositions and methods of use thereof
KR20230107625A (en) 2020-11-13 2023-07-17 알닐람 파마슈티칼스 인코포레이티드 Coagulation factor V (F5) iRNA composition and method of use thereof
LT4136092T (en) 2020-11-18 2024-09-25 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating angiotensinogen expression
TW202237150A (en) 2020-12-01 2022-10-01 美商艾拉倫製藥股份有限公司 Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
WO2022125490A1 (en) 2020-12-08 2022-06-16 Alnylam Pharmaceuticals, Inc. Coagulation factor x (f10) irna compositions and methods of use thereof
WO2022133278A2 (en) 2020-12-18 2022-06-23 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating factor xii
IL303886A (en) 2020-12-23 2023-08-01 Flagship Pioneering Inc Modified TREMS vehicles and their uses
EP4271696A2 (en) 2020-12-31 2023-11-08 Alnylam Pharmaceuticals, Inc. Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
EP4271695A2 (en) 2020-12-31 2023-11-08 Alnylam Pharmaceuticals, Inc. 2'-modified nucleoside based oligonucleotide prodrugs
EP4274896A1 (en) 2021-01-05 2023-11-15 Alnylam Pharmaceuticals, Inc. Complement component 9 (c9) irna compositions and methods of use thereof
EP4291654A2 (en) 2021-02-12 2023-12-20 Alnylam Pharmaceuticals, Inc. Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
TW202245843A (en) 2021-02-12 2022-12-01 美商欣爍克斯公司 Skin cancer combination therapy with il-2 conjugates and cemiplimab
WO2022174102A1 (en) 2021-02-12 2022-08-18 Synthorx, Inc. Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
EP4298220A1 (en) 2021-02-25 2024-01-03 Alnylam Pharmaceuticals, Inc. Prion protein (prnp) irna compositions and methods of use thereof
AU2022226098A1 (en) 2021-02-26 2023-08-24 Alnylam Pharmaceuticals, Inc. KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
JP2024508896A (en) 2021-03-04 2024-02-28 アルナイラム ファーマシューティカルズ, インコーポレイテッド Angiopoietin-like 3 (ANGPTL3) iRNA composition and method of use thereof
WO2022192519A1 (en) 2021-03-12 2022-09-15 Alnylam Pharmaceuticals, Inc. Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
WO2022192038A1 (en) 2021-03-12 2022-09-15 Northwestern University Antiviral vaccines using spherical nucleic acids
TW202305133A (en) 2021-03-26 2023-02-01 英商米納治療有限公司 Tmem173 sarna compositions and methods of use
EP4314296A2 (en) 2021-03-29 2024-02-07 Alnylam Pharmaceuticals, Inc. Huntingtin (htt) irna agent compositions and methods of use thereof
EP4314016A1 (en) 2021-03-31 2024-02-07 Entrada Therapeutics, Inc. Cyclic cell penetrating peptides
EP4314293A1 (en) 2021-04-01 2024-02-07 Alnylam Pharmaceuticals, Inc. Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
JP2024516168A (en) 2021-04-22 2024-04-12 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Compositions and methods for treating cancer
EP4330392A1 (en) 2021-04-26 2024-03-06 Alnylam Pharmaceuticals, Inc. Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof
WO2022232343A1 (en) 2021-04-29 2022-11-03 Alnylam Pharmaceuticals, Inc. Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
JP2024518374A (en) 2021-05-03 2024-05-01 アルナイラム ファーマシューティカルズ, インコーポレイテッド Compositions and methods for treating transthyretin (TTR)-mediated amyloidosis
AU2022271873A1 (en) 2021-05-10 2024-01-04 Entrada Therapeutics, Inc. Compositions and methods for intracellular therapeutics
EP4337263A1 (en) 2021-05-10 2024-03-20 Entrada Therapeutics, Inc. Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
WO2022240760A2 (en) 2021-05-10 2022-11-17 Entrada Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MODULATING mRNA SPLICING
EP4341401A1 (en) 2021-05-18 2024-03-27 Alnylam Pharmaceuticals, Inc. Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
EP4341405A1 (en) 2021-05-20 2024-03-27 Korro Bio, Inc. Methods and compositions for adar-mediated editing
WO2022256283A2 (en) 2021-06-01 2022-12-08 Korro Bio, Inc. Methods for restoring protein function using adar
EP4347823A1 (en) 2021-06-02 2024-04-10 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
EP4346904A1 (en) 2021-06-03 2024-04-10 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab
EP4347822A2 (en) 2021-06-04 2024-04-10 Alnylam Pharmaceuticals, Inc. Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof
AR126070A1 (en) 2021-06-08 2023-09-06 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING STARGARDT DISEASE AND/OR DISORDERS ASSOCIATED WITH RETINOL BORDER PROTEIN 4 (RBP4)
EP4101928A1 (en) 2021-06-11 2022-12-14 Bayer AG Type v rna programmable endonuclease systems
AU2022290382A1 (en) 2021-06-11 2023-11-23 Bayer Aktiengesellschaft Type v rna programmable endonuclease systems
AU2022293556A1 (en) 2021-06-18 2024-01-18 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing ifnar1 expression
AU2022298774A1 (en) 2021-06-23 2023-12-14 Entrada Therapeutics, Inc. Antisense compounds and methods for targeting cug repeats
US20230194709A9 (en) 2021-06-29 2023-06-22 Seagate Technology Llc Range information detection using coherent pulse sets with selected waveform characteristics
EP4363574A1 (en) 2021-06-29 2024-05-08 Korro Bio, Inc. Methods and compositions for adar-mediated editing
AU2022303164A1 (en) 2021-06-30 2024-01-18 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
WO2023283403A2 (en) 2021-07-09 2023-01-12 Alnylam Pharmaceuticals, Inc. Bis-rnai compounds for cns delivery
WO2023285431A1 (en) 2021-07-12 2023-01-19 Alia Therapeutics Srl Compositions and methods for allele specific treatment of retinitis pigmentosa
WO2023003805A1 (en) 2021-07-19 2023-01-26 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
MX2024000981A (en) 2021-07-21 2024-02-12 Alnylam Pharmaceuticals Inc Metabolic disorder-associated target gene irna compositions and methods of use thereof.
AU2022316139A1 (en) 2021-07-23 2024-01-18 Alnylam Pharmaceuticals, Inc. Beta-catenin (ctnnb1) irna compositions and methods of use thereof
WO2023009687A1 (en) 2021-07-29 2023-02-02 Alnylam Pharmaceuticals, Inc. 3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
WO2023015223A2 (en) 2021-08-03 2023-02-09 Verve Therapeutics, Inc. Compositions and methods for targeted rna delivery
CA3227852A1 (en) 2021-08-03 2023-02-09 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna compositions and methods of use thereof
EP4381071A1 (en) 2021-08-04 2024-06-12 Alnylam Pharmaceuticals, Inc. Irna compositions and methods for silencing angiotensinogen (agt)
CN118076737A (en) 2021-08-13 2024-05-24 阿尔尼拉姆医药品有限公司 Factor XII (F12) iRNA compositions and methods of use thereof
JP2024538859A (en) 2021-08-31 2024-10-24 アルナイラム ファーマシューティカルズ, インコーポレイテッド Cell death-inducing dffa-like effector B (cideb) iRNA compositions and methods of use thereof
MX2024002640A (en) 2021-09-01 2024-07-19 Entrada Therapeutics Inc Compounds and methods for skipping exon 44 in duchenne muscular dystrophy.
EP4144841A1 (en) 2021-09-07 2023-03-08 Bayer AG Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof
JP2024535850A (en) 2021-09-17 2024-10-02 アルナイラム ファーマシューティカルズ, インコーポレイテッド iRNA Compositions and Methods for Silencing Complement Component (C3)
AU2022345881A1 (en) 2021-09-20 2024-03-21 Alnylam Pharmaceuticals, Inc. Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
TW202328449A (en) 2021-09-24 2023-07-16 美商艾拉倫製藥公司 Microtubule associated protein tau (mapt) irna agent compositions and methods of use thereof
US12042509B2 (en) 2021-10-01 2024-07-23 Adarx Pharmaceuticals, Inc. Prekallikrein-modulating compositions and methods of use thereof
CN118369427A (en) 2021-10-15 2024-07-19 阿尔尼拉姆医药品有限公司 Extrahepatic delivery of IRNA compositions and methods of use thereof
WO2023069603A1 (en) 2021-10-22 2023-04-27 Korro Bio, Inc. Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
EP4423272A2 (en) 2021-10-29 2024-09-04 Alnylam Pharmaceuticals, Inc. Huntingtin (htt) irna agent compositions and methods of use thereof
CN118302525A (en) 2021-10-29 2024-07-05 阿尔尼拉姆医药品有限公司 Complement factor B (CFB) iRNA compositions and methods of use thereof
US20240200078A1 (en) 2021-11-18 2024-06-20 Cornell University Microrna-dependent mrna switches for tissue-specific mrna-based therapies
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
EP4452327A1 (en) 2021-12-20 2024-10-30 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
CA3243006A1 (en) 2021-12-21 2025-02-27 Alia Therapeutics Srl Type ii cas proteins and applications thereof
WO2023122750A1 (en) 2021-12-23 2023-06-29 Synthorx, Inc. Cancer combination therapy with il-2 conjugates and cetuximab
EP4453191A1 (en) 2021-12-23 2024-10-30 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
WO2023141314A2 (en) 2022-01-24 2023-07-27 Alnylam Pharmaceuticals, Inc. Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
WO2023166425A1 (en) 2022-03-01 2023-09-07 Crispr Therapeutics Ag Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use
WO2023194359A1 (en) 2022-04-04 2023-10-12 Alia Therapeutics Srl Compositions and methods for treatment of usher syndrome type 2a
EP4522742A2 (en) 2022-05-13 2025-03-19 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
CN119403922A (en) 2022-06-10 2025-02-07 拜耳公司 A new small V-shaped RNA programmable endonuclease system
JP2025522880A (en) 2022-06-30 2025-07-17 アルナイラム ファーマシューティカルズ, インコーポレイテッド Cyclic disulfide-modified phosphate-based oligonucleotide prodrugs
WO2024039776A2 (en) 2022-08-18 2024-02-22 Alnylam Pharmaceuticals, Inc. Universal non-targeting sirna compositions and methods of use thereof
EP4569113A1 (en) 2022-09-15 2025-06-18 Regeneron Pharmaceuticals, Inc. 17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
CA3267752A1 (en) 2022-09-16 2024-03-21 Alia Therapeutics Srl Enqp type ii cas proteins and applications thereof
JP2025532127A (en) 2022-09-23 2025-09-29 アイオーニス ファーマシューティカルズ, インコーポレーテッド Compounds and methods for reducing MECP2 expression
WO2024073732A1 (en) 2022-09-30 2024-04-04 Alnylam Pharmaceuticals, Inc. Modified double-stranded rna agents
WO2024105162A1 (en) 2022-11-16 2024-05-23 Alia Therapeutics Srl Type ii cas proteins and applications thereof
IL321270A (en) 2022-12-13 2025-08-01 Bayer Ag Engineered type v rna programmable endonucleases and their uses
WO2024136899A1 (en) 2022-12-21 2024-06-27 Synthorx, Inc. Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
WO2024134199A1 (en) 2022-12-22 2024-06-27 Mina Therapeutics Limited Chemically modified sarna compositions and methods of use
CN120882867A (en) 2023-01-11 2025-10-31 阿利亚治疗有限公司 Type II CAS protein and its application
TW202449152A (en) 2023-02-09 2024-12-16 美商艾拉倫製藥股份有限公司 Reversir molecules and methods of use thereof
EP4665865A1 (en) 2023-02-17 2025-12-24 Anjarium Biosciences AG Methods of making dna molecules and compositions and uses thereof
CN121263208A (en) 2023-03-20 2026-01-02 新索思股份有限公司 Cancer therapy using IL-2 PEG conjugates
KR20260009305A (en) 2023-04-12 2026-01-19 알닐람 파마슈티칼스 인코포레이티드 Extrahepatic delivery of double-stranded RNA preparations
TW202448484A (en) 2023-04-20 2024-12-16 美商雅迪克斯製藥公司 Mapt-modulating compositions and methods of use thereof
WO2024220746A2 (en) 2023-04-21 2024-10-24 Flagship Pioneering Innovations Vii, Llc Rnai agents targeting fatty acid synthase and related methods
WO2024226499A1 (en) 2023-04-24 2024-10-31 The Broad Institute, Inc. Compositions and methods for modifying fertility
EP4709855A2 (en) 2023-05-12 2026-03-18 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
WO2024238396A1 (en) 2023-05-12 2024-11-21 Adarx Pharmaceuticals, Inc. Nmda ligand conjugated compounds and uses thereof
CN121335980A (en) 2023-05-26 2026-01-13 阿达尔克斯制药有限公司 SOD1 regulating composition and its usage
EP4731763A1 (en) 2023-06-20 2026-04-29 Adarx Pharmaceuticals, Inc. Lrrk2-modulating compositions and methods of use thereof
WO2025003344A1 (en) 2023-06-28 2025-01-02 Alia Therapeutics Srl Type ii cas proteins and applications thereof
WO2025015335A1 (en) 2023-07-13 2025-01-16 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
WO2025015338A1 (en) 2023-07-13 2025-01-16 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
AU2024299328A1 (en) 2023-07-21 2026-01-22 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods
KR20260049597A (en) 2023-08-04 2026-04-14 알닐람 파마슈티칼스 인코포레이티드 Method and composition for treating CTNNB1-related diseases
WO2025064660A2 (en) 2023-09-21 2025-03-27 Alnylam Pharmaceuticals, Inc. Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof
WO2025072699A1 (en) 2023-09-27 2025-04-03 Judo Bio, Inc. Aminoglycosides for delivery of agents to the kidney
WO2025072713A1 (en) 2023-09-27 2025-04-03 Judo Bio, Inc. Polymyxins for delivery of agents to the kidney
WO2025072672A2 (en) 2023-09-27 2025-04-03 Judo Bio, Inc. Slc6a19-targeting modulatory nucleic acid agents
WO2025076031A2 (en) 2023-10-03 2025-04-10 Alnylam Pharmaceuticals, Inc. Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof
WO2025076291A1 (en) 2023-10-06 2025-04-10 Bluerock Therapeutics Lp Engineered type v rna programmable endonucleases and their uses
WO2025096809A1 (en) 2023-10-31 2025-05-08 Korro Bio, Inc. Oligonucleotides comprising phosphoramidate internucleotide linkages
WO2025128799A1 (en) 2023-12-12 2025-06-19 Korro Bio, Inc. Double-stranded rna-editing oligonucleotides and uses thereof
WO2025158385A1 (en) 2024-01-25 2025-07-31 Genzyme Corporation Pegylated il-2 for suppressing adaptive immune response to gene therapy
WO2025178854A2 (en) 2024-02-19 2025-08-28 Flagship Pioneering Innovations Vii, Llc Rnai agents targeting cideb and related methods
WO2025199231A2 (en) 2024-03-20 2025-09-25 Vertex Pharmaceuticals Incorporated Mucin-5b (muc5b) targeted sirna and antisense oligonucleotides and methods of use thereof
WO2025207517A2 (en) 2024-03-25 2025-10-02 Synthorx, Inc. Synthetic trna synthetases and cells comprising synthetic molecules for production of polypeptides
WO2025210147A1 (en) 2024-04-04 2025-10-09 Alia Therapeutics Srl Type v cas proteins and applications thereof
WO2025217275A2 (en) 2024-04-10 2025-10-16 Flagship Pioneering Innovations Vii, Llc Immune cell targeted compositions and related methods
WO2025259743A1 (en) 2024-06-12 2025-12-18 Alnylam Pharmaceuticals, Inc. Dual conjugate compounds for extrahepatic delivery
WO2025259747A2 (en) 2024-06-12 2025-12-18 Alnylam Pharmaceuticals, Inc. Dystrophy myotonic protein kinase (dmpk) irna compositions and methods of use thereof
WO2026006436A1 (en) 2024-06-25 2026-01-02 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of tar dna binding protein 43 kda (tdp43)
WO2026027887A2 (en) 2024-08-02 2026-02-05 Mina Therapeutics Limited Hbg1/2-sarna compositions and methods of use
WO2026050243A1 (en) 2024-08-26 2026-03-05 Korro Bio, Inc. Galnac conjugated oligonucleotides for rna editing
WO2026055461A1 (en) 2024-09-05 2026-03-12 Aperture Therapeutics, Inc. Antibody oligonucleotide conjugates comprising an antisense polynucleotide agent conjugated to a cd33 antibody and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4470954A (en) * 1983-06-13 1984-09-11 Chiknas Steven G Rotor or carrier for centrifugal analyzer and bead washer
DD238395A1 (en) * 1985-06-19 1986-08-20 Akad Wissenschaften Ddr METHOD FOR SELECTIVELY FIXING BIOLOGICAL ACTIVE SUBSTANCES
US4806546A (en) * 1985-09-30 1989-02-21 Miles Inc. Immobilization of nucleic acids on derivatized nylon supports
JPS62197425A (en) * 1986-02-25 1987-09-01 Toyo Soda Mfg Co Ltd Production of spherical thermoplastic resin
GB2197720A (en) * 1986-11-20 1988-05-25 Nat Res Dev Immobilisation of polynucleotides
AU1363688A (en) * 1987-02-12 1988-09-14 Sdi Diagnostics, Inc. Test system, test device and method for detecting pathogenic organisms and antibiotic resistance genes in body fluids
IL85551A0 (en) * 1987-04-01 1988-08-31 Miles Inc Rapid hybridization assay and reagent system used therein
US4921805A (en) * 1987-07-29 1990-05-01 Life Technologies, Inc. Nucleic acid capture method
US4921788A (en) * 1988-04-12 1990-05-01 The Research Foundation Of State University Of New York Competitive nucleic acid immunoassay for the detection of analytes
IE904365A1 (en) * 1990-02-13 1991-08-14 Epitope Stick probe device for detection of antibodies

Also Published As

Publication number Publication date
EP0745689A2 (en) 1996-12-04
EP0455905B1 (en) 1998-06-17
ATE167523T1 (en) 1998-07-15
DE69032425D1 (en) 1998-07-23
DK0455905T3 (en) 1998-12-07
EP0745689A3 (en) 1996-12-11
EP0455905A2 (en) 1991-11-13
JPH0420300A (en) 1992-01-23
US5514785A (en) 1996-05-07
ES2116977T3 (en) 1998-08-01
EP0455905A3 (en) 1992-10-07

Similar Documents

Publication Publication Date Title
DE69032425T2 (en) Immersion test strips for nucleic acid hybridization assays and methods for covalently immobilizing oligonucleotides
DE69030672T2 (en) STRENGTHENED TARGET NUCLEIC ACIDS BY USE OF OLIGONUCLEOTIDES COVERED TO POLYMERS
US5667976A (en) Solid supports for nucleic acid hybridization assays
DE69029717T2 (en) Method for immobilizing nucleic acid on a solid surface for use in nucleic acid hybridization tests
DE69419461T2 (en) Device for collecting target molecules and collecting method using this device
DE3486478T2 (en) Composition for use in an assay using polynucleotide sequences
DE3486124T2 (en) METHODS AND STRUCTURES IN WHICH CHEMICALLY MARKED, NON-RADIOACTIVE POLYNUCLEOTID PROBE ARE USED.
DE69214942T2 (en) METHOD FOR SPECIFIC BINDING ASSAYS USING A RELEASABLE LIGAND
DE69225646T2 (en) Process for immobilizing a nucleic acid fragment by passive fixation on a solid support, solid support obtained therefrom and its use
DE69433644T2 (en) Chemical method for the duplication and detection of nucleic acid sequences
DE3650103T2 (en) Nucleic acid sandwich assay in solution phase and suitable polynucleotide sample.
DE3688931T2 (en) Arabino nucleic acid probes for DNA / RNA determinations.
DE69230864T2 (en) METHOD FOR IMMOBILIZING NUCLEIC ACID PROBE ON POLYSTYROL SURFACES
DE69216640T2 (en) Method and device for the detection of nucleic acid sequences.
DE69116236T2 (en) Determination of analytes that have binding sites for at least two binding groups
DE3689954T2 (en) AMPLIFIED HYBRIDIZATION TEST PROCEDURE.
DE3586659T2 (en) HYBRIDIZATION TEST FOR NUCLEIC ACIDS.
DE3785658T2 (en) METHODS AND COMPOSITIONS FOR TESTS WITH NUCLEIC ACID PROBE.
DE68923603T2 (en) Nucleotide probes.
DE3856224T2 (en) Detection of a polynucleotide by etching a chain on a capture probe
DE69624406T2 (en) Method for the analysis of biologically active substances
DE68919706T2 (en) METHOD FOR QUICK DETECTING NUCLEIC ACIDS.
DE69625510T2 (en) METHOD FOR PRODUCING SOLID CARRIERS FOR HYBRIDIZING AND REDUCING NON-SPECIFIC BACKGROUND
DE69032847T2 (en) Hydrophobic nucleic acid probe
DE69031121T2 (en) INTERFERENCE PREVENTION WITH AFFINITY COLLECTION SCHEMES

Legal Events

Date Code Title Description
8364 No opposition during term of opposition